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Definitions: 
Malaria definition: A patient was defined as suffering from malaria if he/she complained 
of fever or had body temperature measured with an oral probe of ≥ 37.5°C plus 
microscopically detected asexual parasitemia. 
Isolate: A sample of parasites collected at one time from an individual (not cultured or 
subject to any procedure which may have changed the mixture of parasites). 
Prepatent period: is defined as the time from infection by mosquito bite until the time 
trophozoites are detectable in erythrocytes. It is fixed and constant for each species of 
parasites. It is associated with the length of pre-erythrocytic cycle, but is longer than it. 
Incubation period: is defined as the time from infection by mosquito bite until the first 
appearance of clinical symptoms. It is variable but usually much longer than the prepatent 
period as it requires parasitemia to reach a sufficient density before symptoms occur. It is 
thought to be influenced by the initial sporozoite load, and subsequently by the load of 
merozoites invading the blood stream: the higher the load the shorter the incubation period. 
Entomological inoculation rate (EIR): vector density, human blood index and 
sporozoite rate allow the entomological inoculation rate to be calculated. The EIR is given by 
the density (number of vectors per inhabitant) multiplied by the human blood index and by 
the sporozoite rate. If we assume for instance that the catches provided a number of 15 
anopheles per inhabitant and per night, that 78% of them were human fed and that 10% of the 
vectors showed to be sporozoite infected, the EIR will be 15x0.78x0.1= 1.17. 
Recrudescence: is the renewed clinical manifestation of the infection due to persistence of 
erythrocytic forms into the circulation. This is typically observed in P. falciparum infection 
exposed to subcurative drug treatment (latency of few days to few weeks) and in P. malariae 
(latency as long as several years). 
Relapse: is a renewed clinical manifestation of the infection started by persistent liver 
merozoites (hypnozoites) which start an exo-erythrocytic cycle months after the invasion of 
the hepatocyte. This is typically observed in P. vivax and P. ovale infection treated with drugs 
which have no action on the parasite liver stages. 
Clone: A set of genetically identical parasites derived from one parasite by asexual 
reproduction. 
Line: Parasites which have been passaged in vitro or in vivo, initially starting from one 
isolate. If parasites have been cloned in the laboratory, they are referred to as cloned lines. 
Genotype: A genetic characteristic of a parasite, the type of allele found at a polymorphic 
locus in an individual. 
Allele: One of several alternative forms of a gene. 
Allelic type: Alleles of a gene can be grouped with regard to similar characteristics, e.g. 
the allelic types of MSP1 and MSP2, also referred to as allelic families. 
Multiplicity of infection: number of infecting genotypes in an isolate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
A hospital-based study was carried out in Gedarif town, an area of markedly unstable malaria 
transmission in eastern Sudan during the two malaria transmission seasons (2000-2002),. 
Among the 2488 diagnosed malaria patients, 110 fulfilled the WHO (2000) criteria for severe 
malaria (SM), and seven died of cerebral malaria (CM). The predominant complication was 
severe malarial anemia (SMA, 45.45%), followed by convulsions associated malaria (CAM, 
20.9%), cerebral malaria (16.4%) and hypotension (HTN, 11.8%). 
DNA was extracted from 616 parasites obtained from 231 donors with asymptomatic 
submicroscopic malaria (ASUM), uncomplicated malaria (UM) and SM. The MSP2 locus 
was exploited for determination of parasite genotype. 51 parasite genotypes were detected. 
There was no correlation between the number of infectious clones and initial parasite count or 
patient age. In all infections, the mean clone number (MCN) was 1.5 clone/infection, and it 
was comparable between SM and UM. However detailed analysis revealed that; individuals 
with ASUM had significantly lower MCN compared with UM, SMA, and non-fatal CM. The 
frequency of IC1 and FC27 allele families was comparable between SM and UM and the 
distribution of the individual allele sizes was correlated. Further analysis showed that, 1. 
FC27 was associated with the mildest form of malaria and was not recognized in fatal CM, 2. 
Faster clearance of IC1 genotype in the multi-clone infections after quinine treatment 3. 
Multi-clone infections with different genotype families (IC1 and FC27) were far more 
frequent than that with the same genotype family, suggesting stronger cross-immunity within 
rather than between MSP2 gene families. 
The diversity of infection (DOI) was estimated by using different molecular markers (pfcrt76, 
pfmdr1 86, glurp and MSP2) separately and by considering them together to generate a multi-
locus genetic profile for each isolate. pfcrt and pfmdr1, are not usually used for parasite 
genotyping, here they revealed DOI of 0.043 and 0.064, respectively. However, when used in 
combination with the most polymorphic markers (MSP2 and GLURP) they disclosed a 
hidden diversity that would have not been detected. The DOI as estimated by MSP2 and 
GLURP was, 0.553 and 0.435, respectively. However, combining all 4 molecular markers 
(multi-locus genetic profile), had revealed a finger print pattern of diversity, DOI of 0.936, 
which almost indicated that there were one unique strain for each patient, and that was 
comparable between SM and UM (although for UM, GLURP was not analyzed). Not only, 
the genetic make up of parasites were different, but clinical data suggest that the virulence 
markers should also be extremely diverse. 
Another hospital-based study was carried out in New Halfa town, where 120 individuals were 
enrolled in the study, including febrile patients with and without microscopically detectable 
parasitemia, and apparently healthy individuals. PCR for parasite detection and ELISA tests 
for measuring serum antibody levels were carried out on all blood samples. A majority of the 
febrile patients, who were parasite negative by microscopy, showed the presence of a P. 
falciparum infection by PCR. The occurrence of P. falciparum infection with parasitemia 
below the detection level of microscopy was recognized more often in patients with CM 
symptoms than SMA, and in older rather than younger patients. Patients clinically suspected 
to have cerebral malaria (CSCM) mostly had a single clone infection and a large proportion of 
them acquired antibodies against MSP antigens. The therapeutic response to quinine 
treatment was comparable between patients with CSCM and CM. 
In a 28-days in-vivo study of pyrimethamine/sulfadoxine (SP) and SP plus chloroquine (CQ) 
efficacy, 260 patients with uncomplicated P. falciparum malaria were enrolled in rural 
Eastern Sudan. The results revealed a comparable treatment failure (TF) for SP alone 
(32.99%) or with CQ (31.7%). Patients who achieved adequate clinical response (ACR), were 
significantly older than patients who had TF. Regarding gametocytogenesis; a. the 
microscopic gametocyte productivity was significantly higher in patients with TF when 
compared to ACR. Thus, gametocytemia was more associated with younger age b. 
gametocyte counts were comparable between TF and ACR groups of patients until Day7 of 
follow up, thereafter, at D14, D21 and D28, gametocytes count was significantly higher in 
patients with TF. However, the longevity of gametocytes in patients with TF and ACR were 
comparable. 
Parasite isolates from 168 patients (including all patients with TF) were genotyped at the 
dhfr, dhps and pfcrt loci. The molecular image of the in-vivo phenotype, revealed the 
following findings: the prevalence of dhfr mutations c51-I, c108-N, and double mutant 
c51I/108N, were estimated to be 91.9%, 92.3% and 79.7%, respectively, while only one 
isolate (0.6%) was found carrying c59R and no c164L mutation was recognized. The dhps 
mutations; c437G, c540E and double mutant c437/c540 had a prevalence rate of 90.2%, 
79.3% and 58.5%, respectively, while those of c436F and c581G were, 0.6% and 13%, 
respectively.  For pfcrt gene at c72-76, 92.26% were the mutant type CVIET, only 6.55% 
were the wild type CVMNK and 2 patients harbored mixed infection. Based on the 
multiplicity of mutation score (MOM) ranging from 1 to 5, the prevalence according to the 
MOM score were; 0.97, 0.931, 0.866, 0.719, 0.121, respectively.                  
  ﺨﻼﺼﺔ ﺍﻟﺩﺭﺍﺴﺔ
–0002)ﻨﺘﻘﺎل ﻤﺭﺽ ﺍﻟﻤﻼﺭﻴﺎ ﻟﻠﻌﺎﻤﻴﻥ ﺍﻟﻘﻀﺎﺭﻑ ﺒﺸﺭﻕ ﺍﻟﺴﻭﺩﺍﻥ ﺨﻼل ﻤﻭﺴﻡ ﺇ ﺒﻤﺴﺘﺸﻔﻲ  ﺠﺭﺍﺀ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔﺘﻡ ﺇ
ﻭ ﻟﺨﺒﻴﺜﺔ ﺃﻜﺎﻨﺕ ﻨﺴﺒﺔ ﺍﻟﻤﺭﻀﻲ ﺍﻟﻤﺼﺎﺒﻴﻥ ﺒﺎﻟﻤﻼﺭﻴﺎ ﺍ.  ﺒﺎﻟﻤﻼﺭﻴﺎ ﻤﺭﻴﻀﺎﹰ8842ﺨﻼل ﻓﺘﺭﺓ ﺍﻟﺩﺭﺍﺴﺔ ﺘﻡ ﺘﺸﺨﻴﺹ (. 2002
. ﻤﻥ ﺜﻡ ﺘﻡ ﺭﺼﺩ ﻋﺩﺩ ﺴﺒﻊ ﺤﺎﻻﺕ ﻭﻓﺎﺓ ﻤﻥ ﻫﺅﻻﺀ ﺍﻟﻤﺭﻀﻲ % 4.4  ﺤﺴﺏ ﻤﺅﺸﺭﺍﺕ ﻤﻨﻅﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔﺍﻟﻤﻌﻘﺩﻩ
 ﻫﻭ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﻤﻌﻘﺩﻩ ﻨﻭﺍﻉ ﺸﻴﻭﻋﺎﹰﻜﺜﺭ ﺍﻷﺃ ﻜﺎﻥ ،  ﺍﻟﻤﻀﺎﻋﻔﺎﺕ ﺍﻟﻤﺭﻀﻴﺔ ﺍﻟﻤﺭﺘﺒﻁﺔ ﺒﻤﺭﺽ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﻤﻌﻘﺩﻩﺘﻤﺕ ﺩﺭﺍﺴﺔ
 ﺍﻟﻤﻼﺭﻴﺎ ،% 9.02ﺭﻴﺎ ﺍﻟﻤﺭﺘﺒﻁﺔ ﺒﺎﻟﺘﺸﻨﺠﺎﺕ ﺒﻨﺴﺒﺔ ﺘﻠﻴﻬﺎ ﺍﻟﻤﻼ% 4.545ﺍﻟﻤﺭﺘﺒﻁﺔ ﺒﻔﻘﺭ ﺍﻟﺩﻡ ﺤﻴﺙ ﻤﺜﻠﺕ ﻨﺴﺒﺔ 
   %.8.11ﺜﻡ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﻤﺭﺘﺒﻁﺔ ﺒﺎﻨﺨﻔﺎﺽ ﻀﻐﻁ ﺍﻟﺩﻡ % 4.61ﺩﻤﺎﻏﻴﺔ ﺍﻟ
 ﻤﺎﻨﺢ ﻤﻥ ﻤﺭﻀﻲ ﺍﻟﻤﻼﺭﻴﺎ ﺒﺩﻭﻥ 132 ﻋﻴﻨﺔ ﺩﻡ ﻤﻥ 616ﻟﻐﺭﺽ ﺩﺭﺍﺴﺔ ﺍﻟﺘﻌﻘﻴﺩ ﺍﻟﺠﻴﻨﻲ ﻭﺴﻁ ﻁﻔﻴﻠﻴﺎﺕ ﺍﻟﻤﻼﺭﻴﺎ ﺘﻡ ﺠﻤﻊ 
ﻭﻤﻥ ﺜﻡ ﺘﻡ ﺇﺴﺘﺨﻼﺹ ﺍﻟﺤﻤﺽ ﺍﻟﻨﻭﻭﻱ ( MS)ﻭ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﻤﻌﻘﺩﻩ ( MU) ﺍﻟﻤﻼﺭﻴﺎ ﻏﻴﺭ ﺍﻟﻤﻌﻘﺩﻩ  ،(MUSA)ﻋﺭﺍﺽ ﺃ
ﻟﺘﺤﺩﻴﺩ ﺍﻟﻨﻭﻉ ﺍﻟﺠﻴﻨﻲ ( 2PSM )2-ﻲﺤﺴﺘﺨﺩﺍﻡ ﺠﻴﻥ ﻤﻴﺭﻭﺯﻭﻴﺕ ﺍﻟﺒﺭﻭﺘﻴﻥ ﺍﻟﺴﻁﺇﺘﻡ . )AND(ﻭﻜﺴﺠﻴﻨﻲ ﻤﻨﻬﻤﺎﻟﻼﺃﺍ
 ﺠﻴﻨﻴﺎ ﻟﻁﻔﻴﻠﻲ ﺍﻟﻤﺘﺼﻭﺭﻩ  ﻨﻭﻋﺎﹰ15 ﺤﻴﺙ ﺘﻡ ﺭﺼﺩ ﻭﺠﻭﺩ ، ﻥ ﺍﻟﻁﻔﻴﻠﻴﺎﺕ ﺘﺘﺒﺎﻴﻥ ﺠﻴﻨﻴﺎﹰﺃﺸﺎﺭﺕ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻟﻲ ﺃ. ﻟﻠﻁﻔﻴﻠﻲ
ﺩ ﻋﻼﻗﺔ ﺒﻴﻥ ﻋﺩﺩ ﺍﻟﻨﺴﺦ ﺍﻟﻤﻌﺩﻴﻪ ﻟﻠﻁﻔﻴﻠﻲ ﻴﺠﺎﻟﻡ ﻴﺘﻡ ﺇ. ﻲ ﻫﺫﻩ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺒﺤﺜﻴﺔﻓ( murapiclaf.P)ﺍﻟﻤﻨﺠﻠﻴﻪ 
ﺼﺎﺒﺎﺕ ﻤﺠﺘﻤﻌﺔ ﻜﺎﻥ ﻤﺘﻭﺴﻁ ﻋﺩﺩ ﻨﺴﺦ ﺃﺨﺫ ﺍﻹﻋﻨﺩ . ﻋﻤﺎﺭﻫﻡ ﻟﺤﻅﺔ ﺍﻟﻔﺤﺹﺃﻭ  ﺃﻭﻤﻌﺩﻻﺕ ﻜﺜﺎﻓﺘﻪ ﻓﻲ ﺩﻡ ﺍﻟﻤﺭﻀﻲ 
ﻗل ﻤﻌﻨﻭﻴﺎ ﻟﺩﻱ ﺃﻟﺩﻱ ﺍﺠﺭﺍﺀ ﺘﺤﻠﻴل ﺠﻴﻨﻲ ﺍﻭﻀﺢ ﺘﺒﻴﻥ ﺍﻥ ﻤﺘﻭﺴﻁ ﻋﺩﺩ ﻨﺴﺦ ﺍﻟﻁﻔﻴﻠﻲ . ﺼﺎﺒﺔ ﺍﻟﻭﺍﺤﺩﺓ ﻟﻺ5.1ﺍﻟﻁﻔﻴﻠﻲ 
  . ﻤﻼﺭﻴﺎ ﻓﻘﺭ ﺍﻟﺩﻡ ﻭ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﺩﻤﺎﻏﻴﻪ ﻏﻴﺭ ﺍﻟﻤﻤﻴﺘﺔ، ﻟﻤﻼﺭﻴﺎ ﻏﻴﺭ ﺍﻟﻤﻌﻘﺩﻩﻪ ﻟﺩﻱ ﻤﺭﻀﻲ ﺍﻋﻨMUSA ﻤﺭﻀﻲ 
 ﻭ ﺍﻟﻤﻼﺭﻴﺎ ﻏﻴﺭ ﻟﻤﻌﻘﺩﻩﻤﺘﻘﺎﺭﺒﺔ ﻟﺩﻱ ﻤﺭﻀﻲ ﺍﻟﻤﻼﺭﻴﺎ ﺍ( 2-PSM) ـﻟ( 72cF ﻭ 1CI)ﻟﻴﻼﺕ ﺍﻟﺠﻴﻨﻴﺔ ﺍﻷﻜﺎﻨﺕ ﺘﺭﺩﺩﺍﺕ 
ﺴﺒﺔ ﺘﻤﺜﻴﻠﻪ ﺒﺼﻭﺭﺓ ﻭﺍﻀﺤﺔ ﻨﻭﺍﻉ ﺍﻟﻤﻼﺭﻴﺎ ﺤﻴﺙ ﻜﺎﻨﺕ ﻨﺃﺨﻑ ﺃﺭﺘﺒﺎﻁ ﻤﻊ ﺇ ﺍ ﺫ72cFﻟﻴل ﻥ ﺍﻷﺃﻟﻲ ﺇﺸﺎﺭﺕ ﺍﻟﻨﺘﺎﺌﺞ . ﺍﻟﻤﻌﻘﺩﻩ
ﺨﺘﻔﻲ ﺇ 1CI ﻟﻴلﻥ ﺍﻷﻜﺫﻟﻙ ﺘﻤﺕ ﻤﻼﺤﻅﺔ ﺃ. ﺘﻠﺔﻜﺘﺸﺎﻓﻪ ﻓﻲ ﻤﺭﻀﻲ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﻤﻌﻘﺩﻩ ﺍﻟﻘﺎ  ﻭﻟﻡ ﻴﺘﻡ ﺇMUSAﻟﺩﻱ ﻤﺭﻀﻲ 
ﻟﻴﻼﺕ ﻤﺨﺘﻠﻔﻪ ﻜﺎﻨﺕ ﺎﺕ ﻤﺘﻌﺩﺩﺓ ﺍﻟﻨﺴﺦ ﺍﻟﺘﻲ ﺘﺤﺘﻭﻱ ﻋﻠﻲ ﺃﺼﺎﺒﺍﻹﻥ ﺃ ﺘﻼﺤﻅ ﻴﻀﺎﹰﺃ. ﺴﺘﻌﻤﺎل ﻋﻘﺎﺭ ﺍﻟﻜﻴﻨﻴﻥﺇﻜﺒﺭ ﻋﻨﺩ ﺃﺒﺴﺭﻋﺔ 
  . ﻟﻴلﺓ ﺍﻟﻨﺴﺦ ﺍﻟﻤﺤﺘﻭﻴﻪ ﻋﻠﻲ ﻨﻔﺱ ﻨﻭﻉ ﺍﻷﺼﺎﺒﺎﺕ ﻤﺘﻌﺩﺩ ﺒﺎﻹﺎﺭﻨﺔﹰﺴﺎﺌﺩﺓ ﺒﺼﻭﺭﺓ ﻜﺒﻴﺭﻩ ﻤﻘ
ﺘﻡ . ﻠﻲ ﻋﻴﻨﻪ ﻤﻥ ﻤﻌﺯﻭﻻﺕ ﺍﻟﻁﻔﻴ001 ﺘﻡ ﺠﻤﻊ ،ﻟﻐﺭﺽ ﺩﺭﺍﺴﺔ ﻤﺴﺘﻭﻱ ﺍﻟﺘﺒﺎﻴﻥ ﺍﻟﺠﻴﻨﻲ ﻭﺴﻁ ﻁﻔﻴﻠﻴﺎﺕ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﻤﻌﻘﺩﻩ 
 ﻋﻠﻲ ﺸﺨﺹ ﻭﺍﺤﺩ ﻓﻘﻁ ﺒﻭﺍﺴﻁﺔ  ﻋﺒﺭ ﺤﺴﺎﺏ ﻋﺩﺩ ﺍﻟﻤﻌﺯﻭﻻﺕ ﺍﻟﺘﻲ ﺘﻜﻭﻥ ﺤﺼﺭﺍﹰﺼﺎﺒﺔ ﻜﻤﻴﺎﹰﻗﻴﺎﺱ ﻤﺴﺘﻭﻱ ﺍﻟﺘﺒﺎﻴﻥ ﻓﻲ ﺍﻹ
 ﺠﻴﻥ ﻤﺘﻌﺩﺩ ،)trcfp( ﺴﺘﺨﺩﺍﻡ ﺠﻴﻥ ﻨﺎﻗل ﻤﻘﺎﻭﻤﺔ ﺍﻟﻜﻠﻭﺭﻭﻜﻭﻴﻥ ﻤﺅﺸﺭﺍﺕ ﺠﺯﻴﺌﻴﺔ ﻤﺨﺘﻠﻔﻪ ﺤﻴﺙ ﺘﻡ ﺇﺴﺘﺨﺩﺍﻡ ﺇ
 ﻭ ﺠﻴﻥ ﺍﻟﺒﺭﻭﺘﻴﻥ ﻏﻨﻲ ﺍﻟﻘﻠﻭﺘﺎﻤﻴﺕ )2PSM( 2-ﻲﺤ ﻤﻴﺭﻭﺯﻭﻴﺕ ﺍﻟﺒﺭﻭﺘﻴﻥ ﺍﻟﺴﻁ، )1rdmfp( 1-ﺍﻟﻌﻘﺎﻗﻴﺭ
   .)PRULG(
ﺔ ﺍﻟﺘﺒﺎﻴﻥ  ﻟﺩﺭﺍﺴﻟﻤﺅﺸﺭﺍﺕ ﻋﺎﺩﺓﹰﺤﻴﺙ ﻻ ﺘﺴﺘﺨﺩﻡ ﻫﺫﻩ ﺍ) ﻤﺤﺩﻭﺩﺍﹰ ﺘﺒﺎﻴﻨﺎﹰ( 1rdmfp ﻭ trcfp)ﻭﺠﺩﺕ ﺍﻟﻤﺅﺸﺭﺍﺕ ﺃ
 ﻋﻠﻲ 534.0 ﻭ 355.0 ﻜﺎﻥ ﻤﺴﺘﻭﻯ ﺍﻟﺘﺒﺎﻴﻥ ﻓﻲ ﺍﻹﺼﺎﺒﺔ ﻫﻭ prulG ﻭ 2PSMﺴﺘﺨﺩﺍﻡ ﻤﺅﺸﺭﺍﺕ ﻟﺩﻯ ﺇ(. ﺍﻟﺠﻴﻨﻴﻥ
 639.0 ﺘﻡ ﻤﻼﺤﻅﺔ ﻨﻤﻁ ﻤﺘﻤﻴﺯ ﻟﻤﺴﺘﻭﻯ ﺍﻟﺘﺒﺎﻴﻥ ﺒﻤﻌﺩل ﺴﺘﺨﺩﺍﻡ ﺍﻟﻤﺅﺸﺭﺍﺕ ﺍﻷﺭﺒﻊ ﺍﻟﺴﺎﺒﻕ ﺫﻜﺭﻫﺎ ﻤﺠﺘﻤﻌﺔﹰﺇﻟﺩﻯ . ﺍﻟﺘﻭﺍﻟﻲ
ﺒﺎﻹﻀﺎﻓﺔ ﻟﻬﺫﺍ ﺍﻹﺨﺘﻼﻑ ﺍﻟﺠﻴﻨﻲ ﺘﺸﻴﺭ . ﻤﺘﻔﺭﺩ ﻷﻨﻭﺍﻉ ﺍﻟﻁﻔﻴل ﺍﻟﺠﻴﻨﻴﺔ ﻟﺩﻯ ﻜل ﻤﺭﻴﺽﻭﻫﺫﺍ ﺍﻟﻤﻌﺩل ﻴﺸﻴﺭ ﺇﻟﻲ ﻭﺠﻭﺩ ﻨﻤﻁ 
  .ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﺍﻟﺴﺭﻴﺭﻴﺔ ﺇﻟﻲ ﺃﻥ ﺍﻟﻤﺅﺸﺭﺍﺕ ﺍﻟﻤﺭﻀﻴﺔ ﺃﻴﻀﺎﹰ ﺘﺨﺘﻠﻑ ﺇﺨﺘﻼﻓﺎﹰ ﻜﺒﻴﺭﺍﹰ ﻤﻥ ﺇﺼﺎﺒﺔ ﺇﻟﻲ ﺃﺨﺭﻯ
ﻤﺭﺽ ﺍﻟﻤﻼﺭﻴﺎ ﻭﻫﻲ ﻤﻨﻁﻘﺔ ﺸﺒﻪ ﻤﺴﺘﻭﻁﻨﺔ ﺒ. ﺘﻡ ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺔ ﺃﺨﺭﻯ ﺒﻤﺴﺘﺸﻔﻲ ﺤﻠﻔﺎ ﺍﻟﺠﺩﻴﺩﺓ، ﻭﻻﻴﺔ ﻜﺴﻼ، ﺸﺭﻕ ﺍﻟﺴﻭﺩﺍﻥ
ﺤﻴﺙ ﺃﻥ ﻗﺎﻁﻨﻲ ﺍﻟﻤﻨﻁﻘﺔ ﻟﺩﻴﻬﻡ ﻤﻨﺎﻋﺔ ﺠﺯﺌﻴﺔ ﻀﺩ ﺍﻟﻤﺭﺽ، ﻟﺫﺍ ﻓﻤﻥ ﺍﻟﻤﻤﻜﻥ ﺃﻥ ﻴﻜﻭﻥ ﻗﺎﻁﻥ ﻫﺫﻩ ﺍﻟﻤﻨﻁﻘﺔ ﻤﻤﻥ ﻴﻅﻬﺭﻭﻥ 
ﻨﻬﻡ ﻴﺤﻤﻠﻭﻥ ﻁﻔﻴﻠﻴﺎﺕ ﻤﻼﺭﻴﺎ ﺒﻜﺜﺎﻓﺔ ﺃﻗل ﻭﺃ.  ﻴﺸﺨﺼﻭﺍ ﻤﻭﺠﺒﻴﻥ ﺒﻭﺍﺴﻁﺔ ﺍﻟﻤﺠﻬﺭﺒﻌﺽ ﻋﻼﻤﺎﺕ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﺩﻤﺎﻏﻴﺔ ﺩﻭﻥ ﺃﻥ
ﻓﻲ ﻫﺫﺍ ﺍﻟﺠﺯﺀ ﻤﻥ . ﻓﺭﺍﺩ ﺍﻟﺫﻴﻥ ﺘﻡ ﺇﺩﺭﺍﺠﻬﻡ ﻓﻲ ﺍﻟﺩﺭﺍﺴﺔ ﺒﻭﺍﺴﻁﺔ ﺍﻟﻤﺠﻬﺭﺘﻡ ﻓﺤﺹ ﻜل ﺍﻷ. ﻤﻥ ﺃﻥ ﻴﻜﺘﺸﻑ ﺒﻭﺍﺴﻁﺔ ﺍﻟﻤﺠﻬﺭ
 ﻤﻥ ﺒﻴﻨﻬﻡ ﻤﻤﻥ ﻟﺩﻴﻬﻡ ﺤﻤﻰ ﺒﻌﻀﻬﻡ ﻟﺩﻴﻬﻡ ﻁﻔﻴﻠﻴﺎﺕ ﺃﻤﻜﻥ ﺘﺸﺨﻴﺼﻬﺎ ﺒﺎﻟﻤﺠﻬﺭ ﻭﺒﻌﻀﻬﻡ ﻟﻡ ﺍﹲ ﻓﺭﺩ021ﺍﻟﺩﺭﺍﺴﺔ ﺘﻡ ﺇﺩﺭﺍﺝ 
( RCP)ﻠﻲ ﺍﻟﻤﺘﺒﻠﻤﺭ ﻓﻴﻤﺎ ﺒﻌﺩ ﺘﻡ ﺇﺨﻀﺎﻉ ﺠﻤﻴﻊ ﻫﺫﻩ ﺍﻟﻌﻴﻨﺎﺕ ﻟﻠﺘﺤﻠﻴل ﺒﻭﺍﺴﻁﺔ ﺘﻘﻨﻴﺘﻲ ﺍﻟﺘﻔﺎﻋل ﺍﻟﺴﻠﺴ. ﻴﻭﺠﺩ ﻟﺩﻴﻬﻡ ﻁﻔﻴﻠﻴﺎﺕ
 ﻨﺘﺎﺌﺞ ﻫﺫﺍ ﺍﻟﺘﺸﺨﻴﺹ ﺇﻟﻰ ﺃﻥ ﻏﺎﻟﺒﻴﺔ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﻜﺎﻨﺕ ﺃﺸﺎﺭﺕ(. ASILE)ﻭﺍﻹﻤﺘﺼﺎﺼﻴﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﺭﺘﺒﻁﺔ ﺒﺎﻹﻨﺯﻴﻡ 
 .RCPﻟﺩﻴﻬﻡ ﺤﻤﻰ ﻭﻟﻡ ﻴﺘﻡ ﺭﺼﺩ ﻁﻔﻴﻠﻴﺎﺕ ﻓﻲ ﻋﻴﻨﺎﺘﻬﻡ ﺒﺎﻟﻤﺠﻬﺭ ﻴﻭﺠﺩ ﻟﺩﻴﻬﻡ ﻁﻔﻴﻠﻴﺎﺕ ﺃﻤﻜﻥ ﺘﺸﺨﻴﺼﻬﺎ ﺒﻭﺍﺴﻁﺔ ﺘﻘﻨﻴﺔ ﺍﻟـ
 ﻭﺴﻁ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﻟﺩﻴﻬﻡ ﺃﻋﺭﺍﺽ ﻤﻼﺭﻴﺎ ﺩﻤﺎﻏﻴﺔ ﺃﻜﺜﺭ ﻤﻥ ﺍﻟﺫﻴﻥ ﻟﺩﻴﻬﻡ ﺃﻋﺭﺍﺽ ﻜﺎﻥ ﻫﺫﺍ ﺍﻟﻨﻭﻉ ﻤﻥ ﺍﻹﺼﺎﺒﺎﺕ ﺴﺎﺌﺩﺍﹰ
ﻜﺫﻟﻙ ﻭﺠﺩ ﺃﻥ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﻟﺩﻴﻬﻡ ﺃﻋﺭﺍﺽ ﻤﻼﺭﻴﺎ . ﻤﻼﺭﻴﺎ ﻤﺭﺘﺒﻁﺔ ﺒﻔﻘﺭ ﺍﻟﺩﻡ، ﻭﻋﻨﺩ ﻜﺒﺎﺭ ﺍﻟﺴﻥ ﺃﻜﺜﺭ ﻤﻥ ﺍﻟﺼﻐﺎﺭ
  . PSMﺤﺎﺩﻴﺔ ﺍﻟﻨﺴﺨﺔ ﻭﻤﻌﻅﻤﻬﻡ ﻜﻭﻥ ﺃﺠﺴﺎﻡ ﻤﻀﺎﺩﺓ ﻟﻸﻨﺘﺠﻴﻥ ﺁﺩﻤﺎﻏﻴﺔ ﻴﺤﻤﻠﻭﻥ ﺇﺼﺎﺒﺎﺕ 
ﺒﺭﻴﻔﻲ ﺸﺭﻕ   ﻤﺭﻴﺽ ﺒﻤﻼﺭﻴﺎ ﻏﻴﺭ ﻤﻌﻘﺩﺓ062ﺎﺭ  ﺘﻡ ﺇﺨﺘﻴﺔ ﺍﻟﺩﻭﺍﺌﻴﺔ ﻟﻤﺭﺽ ﺍﻟﻤﻼﺭﻴﺎﺴﺘﺠﺎﺒﺴﺘﻭﻯ ﺍﻹﻟﻐﺭﺽ ﺩﺭﺍﺴﺔ ﻤ
ﺨﺘﺒﺎﺭ ﻓﻌﺎﻟﻴﺔ ﺍﻟﻔﺎﻨﺴﺩﺍﺭ ﺘﻡ ﺇ.  ﻴﻭﻤﺎﹰ82ﺔ ﺩﺍﺨل ﺍﻟﺠﺴﻡ ﻟﻤﺩﺓ ﺴﺘﺠﺎﺒﺔ ﺍﻟﺩﻭﺍﺌﻴﺘﻡ ﺇﺨﻀﺎﻉ ﻫﺅﻻﺀ ﺍﻟﻤﺭﻀﻰ ﻹﺨﺘﺒﺎﺭ ﺍﻹ. ﺍﻟﺴﻭﺩﺍﻥ
% 7.13ﻭ %  99.23ﻤﺘﻘﺎﺭﺒﺎﹰ ﻓﻲ ﺍﻟﺤﺎﻟﺘﻴﻥﺌﻲ ﻜﺎﻥ ﻤﺴﺘﻭﻯ ﺍﻟﻔﺸل ﺍﻟﺩﻭﺍ. ﻭﺤﻴﺩﺍﹰ ﺜﻡ ﻓﻲ ﺨﻠﻴﻁ ﻤﻊ ﻋﻘﺎﺭ ﺍﻟﻜﻠﻭﺭﻭﻜﻭﻴﻥ
 ﺴﺘﺠﺎﺒﺔ ﻤﻁﻠﻘﺔ ﻟﻠﻌﻘﺎﺭ ﺘﺯﻴﺩ ﻤﻌﺩﻻﺕ ﺃﻋﻤﺎﺭﻫﻡ ﻤﻌﻨﻭﻴﺎﹰ ﻋﻥﺇﺴﺘﺠﺎﺒﻭﺍ ﺕ ﺍﻟﻨﺘﺎﺌﺞ ﺇﻟﻲ ﺃﻥ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﺇﺃﺸﺎﺭ. ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲ
ﺠﻴﺒﻭﺍ ﺒﺎﻟﻨﺴﺒﺔ ﻟﺘﻜﻭﻴﻥ ﺍﻟﺨﻼﻴﺎ ﺍﻟﻤﺸﻴﺠﻴﺔ ﻜﺎﻥ ﻤﻌﺩﻟﻬﺎ ﺃﻋﻠﻲ ﻤﻌﻨﻭﻴﺎﹰ ﻟﺩﻯ ﺍﻷﻓﺭﺍﺩ ﺍﻟﺫﻴﻥ ﻟﻡ ﻴﺴﺘ. ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﻟﻡ ﻴﺴﺘﺠﻴﺒﻭﺍ ﻟﻪ
  . ﺴﺘﺠﺎﺒﺔ ﻤﻁﻠﻘﺔﻤﻊ ﺍﻟﺫﻴﻥ ﻜﺎﻥ ﻟﺩﻴﻬﻡ ﺇ ﻟﻠﻌﻘﺎﺭ ﻤﻘﺎﺭﻨﺔﹰ
    ﻭ sphd ,trcfp ﻟﺠﻴﻨﺎﺕ( ﺴﺘﺠﺎﺒﺔ ﻟﻠﻌﻘﺎﺭﻤﻠﺕ ﻜل ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﻓﺸﻠﻭﺍ ﻓﻲ ﺍﻹﺸ) ﻋﻴﻨﺔ 861ﺘﻤﺕ ﻁﺒﺎﻋﺔ 
 ﻭ 801ﻟﻠﻤﻭﻗﻊ % 3.29 ﻤﻥ ﺍﻟﺠﻴﻥ، 15ﻟﻠﻤﻭﻗﻊ % 9.19 rfhdﻜﺎﻨﺕ ﻨﺴﺒﺔ ﺤﺩﻭﺙ ﺍﻟﻁﻔﺭﺍﺕ ﻓﻲ ﺠﻴﻥ ﺍﻟـ rfhd
 ﻭﻟﻡ ﻴﺘﻡ ﺇﻴﺠﺎﺩ ﺃﻱ ﻁﻔﺭﺓ 95ﻴﻥ، ﻜﺫﻟﻙ ﻭﺠﺩﺕ ﻋﻴﻨﺔ ﻭﺍﺤﺩﺓ ﻓﻘﻁ ﺘﺤﺘﻭﻱ ﻋﻠﻰ ﻁﻔﺭﺓ ﻓﻲ ﺍﻟﻤﻭﻗﻊ ﻟﻠﻤﻭﻗﻌﻴﻥ ﻤﺠﺘﻤﻌ% 7.97
ﻟﻠﻤﻭﻗﻊ % 3.97 ، 734ﻟﻠﻤﻭﻗﻊ % 2.09 ﻜﺎﻨﺕ ﺍﻟﻨﺴﺏ sphdﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﻁﻔﺭﺍﺕ ﻋﻠﻰ ﺍﻟﺠﻴﻥ . 461ﻓﻲ ﺍﻟﻤﻭﻗﻊ 
ﻟﺩﻱ ﺘﺤﻤل ﻁﻔﺭﺍﺕ % 62.29 ﺃﻥ  ﻭﺠﺩtrcfpﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﺠﻴﻥ . ﻟﻠﻤﻭﻗﻌﻴﻥ ﻤﺠﺘﻤﻌﻴﻥ ﻓﻲ ﻨﻔﺱ ﺍﻟﻌﻴﻨﺔ% 5.85 ﻭ045
  . ﻤﻥ ﺍﻟﻌﻴﻨﺎﺕ ﻻ ﺘﺤﻤل ﺃﻱ ﻁﻔﺭﺍﺕ% 55.6 ﺒﻴﻨﻤﺎ ﻭﺠﺩ ﺃﻥ 27 -  67 ﺍﻟﻤﻭﺍﻗﻊ ﻤﻥ ﺍﻟﺠﻴﻥ ﻫﻲ
ﻭﺠﺩ ﺃﻥ ﺍﻟﻤﺭﻀﻰ ﺍﻟﻤﺼﺎﺒﻴﻥ . ﺴﺘﺠﺎﺒﺔ ﻟﻌﻘﺎﺭ ﺍﻟﻔﺎﻨﺴﺩﺍﺭ ﺍﻟﻁﻔﺭﺍﺕ ﻓﻲ ﺍﻹﺼﺎﺒﺔ ﺍﻟﻭﺍﺤﺩﺓ ﻭﺍﻹﻟﻡ ﻴﺘﻡ ﺇﻴﺠﺎﺩ ﻋﻼﻗﺔ ﺒﻴﻥ ﺘﻌﺩﺩ
 ﺍﻹﺼﺎﺒﺔ ﺒﻁﻔﻴﻠﻴﺎﺕ ﺤﺴﺎﺴﺔ ﺃﻭ ﻤﺤﺘﻭﻴﺔ ﺒﻁﻔﻴﻠﻴﺎﺕ ﻟﻬﺎ ﻨﻔﺱ ﻨﺴﻕ ﺍﻟﻁﻔﺭﺍﺕ ﻴﻨﺘﻤﻭﻥ ﻟﻤﺠﻤﻭﻋﺎﺕ ﻋﻤﺭﻴﺔ ﻤﺘﻘﺎﺭﺒﺔ ﻋﻨﺩﻤﺎ ﺘﻜﻭﻥ
ﺍﺩ ﻏﻴﺭ ﺴﺘﺠﺎﺒﺔ ﺩﻭﺍﺌﻴﺔ ﻤﻁﻠﻘﺔ ﺃﻋﻤﺎﺭﻫﻡ ﺃﻜﺒﺭ ﻤﻌﻨﻭﻴﺎﹰ ﻤﻥ ﺍﻷﻓﺭﺠﺩ ﺃﻥ ﺍﻷﻓﺭﺍﺩ ﺍﻟﺫﻴﻥ ﻜﺎﻨﺕ ﻟﺩﻴﻬﻡ ﺇﻋﻠﻰ ﻁﻔﺭﺓ ﻭﺍﺤﺩﺓ ﺒﻴﻨﻤﺎ ﻭ
ﻋﻨﺩﻤﺎ ﺘﻜﻭﻥ ﻁﻔﺭﺘﻴﻥ ﻋﻠﻰ )ﻜﺫﻟﻙ ﻭﺠﺩ ﺃﻥ ﻋﺩﺩ ﺍﻟﻁﻔﺭﺍﺕ . ﺼﺎﺒﺎﺕ ﻤﺤﺘﻭﻴﺔ ﻋﻠﻰ ﻁﻔﺭﺘﻴﻥ ﻓﺄﻜﺜﺭﺍﻟﻤﺴﺘﺠﻴﺒﻴﻥ ﻋﻨﺩﻤﺎ ﺘﻜﻭﻥ ﺍﻹ
  . ﺘﺒﻁ ﻤﻌﻨﻭﻴﺎﹰ ﺒﺈﻨﺘﺎﺝ ﺃﻋﻠﻰ ﻟﻠﺨﻼﻴﺎ ﺍﻟﻤﺸﻴﺠﻴﺔ ﻭﻤﻌﺩل ﻨﻤﻭ ﺃﻗل ﻟﻠﻁﻔﻴﻠﻴﺎﺕﻴﺭ( ﺍﻷﻗل
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Chapter One 
Introduction and Literature Review 
1.1 Global situation of malaria: 
Malaria is among the oldest diseases, in one form or another; that has infected and affected 
our ancestors since a long time ago. During our recent evolution, its influence has probably 
been greater than that of any other infectious agent1. As shown in fig. (1.1) the true magnitude 
of the mortality and morbidity attributable to malaria worldwide is at best a scientific guess, 
although it is not disputable that the greatest burden is in sub-Saharan Africa 2. 
 
 
Figure (1.1): Global malaria distribution and endemicity, 2003 
 
At the end of 2004, 107 countries and territories had areas at risk of malaria transmission, 
where some 3.2 billion people lived at risk of malaria transmission. An estimated 350-500 
million clinical malaria episodes occur annually; most of these caused by P. falciparum and 
P. vivax. P. falciparum causes more than 1 million deaths each year. It also contributes 
indirectly to many additional deaths mainly in young children, through synergy with other 
infections and illnesses 3.  
The pattern of malaria transmission and disease vary markedly between regions and even 
within individual countries. This diversity results from variations between malaria parasites 
and mosquito vectors, ecological conditions that affect malaria transmission and 
socioeconomic factors, such as poverty and access to effective health care and prevention 
services3. 
About 60% of the cases of malaria worldwide, 75% of global falciparum malaria cases and 
more than 80% of malaria deaths occur in Africa south of the Sahara. P. falciparum causes 
the vast majority of infections in this region and about 18% of deaths in children under five 
years of age. Malaria is also a major cause of anemia in children and pregnant women, low 
birth weight, premature birth and infant mortality. In endemic African countries, malaria 
accounts for 25-35% of all outpatient visits, 20-45% of hospital admissions and 15-35% of 
hospital deaths, imposing a great burden on already fragile health-care systems. Malaria 
remains a major global problem, exacting an unacceptable toll on the health and economic 
welfare of the world’s poorest communities3. 
Outside tropical Africa malaria occurs mainly among individuals who lack immunity and are 
infected with P. falciparum in areas where appropriate diagnosis and treatment are not 
available. It is estimated that malaria claims more than 100000 lives per year where it is not 
endemic in the world and these deaths occur in all age groups. The total number of cases 
recorded in these regions is approximately five million per year. About 80% of these cases 
are found in Asia, where extremely severe parasite resistance to the drugs has developed4.  
Malaria is an impediment to social and economic development, being responsible for lost 
days at school and work, draining limited health care budget and rendering some areas 
uninhabitable for non-immune populations. In countries of South America, where malaria is 
endemic, the number of days lost each year because of malaria has been shown to vary 
between 1.5 and 14.3 days per person5. Studies in rural areas of Africa reveal that over one 
third of primary school children had malaria during school term, more than half of this group 
had two or more attacks, missing a week or more of school days with each attack5. 
Malaria is considered as one of the main health problem in Sudan, it is estimated to account 
for 20-40% of the total hospital out-patients visits and 10-40%, from the in-patients 
admissions, and it is the cause of death for 10-15% of the in-patients6.  
1.2 Epidemiology of malaria: 
The “many epidemiologies” of malaria have been characterized by degrees of endemicity7,8. 
Malaria is described as endemic when there is a constant incidence of cases over a period of 
many successive years. At the other extreme malaria transmission may be epidemic when 
there is a periodic or occasional increase in the incidence of cases. A more general 
classification into stable and unstable malaria has been introduced. Stable malaria refers to 
high transmission without any marked fluctuations over the years, although seasonal 
fluctuations may exist. Unstable malaria describes transmission that varies from year to year 
with the possibility of epidemics. The former situation is characterized by high degrees of 
collective immunity whereas the latter is not. These terms describe extremes of a wide range 
of situations9.  
Malaria is transmitted primarily by the bite of infected anopheline mosquitoes. The source of 
infection can be either a sick person or an otherwise symptomless carrier of parasites. It can 
also be transmitted by inoculation of infected blood and congenitally. Anophelines feed at 
night and their breeding sites are primarily in rural areas. The greatest risk of malaria is 
therefore from dusk to dawn in rural areas. In many malaria-endemic areas, there is little or 
no risk in urban areas. However, urban transmission is common in some parts of the world, 
especially Africa. 
Most infected children in malaria endemic areas have asymptomatic parasitemia and only a 
minority of the infection progress to become life threatening. The incidence of severe clinical 
manifestations varies seasonally within endemic areas and it is not possible at present to 
predict which asymptomatic individual will develop severe disease. The observation that host 
genetic factors can modify disease outcome is also of importance in preventing severe 
disease. 
The epidemiological profile and clinical pattern of severe malaria in Africa has been shown 
to vary according to the intensity of exposure in children living in rural areas with different 
levels of transmission10. The degree of endemicity varies between countries and even 
between different areas in the same country. In Sub-Saharan Africa cerebral malaria and 
severe malarial anemia are leading causes of mortality11.  
The pattern of pathology also differs with changes in the degree of endemicity. In areas of 
high endemicity, although individuals after 5 years of age continue to harbour malaria 
parasites, the frequency of disease is greatly reduced. This protection from disease in older 
children and the development of clinical immunity usually is never reached in regions where 
there is low or seasonal exposure to parasite12. 
Morbidity and mortality due to malaria will be substantially greater upon exposure of 
individuals who are innately susceptible to this disease.  Such groups may be selectively 
targeted for interventions.  
Malaria has reinvaded areas in which it has previously been well under control such as 
Azerbaijan, Tajikistan, Iraq and Turkey. Epidemics in these areas resulted from rapid 
deterioration of malaria prevention and control operations brought about by military conflicts 
followed by economic crisis5. 
Migration from rural to urban areas can lead to the movement of infected people to towns 
with consequent enhancement of malaria transmission within the town. The converse may 
also be true where none-immune migrants arrive in an urban area where malaria transmission 
is occurring. Urban migration can also increase malaria a part from increasing transmission in 
peri-urban areas.  
Persons who normally should not be at risk of serious life threatening disease are put in 
danger when they have no access to early diagnosis and adequate treatment of malaria 
disease. This can be due to inadequate health infrastructure, inadequately trained health staff, 
or scarcity of resources (of the patients and/or health services)13. Wars, political unrest and 
famines may cause increased risk of malaria. This may be due to either disruption of existing 
health care structures in endemic areas or the movement of people to new geographic 
locations creating new risk for migrants or the communities they cohabit. Malaria epidemics 
have been associated with military conflicts, social unrest and natural catastrophes. 
The impact of human-induced global climate change poses an obvious threat to human 
health. The insect-vectors of Plasmodium spp. thrive in warm climates of tropical countries. 
Global warming leading to increased temperature in temperate areas, could provide a habitat 
suitable for the increased distribution of anopheline vectors. Whether the potential increase in 
vector populations will lead to a concomitant increase in malaria transmission is not clear14. 
Increased temperature can both increase the mortality of the vector and the biting rate as well 
as effect the duration of the sporogonic cycle 9. 
Malaria is unstable in the semi-arid savannah of central and northern Sudan and the great 
majority of infective bites take place in September and October, immediately prior to the 
seasonal peak of malaria cases during these months15. Malaria morbidity and mortality, with 
special reference to central Sudan, affects all age groups16. . In Sudan it has been found that, 
despite variation between districts, urbanization tends to lead to reduced human malaria 
transmission17. Moreover these results are similar to those of Trape and Zoulani18 in the 
Cango. 
1.3 Clinical Manifestations:  
The most characteristic symptom of malaria is fever. Other common symptoms include chills, 
headache, nausea, and vomiting. Diarrhea, abdominal pain, and cough are occasionally seen. 
As the disease progresses, some patients may develop the classic malaria paroxysm with 
bouts of illness alternating with symptom free periods. The malaria paroxysm comprises 
three successive stages. The first is a 15 to 60 minute cold stage characterized by shivering 
and a feeling of cold. Next comes the 2 to 6 hours hot stage, in which there is fever, 
sometimes reaching 41°C, flushed, dry skin, and often headache, nausea, and vomiting. 
Finally, there is the 2 to 4 hours sweating stage during which the fever drops rapidly and the 
patient sweats. In all types of malaria the periodic febrile response is caused by rupture of 
mature schizonts. In P. vivax and P. ovale malaria, a brood of schizonts matures every 48 
hours, so the periodicity of fever is tertian ("tertian malaria"), whereas in P. malariae disease, 
fever occurs every 72 hours ("quartan malaria").  
The fever in falciparum malaria may occur every 48 hours, but is usually irregular, showing 
no distinct periodicity. These classic fever patterns are usually not seen early in the course of 
malaria, and therefore the absence of periodic, synchronized fevers does not rule out a 
diagnosis of malaria. 
Physical findings in malaria are nonspecific and offer little aid in diagnosis. In many cases 
there may be no positive findings other than fever. Splenomegaly is common but may not be 
apparent early in disease. Hepatomegaly, jaundice, hypotension and abdominal tenderness 
may also be seen.  
A variety of laboratory abnormalities may be seen in a case of uncomplicated malaria. These 
include normochromic, normocytic anemia, thrombocytopenia, leukocytosis or leukopenia, 
hypoglycemia, hyponatremia, elevated liver and renal function tests, proteinuria, and 
laboratory evidence of disseminated intravascular coagulation (although clinically important, 
bleeding is rare). Patients with complicated malaria occasionally show evidence of massive 
intravascular hemolysis with hemoglobinemia and hemoglobinuria.  
If the diagnosis of malaria is missed or delayed, especially with P. falciparum infection, 
potentially fatal complicated malaria may develop. The most frequent and serious 
complications of malaria are cerebral malaria and severe anemia. Cerebral malaria is defined 
as any abnormality of mental status in a person with malaria and has a case fatality rate of 15 
to 50 percent. Other complications include: hyperparasitemia (more than 3 to 5 percent of the 
erythrocytes parasitized); severe hypoglycemia; lactic acidosis; prolonged hyperthermia; 
shock; pulmonary, cardiac, hepatic, or renal dysfunction; seizures; spontaneous bleeding; or 
highoutput diarrhea or vomiting. These manifestations are associated with poor prognosis. 
Persons at increased risk of severe disease from malaria include older persons, children, 
pregnant women, nonimmune persons and those with underlying chronic illness. Other 
complications of malaria infection include gram-negative sepsis, aspiration pneumonia and 
splenic rupture19. 
1.4 Malaria Diagnosis: 
The standard method for detection of Plasmodium in human blood is by microscopical 
examination of Romanovsky-stained thick and thin blood films8. This technique can, when 
used in optimal conditions by a competent microscopist, detect a parasitemia as low as 
0.001% (l0-40 parasites per µl of blood), but it is a time-consuming technique for the 
detection of scanty parasites and often difficult to use accurately to identify mixed infections. 
Several alternative diagnostic methods have been developed in order to reduce the time spent 
examining slides or to enable less-trained personnel to achieve equally reliable results. These 
include fluorescence microscopy20, concentration-techniques such as the Quantitative Buffy 
Coat method (QBC®)21, or immunological ‘methods for the detection of P. falciparum 
antigens such as ParaSight FTM22. These methods have somewhat improved the speed and 
accuracy of individual diagnosis, but at the expense of increased reliance on sophisticated 
equipment and/or much increased cost. Various techniques have been developed, based on 
the detection of malarial deoxyribonucleic acid (DNA), including DNA probes23,24, the 
polymerase chain reaction (PCR)25, and combinations of the PCR and DNA probes26. The 
DNA techniques have the potential advantages of greater sensitivity and the fact that they 
may be used for the detection and identification of the parasite in the vector as well as the 
human host27. While their use for individual diagnosis may be limited, even in reference 
laboratories in the industrialized world, molecular methods have enormous potential for 
epidemiological applications, since they are capable of detecting not only the presence of 
parasites but also of identifying isolate-specific type characteristics28, and they may be used 
to examine the association of mutant genes with anti-malarial drug resistance29. 
PCR is a molecular tool, which revolutionized the epidemiology of malaria, but for case 
diagnosis it is neither practical nor diagnostic in areas where malaria is hyper-endemic, where 
parasite detection in symptomatic cases is not a problem. Parasite detection in early 
symptomatic malaria may be a problem in malaria non-endemic countries or areas of low 
malaria transmission, where low parasitemia is associated with disease manifestations. On the 
other hand the serological diagnosis of current malaria infection by detection of generally 
long-lasting antibodies (Abs) against malaria antigens (Ags) is unreliable30 but it has been 
tried as a crude marker for recent exposure31.  
The ribosomal ribonucleic acid (RNA) genes (rLLX4) have generally proved very useful in 
molecular systematic because they contain a mixture of regions which evolve at different 
rates and hence can be used at different taxonomic levels32. Their structure and function have 
been reviewed in relation to Plasmodium by Waters33. Part of the small subunit ribosomal 
DNA (ssrDNA) was used by Lal et al.,34 to develop oligonucleotide diagnostic probes for the 
4 species of human malaria, but the method involved working with RNA (which is less stable 
than DNA) and radioactively labeled probes25, further developed the method for a PCR 
identification assay, but their approach involved a separate PCR amplification reaction for 
each species-diagnostic pair of primers and there was no control reaction. 
Detection of mixed infections by microscopy is difficult, especially when one of the species 
of Plasmodium is under-represented or if there are more than 2 species involved in the 
infection. In mixed infections of P. malariae and P. falciparum (the most common mixed 
infection in Africa), even when one of the species was under-represented in the sample, the 
SnM-PCR method could detect the mixed infection. When dilutions were made, the double 
infection was still correctly diagnosed even when the species under-represented was reduced 
to the calculated level of 0.01 parasite/µL. In natural infections, it shows that it is possible to 
detect double and triple mixed infection, even in cases where some of the Plasmodium 
species were present at less than one parasite per 100 thick blood film fields. The SnM-PCR 
method is able to detect DNA from considerably less than one parasite per µl of blood, which 
is the validation limit reported for the 4 tubes method35. However, it is likely that the 4 tubes 
method is more sensitive, because it uses a multicopy DNA sequence (ssrDNA), and it is 
possible to detect the merozoite surface protein 1 gene (MSP-1, a single copy gene) at levels 
at least as low as 0.1 parasite per µL of blood36. 
1.5 The Malaria Parasite: 
The malaria parasite was first discovered and described in 1880 by Laveran in Algeria. The 
life cycle and transmission of malaria by mosquitoes was later described by Ross and Grassi 
in 1897- 837. Deployment of electron microscopy had revealed more detailed observations of 
the various stages and species of malaria parasites and enriched the knowledge about the life-
cycle and the fine structure of malaria parasites. With further developments, and the use of 
the immunoelectron microscopy38 information about the subcellular localization of malaria 
antigens and their functions in specific parasite organelles has increased rapidly. The various 
stages of the life cycle of malaria parasites show many common ultrastrucrural features9. 
Plasmodia have arisen from the coccidian stem and share most of the typical features of the 
Apicomplexa13. P. falciparum belongs to the subgenus Laverania, while the remainder belongs 
to the subgenus Plasmodium. The genus Plasmodium consist nearly of 200 named species that 
parasitized reptiles, birds and mammals. Plasmodium belongs to the Apicomplexa, a large and 
complex phylum with about 5000 known species, which are all parasites characterized by 
eponym structure, the apical complex39,40. The microorganisms causing malaria are commonly 
referred to as malaria parasites. This term is restricted to the family Plasmodiidae within the 
order Coccidiida, sub order haemosporidiidea41. 
Over 25 distinct species of malaria parasites of primates have been named; four are the 
recognized malaria parasites of humans, namely: P. falciparum, P. vivax, P. ovale, and P. 
malariae42. The two which almost certainly achieved the widest global distribution are 
Plasmodium vivax and Plasmodium malariae. To the Europeans, these have been known and 
characterized long time ago43,44,45,46 as reviewed by1 as the "benign tertian" (P. vivax) and 
"quartan" (P. malariae) periodic fevers. "Benign tertian" fevers were so named because they 
were not associated with the severe and often fatal manifestations of the "subtertian, 
malignant" periodic fevers (P. falciparum). "Tertian" and "quartan" refers to their 
characteristic feature of an acute febrile episode, or paroxysm, that returns respectively every 
third (P. vivax) or fourth (P. malariae) day. Tertian and quartan fevers are referred to with 
similar frequency in writings from northern Europe through much of the past millennium and 
from around the shores of the Mediterranean Sea from about the 5th century B.C. 
onward44,45,46,47 reviewed by1.  
Today, P. malariae has lost whatever predominance it may once have had and P. vivax and P. 
falciparum are the most commonly encountered malaria parasites. P. vivax is still found 
sporadically in some temperate regions, where in the past it was widely prevalent. It remains, 
however, very common throughout much of the tropics and subtropics. Because of the 
temperature limitations on its transmission by its mosquito vectors, P. falciparum is normally 
present only in tropical, subtropical, and warm temperate regions. In the tropics today, P. 
falciparum remains widely prevalent. 
The fourth human malaria parasite is Plasmodium ovale, which, like P. vivax, is the agent of 
tertian malaria and which, also like P. vivax malaria today, carries a very low risk of fatal 
outcome. P. ovale has the most limited distribution of all the malaria parasites of humans. 
While it is prevalent throughout most of sub-Saharan Africa, it is otherwise known to be 
endemic only in New Guinea and the Philippines48 reviewed by1. 
In P. falciparum malaria, severe and life-threatening conditions commonly arise, it causes the 
most deadly and severe infections, it infects all ages of RBCs, leading to a higher parasitemia, 
mature trophozoites and schizonts are sequestered in the microvascular system leading to 
tissue ischemia and there is widespread drug resistance for it. It associated sometimes with 
serious complications such as, cerebral malaria, severe anemia and others49. It is 
characterized by the tendency of producing a very high density parasitemia, numerous 
clinical manifestations and liability to severe pernicious course of fatal outcome as it 
accounts for 98% of all lethal cases50. The outcome of P. falciparum infection depends on 
several factors. One such factor may be a parasite virulence factor51, which determines the 
course of infection.  
Of the insects that serve as vectors for parasitic diseases, Anopheles species is arguably the 
most important. There are approximately 400 species of Anopheles, about two dozen serve as 
vectors for malaria (Plasmodium spp.) in humans.  Mosquitoes also serve as the vector for 
canine heart worm (Dirofilaria immitis). Six of the seven recognized species in the An. 
gambiae complex occur in Eastern and Southern Africa. Anopheles gambiae and An. 
arabiensis are the major vectors, with An. Arabiensis occurring throughout the region from 
South Africa to Sudan and Egypt, while An. gambiae is prevalent in the tropical belt only. 
The saltwater breeder An. merus is found in mainly coastal areas of Kenya and Tanzania, but 
also far inland in Zimbabwe and South Africa52. 
Female Anopheles mosquitoes seek a blood meal as a protein source for egg production. 
Usually, to lay the first batch of eggs a female mosquito requires 2 or even 3 blood meals, but 
subsequently blood taking and oviposition alternate regular, the duration of the gonotrophic 
cycle, defined as the period between the blood meal and the subsequent oviposition is 
temperature dependent. Under favorable environmental conditions, an anopheles mosquito 
can live for more than 3-4 weeks, but the mean survival in nature is much shorter (6-9 
days)13. 
 
 
1.6 Malaria Life Cycle:  
Malaria parasites are lower eukaryotes, with a genomic complexity which is five times 
greater than that of bacteria, and a complex life-cycle involving both mammalian and 
invertebrate hosts. The parasite has to invade three different types of cells; erythrocytes, 
hepatocytes and mosquito midgut epithelial cells, and need to survive in very different hostile 
environments13. 
A female Anopheles mosquito injects saliva before taking a blood meal. If the salivary glands 
contain malaria sporozoites, these are then injected into the human blood (figure 1.2). After 
approximately 30 minutes in the circulation, the sporozoites reach the liver and invade 
hepatocytes in which they mature during 6-16 days, depending on species. One sporozoite 
develops into approximately 10-30000 merozoites which are released into the blood, where 
they invade red blood cells, grow and multiply asexually into 8-24 merozoites each. When 
mature, the schizonts rupture and the merozoites can then invade new erythrocytes. The 
erythrocytic cycle takes 48 hours for the three common human species, but 72 hours for P. 
malariae. All blood stages are normally found in the peripheral blood, but for P. falciparum, 
the parasites sequester into the deep vascular system during the second half of the cycle. 
Parasites adhere to endothelial cells to escape clearance by the spleen and therefore usually 
not detected in the peripheral blood. 
In the course of the schizogonic cycle (within a red blood cell) some of the merozoites 
become differentiated into sexual forms (the gametocytes); the mechanisms at the basis of 
this differential development are unknown. Gametocytes appear early (approximately from 
the third generation) in infections caused by P. vivax, P .ovale and P. malariae while at least 
10 generation are thought to be required before P. falciparum gametocytes appears in the 
blood, which probably reflect the slow maturation and the sequestration of the immature 
stages in this species13. 
Sexual forms i.e. gametocytes are produced sometimes during the asexual cycle. When a new 
mosquito takes a blood meal containing female and male gametocytes. Sexual reproduction 
commence in the mosquito gut with the development of zygote, ookinete and then oocysts, 
the later can generates up to 1000 sporozoites, which are harbored in the salivary glands and 
can be transmitted at the time of the next blood meal. The life cycle in the mosquito takes 
about 9-16 days and is dependent on conditions such as temperature. 
P. vivax, P. ovale and P. cynomologi have a dormant stage, the hypnosoite53,54 that may 
remain in the liver for weeks or many years before the development of exoerythrocytic 
schizogony. This results in relapse of infection. P. falciparum and P. malariae have no 
persistent phase9. P. malariae can stay undetectable for many years, but it is unclear how and 
where in the host.  
The ring form is the only asexual stage usually identifiable in the peripheral blood of patients 
with P. falciparum infection (gametocytes may be present after the second week of patent 
asexual parasitemia) because more mature stages of this species adhere to the endothelium of 
post-capillary venules in the tissues. In P. vivax and P. ovale, the ring forms have similar 
features, but the cytoplasm may early present amoeboid tendency and traces of stippling start 
to appear in the parasitized erythrocyte. 
 
 
 
Fig (1.2) Malaria Life Cycle 
In these species trophozoites are seen in the peripheral circulation. P. malariae trophozoites 
are regular in shape (except those assuming a characteristic band form across the 
erythrocyte), with a small vacuole, early and abundant pigment, and no stippling.Two types 
of gametocytes are found in the peripheral blood: the female macro-gametocytes and the 
male micro-gametocytes. They can be differentiated by the fact that in the male parasite 
nuclear material is dispersed (preparing to exflagellation) while in the female parasite it is 
condensed13. 
1.7 Malaria Immunity:  
There are two types of clinical immunity against malaria, one which reduces the risk of death 
from malaria and another which reduces the intensity of clinical symptoms. A third type of 
protective antimalarial immunity is antiparasitic immunity, which directly reduces the 
numbers of parasites in an infected individual. These are epidemiological definitions of 
immunity. The actual cellular and molecular mechanisms of immunity may overlap to a 
considerable degree between these categories. The number of malarial inoculations 
experienced, and the intervals between them, are all-important to the malaria immune status 
of an individual1. In the case of acute attacks of P .falciparum malaria, it is possible that a 
degree of immunity to some aspects of severe, life-threatening disease may be achieved after 
only one or two infections55. However, clinical immunity to other, non-life-threatening 
clinical effects of malaria requires more and frequent inoculations of malaria56,57. Effective 
antiparasitic immunity is achieved only after many and more frequent infections58, reviewed 
by1,59. 
1.7.1 Innate immunity: Some individuals are either naturally resistant to malaria 
infection or less likely to develop a severe form of the disease. Innate resistance to infection 
is generally only a partial resistance, and may be linked to the fact that malaria parasites find 
it harder to invade certain types of human erythrocytes. Also, it could be due to the fact that 
certain host erythrocytes have a reduced ability to sustain the growth of parasites13. 
1.7.2 Acquired immunity: The host-parasite relationship has been likened to a 
“molecular arm race”60. In this analogy, the parasite is constantly developing new and 
improved strategies to obliterate the human race. Those individuals who survive this battle 
supposedly produce effective counter-measures that destroy the parasite. In endemic areas, 
most individuals develop an immune response that controls parasite replication but does not 
eliminate parasite from blood. Acquired immunity to malaria develops after repeated 
exposure to the parasite, in individuals living in malaria endemic areas. Immunity is rarely 
sterilizing but protects against high parasite density and clinical disease. 
1.7.3 Strain Specific immunity: 
The long time required to develop protective immunity against malaria may be explained by 
poor immunogenicity of the parasite and/or that immune responses are strain specific. A large 
number of infections would then be required to encounter the whole local repertoire of 
different antigens. 
Early studies of induced malaria indicated that malaria immunity is strain specific. The 
malaria infections were induced to treat neurosyphilis. The natural course of infection and 
transmission could then be studied, and patients were reinfected with homogeneous or 
heterogeneous strains. When homogeneous strains were given, clinical and parasitological 
characteristics were less severe than with heterogeneous strains. If immunity is strain 
specific, clinical episodes should then be caused by new strains not previously encountered 
by the individual. This may however be difficult to study since the repertoire of different 
antigens that an individual has met in endemic areas cannot be identified. New genotypes 
were however detected during clinical episodes in a longitudinal study in Senegal. Another 
way to approach this issue might be serological analyses of polymorphic antigens. However, 
antibodies to two merozoite surface antigens, MSP1 and MSP2, where relatively short lived 
and represented only the ongoing or recent infections37. 
1.8 Antigenic diversity:  
Since the malaria parasites invade three different types of cells (human erythrocytes and 
hepatocytes and mosquito midgut epithelial cells) they need to survive in very different 
hostile environments. In the circumstances, it is not surprising that the antigenic structure of 
the parasite will be radically different from one stage of the life cycle to another. There are 
about 40 major antigens of P. falciparum in sporozoites, pre-erythrocytic schizonts, 
merozoites, erythrocytic schizonts, gametocytes and gametes. 
Many P. falciparum antigens have now been studied by gene cloning and sequencing. 
Comparison of these sequences has shown that there is a high degree of diversity among 
different parasite clones. A major cause of antigenic polymorphisms is variation in the 
sequence of the short tandem repeats that are a prominent characteristic of many malaria 
antigens. More conventional polymorphisms resulting from point mutations have been 
described in antigens with or without repetitive regions. Some examples of the particular 
polymorphisms that characterize the leading asexual blood-stage vaccine candidates are 
summarized below: 
1.8.1 Meozoite Surface Protein-1 (MSP1): 
The merozoite surface protein-1 (MSP1), a large polypeptide 200 KDa, is expressed at the 
surface of the merozoite (Appendix 3). The function of MSP1 is related to invasion of 
erythrocytes since antibodies against MSP1 can inhibit invasion61. The msp1 gene, located on 
chromosome 9, contain 17 discrete blocks, classified as conserved, semi conserved and 
variable depending on the homology at the amino acid level62. The two most highly 
conserved regions, block1 and 17, encode the N- and C- terminal sequences respectively. The 
variable blocks, except four blocks, can all be assigned to two allelic types, K1 and MAD20, 
but through intra-genic recombinat0ion other forms have been found. The block 2 which is 
the most polymorphic region of msp1 contains tripeptide repeats, which vary in number and 
sequence between different isolates63. It can be one of three allelic types/families: K1-, 
MAD20-and RO33- types. Block2 of RO33 form, unlike that of K1 and MAD20, lacks the 
N-terminal tripeptide repeats and was previously described as a rare type in culture 
collection64. The variable blocks are flanked by highly conserved regions. The msp1 gene has 
high sequence diversity. MSP119 (corresponding to block 17) and MSP1-block 2 has been 
found to targets for protective immunity in many studies and are therefore considered 
potential vaccine candidate antigens. A fragment of MSP1 was included in the Spf66 
vaccine37.   
The sequence polymorphism is true of the molecule as a whole, however, in the block two 
region, extensive sequence diversity exists. Over 50 different sequences have been identified 
in block 2, which fall into three main types represented by variants of the K1, MAD20 and 
RO33 isolates. Block2 sequences of the K1–like and MAD20–like types contain variable tri–
or hexa peptide repeats, whereas block2 of the RO33 type contain a non-repetitive sequence, 
which varies only little. The 19 KDa fragment appears to confer immunity in monkeys and in 
some epidemiological studies were found to be associated with protective immunity in 
humans. 
 
 
1.8.2 Meozoite Surface Protein-2 (MSP2): 
The merozoite surface protein 2 (MSP2), denoted as MSA-2 or GP3 by different researchers. 
It is a smaller polypeptide, with a molecular weight of 45Kda, which is not processed during 
parasite maturation (Appendix 4), but like MSP1, appeared to be anchored in the merozoite 
membrane by a glycocylphosphatidylinositol moiety65. The msp2 gene is located on 
chromosome 2 and is composed of 5 blocks of which the central block 3 is the most 
polymorphic. The msp2 alleles can be grouped according to two allelic types/families, FC27 
and IC1/3D7 according to the dimorphic structure of the central variable non-repetitive 
region66,67. The extensive diversity is due to the allele-specific sequences in the central 
region, which comprises tandem repeats of varying size. Difference in the number of copies 
of these repeats will result in length polymorphism. These characteristics of msp2 have been 
exploited by several genotyping methods. Common to all methods of msp2 genotyping is a 
polymerase chain reaction (PCR) amplification of a central part of the msp2 gene which 
comprises the allele-specific repetitive region and conserved flanking sequences68. 
The major methods used for msp2 genotyping are: (i) analysis of size polymorphism with 
subsequent hybridization with family-specific probes69,70,71,72, or (ii) restriction fragment 
polymorphism (RFLP) of the amplified product73. The msp2 gene has been used extensively 
as polymorphic marker gene in field studies showed extensive polymorphism at this locus, 
even in areas of low endemicity68. 
The use of msp2 as marker has proven to be of great use when individual Plasmodium 
falciparum infections need to be identified. PCR-RFLP genotyping of parasites for msp2 
makes it possible to distinguish the individual parasite infections concurrently present in a 
blood sample. The possibility of tracing individual parasite clones over time allows detailed 
studies of infection dynamics. In immunological studies, genotyping can also provide 
important information on the diversity of antigenic challenge. Most importantly, genotyping 
makes it possible to determine the multiplicity of infection, which can be used as an outcome 
measurement of interventions such as drug trials, vaccine trials, or exposure-reducing 
interventions68. 
The msp2 is not only an extremely polymorphic marker gene, but its product is also a vaccine 
candidate. MSP2, as part of a subunit vaccine, is currently under field trial in Papua New 
Guinea (PNG)74. Two genotyping studies from PNG have already shown that the two allelic 
families of msp2 are differently associated with morbidity75,76. 
Hybrids between FC27 and IC/3D7 have been found in the field isolates77 but intra-genic 
recombination between the two allelic families appears to be rare78. In four epidemiological 
studies, with about 3500 infections analyzed by PCR-RFLP, 82 different msp2 alleles were 
found, of which 41 were FC27-types and 41 were 3D7-types68. 
The MSP2 protein exhibits considerable sequence diversity65,79,80 and this diversity translates 
into antigenic polymorphism80,81,82. The single copy gene encoding this antigen contains 
highly conserved N- and C-terminal regions which flank a central polymorphic region. This 
central region contains two segments of tandem repeats, which vary in number, length and 
sequence in different alleles65,83. The blocks of repeats are flanked by non-repetitive variable 
regions, which can be used to define two allelic families designated the IC1 type (serogroup 
A) and the FC27 type (or serogroup B)66,79,80. These two groups, which are defined by 
distinct sequences flanking the central repeat region, also differ with respect to their central 
repeats. The central repetitive region consists of one or more 32 amino-acid repeats, which 
occur as two tandemly repeated units in FC27 and as a single copy in the P. falciparum strain 
IC166,83, followed by one or more copies of a 12 amino-acid repeat. Members of the IC1/3D7 
CAMP (serogroup A) allelic family are characterized by shorter sequence repeats (4-8 
residues) and can be sub grouped both according to repeat type and number and also 
according to the presence or absence of short sequence stretches within the 3 non repetitive 
variable region84. 21 alleles of MSA-2 have been derived from isolates of different 
geographic regions and have been sequenced85. 
1.8.3 Glutamate Rich Protein (GLURP): 
The glutamate rich protein (GLURP), of 220 KDa, is a soluble antigen which is released 
during schizont rupture but can be detected in all stages of the parasite i.e. the hepatic, 
asexual and sexual stages (Appendix 5)86. The gene is located on chromosome 10 and has 
two repeat regions, which are moderately polymorphic. High level of IgG antibodies in older 
children has been associated with clinical protection87. It contains 22% glutamate residues 
and includes two repeat regions, R1 and R2. The R1 region consist of 6 repeat units, each 
contain 15 or 16 amino-acid residues and 2 repeat units of 50 amino–acid residues. These 
repeat units of R1 are poorly conserved along the gene. R2 region consists of 14 repeat units, 
each composed of 19 or 20 residues, and 11 of which are well conserved along the gene. At 
the N-terminal end of glurp there is a 32 amino-acid residue segments that may represent a 
single sequence. PCR analysis of R2 region has shown considerable size polymorphism of 
different alleles in different P. falciparum isolates86. 
1.8.4 Microsatellite markers: 
Microsatellite (MS) markers are simple sequence repeats that have been found in every 
eukaryotic study88, although their density varies among species. In P. falciparum, markers 
generated from these repeats are often polymorphic with variable length in different parasite 
clones. Consequently MS markers exhibit multiple alleles in general populations and are very 
informative for genetic studies89. The advantages of MS markers include their general 
omnipresence and the ease with which they can be scored. MS typing is based on PCR and 
requires only small amount of DNA. Moreover the process of genotyping can be automated, 
and multiple markers can be assayed by multiplexing PCR and labeling PCR products with 
different florescent dyes90. 
The P. falciparum genome is rich with microsatellites mostly (TA)n or (T or A)n, where n is 
typically between 10 and 30, occurring at a frequency of about one per kilobase genome-
wide91,92. The abundance of microsatellite markers in P. falciparum genome has facilitated 
the development of linkage map, laying the foundation for identification and characterization 
of P. falciparum functional genes. 
1.9 Genetic diversity in malaria parasites: 
All the evidences are indicating the enormous genetic diversity of P. falciparum in a given 
parasite population in malaria hyperendemic regions77,93,94,95,96, however, low parasite 
diversity was reported, mainly from areas of low transmission97,98,99,100. Thus, the extensive 
polymorphism of the parasite antigens is not surprisingly; however, it is accused for the delay 
in the naturally acquired immunity and for the redundancy in the vaccine development. The 
differences between parasites with regard to; enzymes101 antigens102, other proteins103, and 
response to drugs104, is well documented.  
Molecular characterization of different P. falciparum antigens has shown extensive 
polymorphism94. In high-transmission area, parasite population diversity is highly complex 
and dynamic. Recombination during the sexual stage of the parasite in the anopheles 
mosquito is believed to generate this diversity105,106. 
The genetic diversity of P. falciparum may be limited by two variables in a natural 
population: Firstly by the number of frequencies of different alleles present in the population, 
and secondly by the frequency of genetically mixed infections since this only offer the 
possibility of cross fertilization in the mosquito vector81. The role of age and acquired 
immunity were highlighted in many studies, but indirectly are indices for transmission 
intensity. The phenomenon of clone fluctuation, which consists of kinetic changes in the 
relative load of each parasite subpopulation present in blood107,108, is another aspect of 
genetic diversity. Serotyping with monoclonal antibodies was used to estimate the number 
and frequencies of allelic variants of two merozoite surface proteins (MSP1 and MSP2) and 
the exported protein Exp1 in P. falciparum in an urban region of the Gambia, results showed 
that the combination among unlike loci is a common consequence of sexual reproduction of 
P. falciparum. The use of the polymerase chain reaction (PCR) amplification of 
deoxyribonucleic acid (DNA), for the detection of the genetic polymorphism in malaria 
parasite, has expanded the understanding of the parasites natural genetic diversity originally 
characterized by protein electrophoresis109,110. 
High genetic diversity has been found in the population of the malaria parasite, P. 
falciparum77,93,95,111                                                                                                                                                                          11. 
High diversity increases the risk that an individual is infected with different parasite 
genotypes. Such infections are generally described as complex or multiple infections. The 
phenomenon of clone fluctuation, which consists of kinetic changes in the relative load of 
each parasite subpopulation present in blood107,108. 
Studies in Tanzania112,113 and in Papua New Guinea76 have suggested that multiple infections 
can protect against clinical malaria attacks in partially immune children, presumably as a 
result of immunological cross-reaction against superinfecting parasites. This protection is not 
evident in very young; immunological relatively naive hosts68. 
In areas highly endemic for malaria, many individuals are infected simultaneously with 
several P. falciparum clones. The term multiplicity of infection (MOI) has been used to 
describe the number of concurrent infections per carrier. . Multiplicity of infection, also 
termed as complexity of infection (COI), is determined by genotyping of a highly 
polymorphic marker genes and it reflects the minimal number of different genotypes 
detected17. In areas of high endemicity, multiplicity depends on the age of the host71,114 and 
on the transmission intensity115. In Idete, Tanzania, mean MOI in asymptomatic children 
aged 3-7 years was five infections per carrier116. In contrast, in children aged less than one 
year in the same village, mean multiplicity was only two infections per child117. 
A number of studies have found relationships between MOI and the risk of malaria 
morbidity. Several studies of partially immune children have found that multiple malaria 
infections are associated with reduced incidence of clinical episodes of P. falciparum76,116,118. 
A study in Sao Tome found that the apparent protection extended also to non-malaria fever 
episodes119. Other studies, such as those of infants in Idete114,117, of children aged less than 
three years in western Kenya120, of children in Ghana121 and of individuals in relatively low 
transmission settings in the Sudan15 and Mozambique (Mayor et al., 2003) 122 have found that 
multiple infections were a risk factor for clinical malaria attacks. 
A series of epidemiological studies in Senegal, Tanzania and Papua New Guinea has 
indicated the importance of multiplicity of infection36,71,76,116. These studies established that: 
firstly, the multiplicity of infection within a host appears to depend not only on exposure but 
also on age; secondly, multiplicity can reach high levels; thirdly, multiplicity of infection can 
be positively associated with protection against mild episodes of malaria. In older children, a 
high multiplicity of P. falciparum infection is the feature of chronic, low level parasitemia. 
This in turn appears to confer cross-protection against newly inoculated parasites based on 
partially genotype-specific response, that might last only a little longer than the infection 
itself123. 
Current molecular studies on malaria parasite have been directed towards identifying 
functional genes, such as genes controlling response to drugs and malaria vaccines candidate 
genes. Most of these genes encode polypeptides that are found to be polymorphic, and their 
alleles can be distinguished by regions containing variable numbers of tandemly repeated 
codons as well as sequence variations. One of the most commonly used markers for the 
genotyping of P. falciparum populations is the gene coding for the merozoite surface protein2 
(msp2). This has been considered a suitable marker as it exhibits a large degree of 
polymorphism, both in length and sequence71,85. 
Molecular techniques have proven to be powerful in revealing such polymorphism. This 
includes relative differences in mobilities of PCR-amplified fragments, following 
electrophoresis. This is in addition to the sequence specific amplification by use of restriction 
fragment length polymorphism (RFLP) in the amplified product, blotting and hybridization of 
PCR products with allele-specific probes and direct sequencing of the amplified products.  
The recombination during the sexual life of the parasite in the mosquito is believed to be a 
major source for diversity105,106. Heterozygous recombination, which occurs during meiosis, 
is one mechanism for generating genetic diversity. The rate, at which such recombination 
occurs, defines the genetic structure of the parasite population and can influence the ability of 
the parasite to respond to selection pressure124. Population dynamic studies, which consider 
genetic heterogeneity of P. falciparum, have shown fluctuations of different serotypes in 
space and time. The host immune response appears to play an important role in generating 
these dynamics. Children are often subject to concurrent infections with numerous diverse 
parasite strains71,125. Longitudinal variations in parasite populations within individuals have 
been demonstrated when observed over weeks107,126. 
The malaria genome has shown extensive polymorphism, the arrangement and composition 
of the subtelomeric blocks suggests frequent recombination between the telomeres. Many 
genes coding for antigens are located near the chromosome ends, i.e. the most labile regions, 
this might be a way to generate new antigenic variants and thereby evading immunity. The 
crossing experiments have shown that intragenic recombination occurs between different 
alleles during meiosis127.  
The daily dynamics of P. falciparum subpopulations were investigated in asymptomatic 
children in Tanzania. In children harboring chronic parasitemia, infections were found to be 
highly complex with daily changes in both parasite density and genotypic pattern suggesting 
that these infections consist of inherently synchronous subpopulations of parasites108. P. 
falciparum has a number of polymorphic antigens, only single copies of genes encoding these 
antigens have been found in the haploid genome94,128. 
As most polymorphic antigens lie on different chromosomes, novel genotypes can be created 
by independent assortment of chromosomes, as well as by crossing over during meiosis124. 
Two distinct terms were brought into the discussion of resistance to malaria, firstly, semi" 
immunity, referring to a situation of acquired immunity as consequence of continual exposure 
controlling infection and leading to low level chronic parasitemia, but clearing the 
infections129. The second is, premunition describing protection against superinfection results 
from existing infection130.  
1.10 Malaria chemotherapy and parasite resistance: 
The use of chemotherapy is important in alleviating the suffering and reducing the mortality 
caused by the disease. The action of antimalarial drugs lies in their effect on the metabolic 
process or the vital structure of the parasite which lead to the disruption of its activity and 
then to death. However the efficacy of the drug depends also on the species and strain of the 
parasite and its sensitivity towards a given drug, as well as the stage of the immunity and the 
specific protective forces of the body131. 
Patients successfully treated with antimalarial drugs may thus be healthy but may infective 
for up to two months until the P. falciparum gametocytes die off naturally, or until another 
drug such as primaquine is given to eliminate the mature gametocytes13. Hereunder are an 
example of drugs commonly used in malaria chemotherapy, they are also in common use in 
our study sites, and we used them in this study.   
1.10.1 4,8-aminoquinoline drugs: 
Such as chloroquine, amodiaquine, and primaquine. Chloroquine is a 4-aminoquinoline that 
has marked and rapid schizonticidal activity against all infections of P. malariae and P. ovale 
and against chloroquine-sensitive infections of P. falciparum and P. vivax. It is also 
gametocytocidal against P. vivax, P. malariae and P. ovale as well as immature gametocytes 
of P. falciparum. It is not active against intrahepatic forms, and should therefore be used with 
primaquine to effect radical cure of P. vivax and P. ovale .It was the most important 
antimalarial for more than 40 years because of its activity against the four plasmodia that 
infect human132. In addition, chloroquine is the only antimalarial known to be safe for 
children and pregnant women133,134. However, the value of chloroquine has been severely 
compromised by the spread of chloroquine–resistant strains of P. falciparum, which are now 
prevalent in Southeast Asia, South and Central America, and sub-Saharan Africa135,136. Thus 
although chloroquine remains safe, chloroquine resistance has increased the morbidity and 
mortality of malaria137 and has led to the wide spread use of alternative antimalarial drugs. 
1.10.2 Antifolate drugs: 
The only useful combinations of antifolate drugs for the treatment of malaria are synergistic 
mixtures that act against the parasite-specific enzymes, dihydropteroate synthetase and 
dihydrofolate reductase. Available combinations include the sulfa drug-pyrimethamine 
combinations sulfadoxine-pyrimethamine and sulfalene-pyrimethamine, the former being 
more widely available. Cotrimoxazole, the co-formulated combination of sulfamethoxazole 
and trimethoprim, has weak antimalarial properties because trimethoprim has a much lower 
affinity than pyrimethamine for the parasite dihydrofolate reductase enzyme138. 
Cotrimoxazole should not be used for the treatment of malaria. The use of sulfa drug 
pyrimethamine combinations for chemoprophylaxis is no longer recommended because of the 
risk of severe skin reactions. 
Antifolate drugs such as pyrimethamine and proguanil are slow blood schizonticides but they 
have the advantage that they are effective in smaller doses, safe and free from side effects. 
The ability of sulfa (sulfonamides and sulfones) to show potentiating effect with proguanil or 
pyrimethamine139,140,141,142 suggested that combination of these two groups of drugs would 
not only be more effective antimalarial agent, but would also delay, if not avoid, the 
development of resistance. The most commonly used combination is that of sulfonamide, 
sulfadoxine, and pyrimethamine (fansidar), which has been particularly effective in areas 
such as Africa where chloroquine resistance is now wide spreading104. However, resistance to 
the pyrimethamine sulfadoxine combination became widespread and the successive failure of 
these two drugs in Africa was described in 1998 as malaria disaster143. 
1.10.3 Quinine: 
It is normally effective against falciparum infections that are resistant to chloroquine and 
sulfa drug-pyrimethamine combinations. Decreasing sensitivity to quinine has been detected 
in areas of South-East Asia where it has been extensively used for malaria therapy. This has 
occurred particularly when therapy was given in an unsupervised and ambulatory setting with 
regimens longer than 3 days. In these settings, patient adherence to therapy is low, leading to 
incomplete treatment; this may have led to the selection of resistant parasites. There is some 
cross-resistance between quinine and mefloquine, suggesting that the wide use of quinine in 
Thailand might have influenced the development of resistance to mefloquine in that 
country144. Strains of P. falciparum from Africa are generally highly sensitive to quinine. 
Quinine, for various reasons is not in use for treatment of mild to moderate malaria145. There 
are other chemically related drugs to quinine such as mefloquine, lumefantrine, halofantrine, 
quinidine and quinimax. 
1.10.4 Artemisinin and its derivatives: 
Artemisinin is poorly soluble in oils or water but the parent compound has yielded 
dihydroartemisinin, the oil-soluble derivatives artemether and arteether, and the more water-
soluble derivatives sodium artesunate and artelinic acid. These derivatives have more potent 
blood schizonticidal activity than the parent compound and are the most rapidly effective 
antimalarial drugs known. They are used for the treatment of severe and uncomplicated 
malaria146. They are not hypnozoiticidal but gametocytocidal activity has been observed147. 
These compounds are not recommended for use in the treatment of malaria due to P. vivax, P. 
malariae or P. ovale since other effective antimalarial drugs are available for this purpose.  
1.10.5 Combination therapy to combat the spread of drug resistance: 
Combination therapy (CT) is defined as “the simultaneous use of two or more antimalarial 
drugs with different biochemical targets in the parasite or in tissue hosting the parasite, which 
are synergistic, additive or complementary in their effect”. Using this definition, two or more 
drugs which have the same biochemical target in the parasite such as SP, chlorproguanil-
dapsone, atovaquone-proguanil are not considered CT. Similarly, an antimalarial which is 
coadministered with a non-antimalarial drug which enhances its action is also not classified 
as CT. Suffice to say that CT therefore can be either fixed combinations, where all 
components are coformulated in a single tablet/capsule or free combinations where the 
components are in separate tablets/capsules but are coadministered148. 
Due to the rapid emergence and spread of resistance to almost all available antimalarial 
drugs, much of interest has been focused upon the use of drugs in combination. The 
underlying science behind the therapeutic effect of the combinations that include an 
artemisinin derivative is that the artemisinin rapidly kills most of the parasites and then those 
that remain are killed by the companion drug149. 
In sub-Saharan Africa, the first two combinations to be considered on a larger scale were 
pyrimethamine/sulfadoxine plus chloroquine and pyrimethamine/sulfadoxine plus 
amodiaquine150. Recently interest has been directed towards the use of drugs in combination 
with artesunate in purpose of delaying the emergence of resistance151. The antifolate product 
proguanil has been formulated together with a new type of inhibitor, atovaquone, to yield 
malarone, recently licensed for clinical use152. Several other combination regimens are 
undergoing field testing, especially in Africa to find out which would be the most effective 
and appropriate for a given endemic region153. 
1.10.6 Definition of Parasite Resistance: 
The term “parasite resistance” has been used with different meanings. It has been defined as 
“the ability of a parasite strain to survive and/or multiply despite the administration and 
absorption of a drug in doses equal to or higher than those usually recommended but within 
the limits of tolerance of the subject”154,155. This definition was subsequently modified to 
specify that “the drug must gain access to the parasite or the infected red blood cell for the 
duration of the time necessary for the normal action of the drug”156. Despite this 
modification, the term “parasite resistance” has been used interchangeably in the published 
literature when referring to the parasite phenotype characterized in vitro by the confirmed 
ability to survive a threshold (nanomolar) concentration of the drug under standard conditions 
of continuous culture. Resistance has also been used when referring to therapeutic failure 
after administration of a standard dose of a drug; this definition is used in the WHO standard 
in vivo test protocol157. However, in this test, serum drug levels are not normally measured 
and the observed therapeutic failure might be due to malabsorption, rapid or abnormal 
metabolism, or the presence of latent infections other than malaria. Therefore, it is important 
to define the terms being used in order to avoid confusion. 
Although the definition of resistance in vitro more accurately reflects biological resistance to 
the drug, true parasite resistance requires a demonstration of the ability of parasites to survive 
in vivo in the presence of an adequate therapeutic concentration of the drug in serum. When 
serum drug concentrations are not measured, the in vivo therapeutic failure data should be 
interpreted with caution since these might overestimate the true parasite resistance; this is 
particularly true for slowly acting or long-acting drugs such as SP and mefloquine. 
1.10.7 Malaria Parasite Resistance: 
The escalation in P. falciparum malaria morbidity and mortality in recent years is attributed 
to the parasite resistance to the affordable drugs, chloroquine (CQ) and 
sulfadoxine/pyrimethamine (SP)158,159,160. The resistance has propagated and upsurge in the 
last 20 to 25 years in sub-Saharan Africa143,161.  
Although, the increment in malaria morbidity is beyond doubt, we believe that the rise in 
mortality due to resistance is doubtful, as the resistance-virulence relationship is not 
harmonized, and it is possibly in an opposing relation162. As yet, no solid clinical data, or 
appropriate laboratory investigation confirmed the increased virulence of mutant isolates. The 
fitness of mutant parasites was brought to light by a series of recent publications, discussed 
the evolution of drug resistance and parasite population genetics163,164,165,166. 
Despite the relatively recent introduction of SP as a first line for malaria treatment it is 
efficacy has been eroded dramatically in many malaria endemic regions, for example in east 
Africa, alarming levels of P. falciparum treatment failures to SP have been recorded167. 
However, investigation of SP resistance is important for many reasons; it is still in wide use 
as monotherapy or as a component of combination therapy (in the Sudan SP is used with 
artesunate), the clinical and molecular link between CQ and SP resistance168,169 and the 
unique association between SP treatment and resistance with gametogenesis170,171. 
Furthermore, historically, it was mentioned that SP resistance has evolved more rapidly in 
areas of low transmission172, which mimic the situation in eastern Sudan. 
The sulfadoxine-pyrimethamine drug combination is widely used in malaria-endemic 
countries in sub-Saharan Africa as a first-line drug to treat uncomplicated Plasmodium 
falciparum malaria and has replaced chloroquine in many endemic countries due to 
widespread resistance. Despite the relatively recent introduction of SP into, for example, east 
Africa, alarming levels of P. falciparum treatment failures to SP have been recorded in the 
region. The continuous monitoring of resistance to SP and other antimalarial drugs is 
therefore of major importance for rational decisions regarding future treatment guidelines. 
The reduction of malaria-attributable mortality depends on accurate and early diagnosis 
followed by prompt treatment with effective drugs (the choice of which depends on 
knowledge of the antimalarial sensitivity profile of the local strains of P. falciparum). During 
the last 50 years, the development and spread of resistance in P. falciparum, to most of the 
drugs used in the first-line prevention and treatment of malaria, has given reason for great 
concern, especially in the continued absence of very effective vaccines173,174. 
Various factors relating to drug, parasite and human host interactions contribute to the 
development and spread of drug resistance. The molecular mechanism of drug action is a 
critical element in the speed at which resistance develops. In addition, drugs with a long 
terminal elimination half-life enhance the development of resistance, particularly in areas of 
high transmission. Similarly, increased drug pressure is a significant contributor to drug 
resistance. As increased amounts of a drug are used, the likelihood that parasites will be 
exposed to inadequate drug levels rises and resistant mutants are more readily selected175. 
Parasite factors associated with resistance include the Plasmodium species concerned, the 
intensity of transmission and the widespread and/or irrational use of antimalarial drugs. The 
role of host immunity in propagating resistance is unclear. However, immunity acts 
synergistically with chemotherapy and can enhance therapeutic effects and even parasite 
clearance of drug-resistant infections. The role of immunity in clearance of drug resistant 
parasites was shown before in Mali, an area hyperendemic for malaria, where age was used 
as a surrogate marker for immunity176. However, it is tempting to know the efficacy of 
immunity in drug-resistant parasite clearance in semi-immune population living in an area of 
moderate to low malaria transmission. Previously, study in eastern Sudan showed that risk of 
clinical malaria infection reduced to the half by the age of twenty years, while the disease 
affects all age groups16, that indicate acquisition of some sort of immunity after the age of 
twenty. 
Resistance to antimalarial drugs arises as a result of spontaneously-occurring mutations that 
affect the structure and activity at the molecular level of the drug target in the malaria parasite 
or affect the access of the drug to that target104. Mutant parasites are selected if antimalarial 
drug concentrations are sufficient to inhibit multiplication of susceptible parasites but are 
inadequate to inhibit the mutants, a phenomenon known as "drug selection"177,178. This 
selection is thought to be enhanced by subtherapeutic plasma drug levels and by a flat dose-
response curve to the drug. 
Combinations of single nucleotide polymorphisms (SNPs) in the dihydrofolate reductase 
(dhfr) gene at codons 51, 59, 108 and 164 and the dihydropteroate synthetase (dhps) gene at 
codons 436, 437, 540, 581, and 613 correlate with P. falciparum resistance to SP in 
vivo179,180. There are evidences that the dhfr triple mutations with or without the dhps 
mutations can predict SP resistance (SPR), studies conducted in East Africa have showed that 
the triple (dhfr Asn-108, Ile-51, and Arg-59) mutant genotype was associated with SPR181,182. 
However, in another study conducted in Malawi, it was found that the quintuple mutant 
genotype (dhfr Asn-108, Ile-51, and Arg-59 plus dhps Gly-437 and Glu-540) was more 
strongly associated with SP treatment failure than was the dhfr triple mutant180.  
Mutant parasites are selected if anti-malarial drug concentrations are sufficient to inhibit 
multiplication of susceptible parasites but are inadequate to inhibit the mutants, a 
phenomenon known as "drug selection"177,178. This selection is thought to be enhanced by 
sub-therapeutic plasma drug levels and by a flat dose-response curve to the drug. 
Although elimination of the asexual stages of Plasmodium falciparum is the focus of 
treatment of individual symptomatic patients, at a population level, reducing the carriage of 
gametocytes - the sexual stage responsible for infection of the mosquito vector - is necessary 
to limit the transmission of malaria parasites and the spread of anti-malarial resistance. The 
factors that trigger and regulate the switch from asexual to sexual development of the malaria 
parasite remain largely mysterious, but may involve both genetic mechanisms183, and 
environmental mechanisms184. In relation to SP treatment, the gametocyte carriage and 
infectivity to mosquitoes was found to be consistently higher in patients infected with drug 
resistant compared with drug sensitive malaria parasites185.  
The ambiguity in the association between the in-vivo response and the prevalence of the 
molecular markers, as the later is always higher, is attributed to many factors of which the 
most important is the host immunity. However, other factors include micronutrients, 
bioavailability and pharmacokinetics, in addition to the complexity of data analysis186 need to 
be considered. The term, genotype-resistance index (GRI) was suggested to encounter for the 
confounding factors mainly immunity, it is calculated by dividing the prevalence of resistant 
genotype by prevalence of in-vivo resistance and it was found to be varying from place to 
another. In Mali, for CQ resistance and pfcrt, the GRI values felled between 1.6 and 2.8 in 
different sites over 3 years187. 
In this study, we planed to estimate the prevalence of and the linkage between the individual 
dhfr and dhps mutations and the association between the mutations and the response to SP 
treatment (in-vivo). Furthermore, we wanted to investigate the relation between these 
mutations and the parasite fitness in term of, in-vivo parasite growth and gametocytogenesis. 
It is worth to mention that we are benefiting from a unique setting that well suits our 
objectives, of the credits of this study are; been a village-based whole population study, low 
transmission rate with minimal overlap of infections, and the relative homogeneity of the 
study populations. 
1.10.8 Evolution of antimalarial drug resistance: 
Drug resistance in malaria is considered to result from spontaneous gene point mutations, a 
process though to be independent from drug pressure, followed by the selection of the more 
resistant mutants under drug pressure174. Evidence from field and theoretical studies indicate 
that resistance continues to spread as long as there is any drug pressure, and that beyond a 
certain frequency, the rate of spread is very rapid188,189,190. 
A number of models were suggested for the evolution of drug resistance, except for the role 
of the drug selective pressure, these models are not consistent and the predictions obtained 
are contradictory. Various factors have been considered in these models include the degree of 
drug use, the drug elimination half-life, and host heterogeneity191, parasite biomass192,193. 
That in addition to the malaria transmission intensity194 and its proxy factors such as the 
number of parasite clones in a single infection (clone multiplicity), the immunity of hosts, 
and intrahost dynamics195. 
1.10.9 Methods for Monitoring Parasite Resistance: 
Several methods for monitoring antimalarial drug resistance exist; they include in vivo and in 
vitro tests and, more recently, molecular markers. 
1.10.9.1 The in-vivo tests: 
Are traditionally the “gold standard” methods for detecting drug resistance196. The advantage 
of the in vivo tests over the in vitro assays is that they can be conducted in the field with little 
equipment and personnel and the results are easy to interpret. They reflect the true biological 
nature of treatment response, which involves a complex interaction between the parasites, the 
drugs, and the host response, while in vitro tests measure only the interaction between the 
parasites and the drugs.  
1.10.9.2 The in-vitro tests: 
Are based on the inhibition of the growth and development of malaria parasites by different 
concentrations of a given drug relative to drug-free controls. The WHO in vitro microtest is 
based on counting the parasites developing into schizonts, while the isotopic microtest is 
based on measurement of the quantity of radiolabeled hypoxanthine, a DNA precursor, 
incorporated into the parasites197. There are newer colorimetric tests that can test low 
parasitemias taken directly from patients in the field: the parasite lactate dehydrogenase 
enzymatic assay198, the parasite lactate dehydrogenase double-site enzyme-linked 
immunodetection assay199 and the histidine-rich protein II assay200. However, because of the 
limited amount of data published, it is still unclear whether these new tests will replace the 
traditional (micro and isotopic) tests. In the latter, drug resistance is identified when parasite 
growth occurs above a threshold concentration. 
1.10.9.3 Drug resistant genes: 
1.10.9.3.1 Genes implicated in resistance to chloroquine: 
There has been a prolonged search for the genetic and biochemical basis of resistance to 
chloroquine. Several genes encoding candidate proteins, suggested being involved in the 
transport of chloroquine into or out of the digestive vacuole, have been proposed over the 
past decade. P. falciparum multi-drug resistance gene (pfmdr1)201,202 a candidate gene 
(Cg2)136 and the chloroquine resistance transporter gene (pfcrt)203. 
pfmdr1: Two genes pfmdr1 and pfmdr2, homologue of human mdr-type gene were initially 
identified202,204. Later pfmdr2 gene expression levels were found to be unchanged between 
resistant and sensitive P. falciparum parasites205,206 and no polymorphism has been observed 
between them207. So pfmdr2 was excluded as candidate gene. However, polymorphism in 
pfmdr1 gene was found to be strongly linked to chloroquine resistance in a number of P. 
falciparum parasites201. pfmdr1 is localized in chromosome 5 in P. falciparum and it consists 
of continuous open reading frame of 4257 nucleotides204. It encodes a 162 KDa polypeptide, 
which has been named P-glycoprotein homologue1 (Pgh1)208. Pgh1 is expressed in the 
membrane of the parasites digestive food vacuole throughout all sexual stages in the life 
cycle208. It has been suggested that, resistance could be due to amplification of pfmdr1 
allowing more gene product to be expressed202 or to mutation in pfmdr1 causing alteration in 
transport by the encoded P-glycoprotein201. A key amino acid substitution (Tyrosine to 
Asparagine) at position 86 has been suggested to be involved in chloroquine resistance201. 
However this was not always evident in subsequent surveys208,209,210.  
A clear evidence against the involvement of this gene in resistance was shown in genetic 
cross experiment between the resistant clone Dd2 and the sensitive one HB3, in which the 
Dd2 allele of the pfmdr1 did not co segregate with resistance phenotype211. More field studies 
have found no significant association between allelic variants or level of expression of 
pfmdr1 and chloroquine resistance210,212,213,214,215 suggesting that there can be no simple 
association between mutations in the pfmdr1 gene and the degree of chloroquine susceptibly. 
However, transfection work indicated that one allele of the pfmdr1 plays a role in modulating 
the level of chloroquine response. The resistant pfmdr1 allele of the P. falciparum 7G8 was 
replaced by a sensitive form containing codons determining amino acids Ser 1034, Asn 1042 
and Asp 1246216. Results showed that the transfectants accumulated nearly twice the level of 
chloroquine of that of the original 7G8 isolate. 
In general, work on pfmdr1 showed that mutations or increased expression of this gene might 
be important for the modulation of chloroquine response observed in some parasite isolates 
and laboratory clones. 
Cg2: The analysis of a genetic cross between two cloned parasite populations, Dd2 
(chloroquine resistant parasite) and HB3 (chloroquine sensitive parasite) had shown that a 
region of 400 Kb locus on chromosome 7 segregated with chloroquine resistance in P. 
falciparum217. Subsequent genetic mapping on this 400 Kb segment using RFLP217,218 and 
microsatellite markers219 has localized a key gene to a region of about 36 Kb on chromosome 
7. Analysis of polymorphism within this region indicated an association of a gene candidate 
(Cg2) with chloroquine resistance136. Few field studies have been done in the involvement of 
Cg2 in chloroquine resistance. It appears that polymorphism in this gene are represented 
differentially in chloroquine sensitive and chloroquine-resistant P. falciparum parasites220,221. 
However, transfection studies, replacing alleles of this gene in resistant parasites by their 
counterparts from sensitive parasites, showed that they had no effect on chloroquine response 
of the transformed parasites203. 
pfcrt: Further transcriptional analysis of the DNA sequences near the Cg2 gene has 
identified the pfcrt gene203. The coding region of this gene spans 3.1 Kb in 13 exons ranging 
in size from 45-269 bp. This gene encodes a transmembrane protein in the digestive vacuoles 
of malaria parasite.  pfcrt gene was found to segregate perfectly with chloroquine resistance 
among field isolate of P. falciparum polymorphism in this gene showed complete linkage to 
the chloroquine resistant phenotype in 40 strains examined203. Sets of point mutations in pfcrt 
were associated with chloroquine resistance in vitro in laboratory lines of P. falciparum from 
Africa, South America and Southeast Asia203. Chloroquine resistant parasites from Africa and 
Southeast Asia carry point mutations at codons 74, 75, 76, 220, 271, 326, and 371, whereas 
South America parasites carry mutations at codons 76, 220 and either 72, 326 and 356, or 75, 
97 and 371. Only one mutation, the substitution of threonine for lysine at position 76 (K76T) 
was present in all resistant isolates and absent from all sensitive isolates tested in vitro. 
Furthermore, genetic transformation experiments with plasmids expressing mutant forms of 
pfcrt conferred chloroquine resistance on three different chloroquine-sensitive clones. These 
studies point to key role for pfcrt K76T mutation in conferring in vitro chloroquine 
resistance. Numerous recent field studies have provided additional evidence for the central 
role of pfcrt in determining response to chloroquine: Clinical studies in Mali suggested that, 
the key pfcrt amino acid substitution, pfcrt K76T, is selected after chloroquine treatment and 
is a reliable genetic marker for chloroquine resistance187. This pfcrt mutation was found to be 
significantly associated with in vivo response to chloroquine in Mozambique222 and with both 
in vivo and in vitro response in Cameroon223 and in Sudan224. Other studies from Brazil225, 
Uganda226, Laos227 and Papua New Guinea228 have described the role of pfcrt K76T mutation 
in chloroquine treatment failures. These studies provide substantial support for a sweeping 
association of pfcrt K76T mutation with different foci of chloroquine resistance. 
1.10.9.3.2 Genes implicated in resistance to pyrimethamine/sulfadoxine: 
The combination of pyrimethamine and sulfadoxine has widely been used in malaria 
chemotherapy. The target molecule of pyrimethamine is dihydrofolate reductase (DHFR) and 
for sulfadoxine is dihydropetroate synthase (DHPS), both enzymes being components of the 
folate biosynthesis pathway. 
dhfr:  The dhfr in P. falciparum exist as a bi-functional enzyme together with thymidylate 
synthase (TS), which forms d-TMP from d-UMP methylenetetrahydrofolate as methylating 
agent229. DHFR activity is essential in maintaining a constant supply  of folate factors for key 
one-carbon transfer reactions, in which only the fully reduced (terahydro) forms are 
functional12. The dhfr gene was cloned from P. falciparum in 1987. P. falciparum dhfr gene, 
unlike its human counterpart, is found to be very sensitive to inhibition by pyrimethamine230. 
DHFR sequences from various P. falciparum parasites were examined 
extensively231,232,233,234. These studies showed that, a single intronless open reading frame of 
about 1.8 kb coding sequence was observed, with the DHFR domain residing at the amino 
terminus and TS at the carboxyl terminus, and a peptide junction of approximately 100 amino 
acid residues separates the DHFR and TS domains. The findings of these studies have 
revealed correlation between pyrimethamine resistance and point mutations in the dhfr gene. 
Mutations in P. falciparum dhfr involving amino acid residues 16, 51, 59, 108 and 164 have 
been reported across a number of geographical areas64,213,232,235,236,237,238. Asn-108 mutation is 
critical point mutation found in all pyrimethamine-resistant isolates, and is believed to be the 
prime point mutation necessary for the development of mutants with higher degree of 
pyrimethamine resistance in malaria. 
dhps: dhps genes codes for an enzyme involved in the de novo folate biosynthesis pathway 
located upstream dhfr. This enzyme is responsible for the synthesis of 7,8-dihydropteroate 
diphosphate and p-amino benzoic acid (PABA), forming dihydropteroate in the step 
preceding dihydrofolate synthesis. The gene encoding dhps enzyme has been cloned and 
shown to be a bi-functional enzyme with 6-hydroxymethyl-7,8-dihydroprotein pyrophosphate 
(PPPK) at the N- terminus of the protein239,240. Expression and purification of the functional 
PPPK-DHPS enzyme from P. falciparum in E. coli shows that the activity purifies as an 83-
Kda protein and molecular mass range from 204 to 246 Kda, suggesting that the enzyme is 
multimer of two or three subunits241. The drugs of sulfa group are PABA analogues and have 
been shown to be competitive inhibitors of DHPS enzyme in P. berghei242,243. 
Characterization of P. falciparum dhps gene revealed mutations in codons, 436, 437, 540, 
581 and 613, which could be associated with sulfadoxine resistance234,239,240,244. Mutations in 
these five codons have been observed in large number of field samples of diverse 
geographical origins234,241,244,245. 
1.10.9.3.3 Drug resistant genes as molecular markers:  
The increased understanding of the molecular mechanisms for parasite resistance to the 
antifolates and, to some extent, to CQ has led to a proliferation of field studies investigating 
the role of molecular markers in detecting drug resistance. Some studies have demonstrated a 
causal relationship between discrete polymorphism in the candidate genes and parasite 
resistance to either CQ or SP in vitro and in vivo, but others have not.  
The precise role of molecular markers in detecting and estimating P. falciparum resistance 
still needs to be established because the genetic mutations that predict parasite resistance 
remain unclear. A genotype resistance index (GRI) and genotype failure index (GFI), derived 
by computing the ratio between the age-adjusted frequency of the pfcrt mutation at position 
76 and the prevalence of parasitologic and clinical CQ resistance, respectively187, have been 
proposed for the surveillance of CQ resistance. Such indices consistently gave a stable value 
of 2 to 3 for several sites or different years246, indicating that the prevalence of clinical or 
parasitologic failure was two to three times lower than the prevalence of the gene mutation. 
The association of the pfcrt codon 76 mutations with in vivo CQ treatment failure has been 
observed in several settings224,225,228,247 but not in others226,248, especially in areas where CQ 
resistance was very high. In these situations, the GRI and GFI might not predict CQ treatment 
failure because the prevalence of the gene mutation in these populations has reached a 
plateau248. In such settings, other indices are needed. In Uganda, a strong positive correlation 
between the pfcrt codon 76 mutant/wild (M/W) ratio and the late stages of high-grade CQ 
treatment failure (i.e., ETF and RIII parasitologic failure) has been observed249. Such a ratio 
could be useful in estimating high-grade CQ resistance in cases where the prevalence of the 
pfcrt mutation is already high. 
For SP resistance, there is growing evidence that the dhfr triple mutations with or without the 
dhps mutations can predict SP treatment failure (SP-TF). Studies conducted in East Africa 
have observed that the triple (dhfr Asn-108, Ile-51, and Arg-59) mutant genotype was 
associated with SP treatment failure181,182. However, a study in Malawi observed that the 
quintuple mutant genotype (dhfr Asn-108, Ile-51, and Arg-59 plus dhps Gly-437 and Glu-
540) was more strongly associated with SP-TF than was the dhfr triple mutant180. Lack of 
consistency in the results is probably a consequence of differences in the laboratory methods 
used to identify the mutations and in the estimation of the frequency of the gene mutations. 
In most studies, the prevalence of the gene mutations in host infections, i.e., the number of 
infected individuals carrying the mutations divided by the total number of infected 
individuals sampled has often been used. However, the prevalence of infections with the 
mutant genotype might differ from the frequency of the mutant allele in the parasite 
population, and the latter is likely to be a more appropriate measure for estimating the 
number of circulating mutant parasites. In Ugandan sentinel sites, the dhfr codon 59 M/W 
ratio, but not the prevalence of infections with the dhfr codon 59 mutation, was positively 
correlated with SP treatment failure250. 
1.11 The malaria parasite genome: 
Evolution of both the anopheles species and Plasmodium species in the face of natural and 
man-made selection will inevitably occur. The developments of molecular epidemiological 
approaches to monitor changes in the parasite and vector biology at a level of detection are 
able to identify rare variants in populations. They may allow us to respond more rapidly to 
potential failure of drugs, vaccines and pesticides. A fundamental understanding of the 
population biology of P. falciparum may also help design innovative control strategies in the 
face of social change and human migration. 
Genome analysis in several laboratories revealed unique features of P. falciparum 
chromosome organization which appear to allow rapid evolution of genes involved in 
parasite/host interaction. Plasmodium has, in addition to the nuclear genome, two unrelated 
organellar genomes, one mitochondrial (6kb) and the other probably of plasmid origin 
(35kb)9. 
In the analysis of the parasite Plasmodium falciparum genome sequence of clone 3D7, there 
is a 23-megabase nuclear genome consists of 14 chromosomes, encodes about 5,300 genes, 
and is the most (A + T)-rich genome sequenced to date. Introns were predicted in 54% of P. 
falciparum genes. Excluding introns, the mean length of P. falciparum genes was 2.3 kb. 
Genes involved in antigenic variation are concentrated in the subtelomeric regions of the 
chromosomes. Compared to the genomes of free-living eukaryotic microbes, the genome of 
this intracellular parasite encodes fewer enzymes and transporters, but a large proportion of 
genes are devoted to immune evasion and host–parasite interactions. Many nuclear-encoded 
proteins are targeted to the apicoplast, an organelle involved in fatty-acid and isoprenoid 
metabolism. The genome sequence provides the foundation for future studies of this 
organism, and is being exploited in the search for new drugs and vaccines to fight malaria251. 
The genome of P. falciparum contains a number of simple sequence repeats (microsatellite 
DNA). Microsatellite DNA has been found to occur at an average rate of one in every 2-3kb. 
These repeats were predominantly of the forms ATn, Tn and TAAn while the CAn repeat 
forms that frequent mammalian genomes were not found91. The size polymorphism 
associated with these repeats and their regular distribution in the genome make them a useful 
tool for genetic linkage analysis. 
Plasmodium falciparum chromosomes vary considerably in length, with most of the variation 
occurring in the subtelomeric regions. Field isolates, even those from individuals residing in a 
single village252, exhibit extensive size polymorphism that is thought to be due to 
recombination events between different parasite clones during meiosis in the mosquito253. 
Chromosome size variation is also observed in cultures of erythrocytic parasites, but is due to 
chromosome breakage and healing events and not to meiotic recombination254,255.  
Subtelomeric deletions often extend well into the chromosome, and in some cases alter the 
cell adhesion properties of the parasite owing to the loss of the gene(s) encoding adhesion 
molecules256,257. Because many genes involved in antigenic variation are located in the 
subtelomeric regions, an understanding of subtelomere structure and functional properties is 
essential for the elucidation of the mechanisms underlying the generation of antigenic 
diversity. 
Centromeres have not been identified experimentally in malaria parasites. However, putative 
centromeres were identified by comparison of the sequences of chromosomes 2 and 3. Eleven 
of the 14 chromosomes contained a single region of 2–3 kb with extremely high (A + T) 
content (>97%) and imperfect short tandem repeats, features resembling the regional S. 
pombe centromeres; the 3 chromosomes lacking such regions were incomplete251. 
Meiosis is followed by mitotic division to haploid sporozoites. Crossing experiments have 
shown that intragenic recombination occurs between different alleles during meiosis127,258. 
Many genes coding for antigens are located near the chromosome ends, i.e. the most labile 
regions. This might be a way to generate new antigenic variants and thereby evading 
immunity. 
The issue of sexual mating has been debated. One view is that natural infections are derived 
from one or few genotypes, which undergo mating infrequency, implying mainly clonal 
reproduction259. Recombinations however do occur frequently in nature70,260 but with higher 
selfing rate in areas of low transmission105. In strain theory, it was suggested that malaria 
parasites only exist as a limited number of stable antigenic types, called strains261 and that 
cross-immunity between mild and virulent strains is slow51. 
1.12 Malaria prevention and control strategies: 
Strategy is the art of planning and managing different activities in a coherent design for the 
attainment of specific objectives. The aim of any malaria control strategy is to prevent 
mortality and to reduce morbidity and the social and economic losses due to disease262. In 
areas where the malaria transmission has been interrupted, the goal is to avoid the re-
introduction of malaria13. 
Malaria is preventable, treatable and curable. Its epidemiology, however, is highly variable, 
and control strategies must therefore be adapted according to local biological, social and 
health system factors. Despite this complexity, in most countries, especially those in Africa 
with the highest burden, three approaches to reduce mortality and morbidity based on 
effective and low-cost interventions can and should be applied to give full coverage of all 
populations at risk. These are: (i) prompt access to treatment, especially for young children; 
(ii) prevention and control in pregnant women; and (iii) use of insecticide-treated nets and 
other methods of vector control. Prompt access to treatment160. 
A large proportion of deaths from malaria results from delayed administration of effective 
antimalarial treatment, as death can supervene within days or even hours of onset of the 
disease. It is essential that all people who develop the disease, especially young children and 
pregnant women, have prompt access to effective treatment.  
After the widespread failure of malaria eradication campaigns in the 1950’s and 1960’s, 
malaria has returned with renewed vigor to most tropical countries where its impact is 
increased with the spread of multidrug resistant parasites and insecticide resistant vector. 
Many methods have been proposed for intervening in parasite transmission and thus reducing 
malaria incidence:   
1.12.1 Vector Control: 
Attempts to control malaria by targeting the vector started as early as the beginning of this 
century. The advent of DDT as an immagociding agent in the early 1940’s was a 
breakthrough in the fight for malaria control, before that vector control relied mainly on 
reducing larval populations by drainage and using larvicides. This programme saw initial 
success, as malaria was eliminated or reduced from 77 countries, however soon the number 
of reported cases recovered and then quickly exceeded the previous levels. The failure was 
due to development of insecticide-resistant mosquitoes. Nevertheless in most cases 
insecticide-based approaches are relatively cheep and still very effective in reducing the 
impact of malaria in highly endemic areas193,263. 
To overcome insecticides resistance, new synthetic insecticides were developed. For 
example, pyrethrum impregnated bed nets were used for malaria control in African villages 
and have achieved encouraging results264.  
Recently great attention has been given to the use of environmental management measures 
for vector control. This approach aims at intensifying and extending the natural factors 
involved in limiting vector breeding or survival, and contact with man. Many biological 
agents ranging from viruses to invertebrate predators are under investigations and some 
bacterial, fungal and protozoan pathogens nematodes and invertebrate predators have reached 
the field of entomological evaluation. 
1.12.2 Malaria vaccine: 
The prevention of malaria by vaccination is a conceivable approach, which may eventually 
have a place in malaria control. Attempts to develop a malaria vaccine began early in the 
twentieth century265, and in spite of advances in biomedical technology and periodic bouts of 
unsubstantiated optimism in the field, no effective vaccine is available for widespread use. 
There are indeed formidable reasons for pessimism. There is as yet no precedent for a broadly 
applicable human vaccine against an organism’s complex as a protozoan an even a lifetime of 
repeated exposure to malaria rarely, if ever, induces sterile immunity. Plasmodium species 
have evolved multiple mechanisms of immune evasion at the individual and population level, 
including stage specific antigen expression, allelic variation, “hot spots” of variability within 
T cell epitope sequence, and antigenic variation9.  
The ability of the malaria parasite to adapt against and survive environmental changes, drug 
pressure and the host immune responses, has hindered malaria control programs. For these 
reasons vaccination against malaria has now greatly increased in importance, although it is 
potentially hindered by the fact that Plasmodium falciparum exhibits extensive 
polymorphism127. One of the major obstacles to the design of an efficient malaria vaccine is 
the large genetic diversity of P. falciparum parasite. 
1.12.3 Chemoprophylaxis: 
Several factors must be considered when choosing the chemoprophylactic regimen for a 
patient: (i) Whether the patient will actually be at risk of acquiring malaria. (ii) Whether the 
patient is allergic to or has other contraindications to the antimalarial drug of choice. (iii) 
Whether the patient is a risk of acquiring drug-resistant P. falciparum malaria. Resistance of 
P. falciparum to chloroquine has been confirmed or is probable in all countries with P. 
falciparum malaria except the Dominican Republic, Haiti, and Central America north of the 
Panama Canal, Egypt, and most countries in the Middle East. (iv) Chemoprophylaxis should 
preferably begin 1-2 weeks before travel to endemic areas. This allows any potential side 
effects to be evaluated and treated before departure. (v) Chemoprophylaxis should continue 
during travel in the endemic areas and for 4 weeks after leaving the endemic areas. 
Chemoprophylaxic Regimens as follows: Regimen A: For travel to areas of risk where 
chloroquine-resistant P. falciparum has not been reported: Once-weekly use of chloroquine 
Regimen B: For travel to areas of risk where chloroquine-resistant P. falciparum exists: 
Mefloquine 
1.12.4 Prevention and control of malaria epidemics: 
Areas prone to epidemics can be identified by epidemiological stratification that takes 
account of vectorial transmission capacity, environmental (including meteorological) 
conditions, social and economic conditions, population migration patterns and other factors. 
The entomological inoculation rate has been proposed as a comprehensive indicator of 
epidemic risk on which to base forecasting. It is defined as the mean daily number of bites 
inflicted on an individual by mosquitos infected with sporozoites, and therefore requires the 
determination of the man-biting and sporozoite rates which, particularly the latter, may be 
practically impossible to determine in many epidemic-prone areas. Epidemics may occur with 
very low sporozoite rates, often undetectable by common practices of entomological services, 
particularly in areas where the vectors are only partially anthropophilic, such as most areas of 
the Americas and the Indian subcontinent.  
Local health services have much to contribute to this process, and should be the first to report 
a suspicious increase in the number of patients with fever. On the basis of this stratification, a 
limited set of indicators of epidemic potential or risk factors can be prepared that can be 
monitored by local health personnel and used to build up community preparedness and 
prevention. 
1.13 Malaria during pregnancy: 
Malarial infection during pregnancy is a major public health problem in tropical and 
subtropical regions throughout the world. In most endemic areas of the world, pregnant 
women are the main adult risk group for malaria. Malaria in pregnant women has been most 
widely evaluated in sub-Saharan Africa, where most malaria is due to Plasmodium 
falciparum infection, the most deadly form of the disease. Africa south of the Sahara bears 
90% of the global malaria burden. Every year at least 24 million pregnancies occur among 
women in malarious areas of Africa, yet less than 5% of pregnant women have access to 
effective interventions266. 
Of the 50 million pregnancies that occur in malaria-endemic areas every year, approximately 
half are to be found in sub-Saharan Africa267. The problem posed by, and epidemiology of, 
malaria during pregnancy depends on the local level of transmission. In areas where the 
intensity of transmission is low, malaria can cause severe materno–foetal syndromes, such as 
cerebral malaria, abortion, stillbirth and low birth weight. In contrast, those women who live 
in areas of stable and intense transmission enjoy considerable immunity and generally 
experience few symptoms during episodes of malarial infection, although some may develop 
severe anemia268,269,270,271. 
A paradoxical situation prevails during pregnancy in women with lifelong residence in a 
malarious area (example having reached a state of semi-immunity): an apparent loss of 
immunity occurs during pregnancy, while at the same time, these women are able to transfer 
a fully effective protective immunity to their infant. This phenomenon is particularly 
pronounced in primigravidae and becomes less of a problem during later pregnancies. The 
features of falciparum malaria in a primigravida are the following: infection takes place and 
the parasite develops in the placenta, while remaining at a low level in the peripheral 
circulation; in the absence of treatment, an infection acquired during the early stages of 
pregnancy will be maintained throughout pregnancy in the placenta, often with a heavy 
parasite load. 
The classical explanation of what happens during malaria in first pregnancies is a reduction 
of acquire immunity, consistent with the immunosuppression generally observed in all 
pregnancies; this is in line with the observation of reduced lymphoproliferative responses in 
pregnant women compared to age-matched non pregnant individuals. 
Two alternative explanations for malaria in pregnancy have been proposed. The first takes 
into account of the fact that the placenta is a “new” origin in primigravidae. Which could by-
pass existing immune responses in the host (without implying an actual loss of immunity) or 
allow for the development of unusual phenotypes of P. falciparum; the acquisition of a 
placenta-specific immunity or the previous exposure to new malaria phenotypes (in an earlier 
pregnancy), would explain the decrease susceptibility to infection in multigarvidae. The 
second alternative suggests that what happens in pregnancy is a change in the balance of the 
local placental environment from an essential TH2 environment (prevailing in normal 
placenta) to a TH1 environment during acute malaria; this is consistent with the presence of a 
large number of monocytes in the infected placenta13. 
Plasmodium falciparum infection during pregnancy increases the chance of maternal anemia, 
abortion, stillbirth, prematurity, intrauterine growth retardation, and infant low birth weight 
(defined as less than 2500 grams), which is the greatest single risk factor for death in the first 
month of life. Malaria has been estimated to cause 8% to 14% of all low birth weight babies 
and 3% to 8% of all infant deaths in areas of Africa with stable malaria transmission. In terms 
of its effect on mothers, severe anemia increases the risk for maternal mortality, and malarial 
anemia is estimated to cause as many as 10,000 maternal deaths each year in Africa. The 
impact of the other three human malaria parasites (P. vivax, P. malariae, and P. ovale) is less 
clear266. 
In programmes for the prevention or treatment of malaria in pregnant women, two major 
issues are the safety and effectiveness of the antimalarial drug regimen. The programmatic 
effectiveness of a given drug is determined by the efficacy of that drug against the parasite 
and by the drug’s characteristics, including affordability, availability, acceptability to the 
target population, and deliverability in terms of dosing requirements and incorporation into 
existing antenatal care delivery systems. 
1.14 Malaria in Sudan: 
Excluding a narrow band in Northen Sudan, all the Sudanese people are prone to have malaria.  
 
Figure (1.3) 
Taking into consideration the endemicity of malaria (fig. 1.3) and other factors that lead to 
malaria infection (inbreeding sites, parasite, vector and others.) we can divide Sudan into five 
parts (high perineal transmission, irrigated malaria, seasonal malaria, urban malaria and 
riverine malaria (fig. 1.4)6.  
 
Figure (1.4)  
In the same report, malaria death cases have also been reported for the same period in in-
patient clinics as ranging between 10-15% from total hospital in-patients. 
As shown in fig. (1.3 & 1.4) the whole country is now endemic with varying degrees. 
Generally speaking, the endemicity increases from north to south. Certain geographical and 
topographical features like the annual fluctuations of the Nile floods, the winter rains of the 
Red Sea Hills and the irrigated areas in the central regions, alter this transition of endemicity 
creating pockets of elevated levels of endemicity. Thus malaria is hypoendemic in the north 
with mesoendemic areas determined by the cultural schemes in the area and the Nile floods. 
It is mesoendemic in the central areas with hyperendemic spots resulting from agricultural 
practices mainly, and the intensity of the annual rains. In the southern part hyper- to 
holoendemic malaria prevails and transmission is perennial6. 
All four types of human malaria have been reported in Sudan but the predominant parasite 
species is P. falciparum which is responsible for >95% of reported cases, followed in 
descending order by P. vivax, P. malariae and the relatively rare P .ovale. As a result of 
migration the parasite prevalence map in Khartoum State was changed from that in 30 years 
ago since the infection with P. vivax and P. ovale increased6. 
Chloroquine is the first line drug for malaria treatment in Sudan untill 2004, when the 
Ministry of Health replaced it with combination of artesunate plus fansidar. The possible 
emergence of chloroquine resistance in Sudan was first suggested in 1978 in Central 
Sudan272. However, confirmation by in vivo test came in 1982273. High grade chloroquine 
resistance was noted in eastern Sudan later274. Chloroquine failure rate was estimated by in 
vitro tests to be 35.2% in study carried in the Khartoum the capital in 1997. A subsequent 
study in different area in Khartoum in 1998 revealed high rate (55.2%) of all grades of 
chloroquine resistance275. 
The deterioration of malaria situation in Sudan is due to appearance of parasites resistant to 
antimalarial drugs, and vector resistance to some insecticides in use and the vast extension in 
agriculture and irrigation schemes. Other contributing factors are inadequate financial 
recourses, poor community participation and the lack of expert staff due to brain drain. These 
are coupled with poor health coverage and weak information system in a large country like 
Sudan. The mosquito vector, Anopheles arabiensis occurring throughout the country and An. 
gambiae and An. Funistus increases towards the south6. 
 
1.14.1 Malaria in Eastern Sudan: 
Malaria field research has been established since 1986 in Gedarif, eastern Sudan, aiming to 
study the population dynamics of P. falciparum malaria and the human immune responses to 
this infection. In this area, malaria transmission is seasonal and unstable. The dominant 
influence on malaria transmission in the Sahel and savannah belts of Sudan is the short rainy 
season in which 80-90% of precipitation falls in July and August. 
The epidemiology of malaria in eastern and central Sudan is considered to be at the unstable 
end of the spectrum described by MacDonald59. The brief exposure of the semi-immune 
inhabitants to mosquitoes after the short rainy season leads to a major health problem during 
October and November each year. In this area malaria incidence is not confined to young 
children, but older children and young adults are at great risk. No obvious source of 
Anophline mosquitoes was observed during the lengthy dry season276.  
During the 1991 and 1992 there was no rain in the area which led to severe drought all over 
the country. Less than ten malaria cases were detected through out the whole transmission 
season in a study site of about 450 inhabitants, but epidemics and outbreaks occurring during 
the transmission season of 1993. It is puzzling, the dynamics by which the parasite, the host 
immune responses and the Anopheles vector committed to survive this long period of severe 
drought when malaria transmission had actually ceased. 
Studies in Daraweesh village have demonstrated that a significant proportion of the 
population harbour asymptomatic infections detectable by transmission season associated 
rises in anti-malaria antibody titers, despite the absence of clinical disease31,277,278. 
Parasitological conformation of the presence of persistently microscopically negative but 
PCR positive individuals had been reported15,279,280. These results were unexpected since 
malaria in Daraweesh did not show the pattern of age stratification of clinical malaria 
incidence characteristic of areas of holo-endemic transmission. Individuals living in areas of 
unstable and low intensity transmission have not traditionally been considered to acquire 
significant immunity to the disease59,280. 
In the past 15 years, regular surveys have been carried in Asar village70,252,279,281. These 
studies have revealed remarkable amount of allelic polymorphism and great genetic diversity 
among P. falciparum parasites that raise the annual malaria epidemics in the village. The 
parasite population of this village was compared to that of a community with a similar 
population size in Tanzania93. In Asar village there were fewer alleles of each gene studied 
than in Tanzania, and the average number of clones was less. These differences reflect the 
differences in transmission intensities in each region, which can be expected to have an 
impact on the prevailing mode of reproduction and responses to locally selective forces. 
Surveys carried in Asar village have also shown that, some patients do not clear their acute P. 
falciparum infections following treatment, but remain harboring sub-patent parasitemia 
throughout the dry season279. Thus it seems clear that the malaria epidemics following rains, 
most probably originates from parasites surviving the dry season among the inhabitants rather 
than that from infections brought into the village by human or mosquito immigration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.15 Rationale: 
Molecular techniques, more specifically the most simple, popular and affordable technique, 
the polymerase chain reaction (PCR), have revolutionized the knowledge about disease, 
including the tropical diseases. Plasmodium falciparum malaria is the most important tropical 
infection and it is the real hurdle to development that challenged mankind over the centuries. 
The mortality is mainly due to the severe and complicated form of the disease, and the rest of 
the malaria burden is attributed to the drug resistance of the parasite (morbidity). 
Pathogenesis and mechanisms of severe disease and the drug resistance are both crucial 
issues which are not yet well understood. But what is not beyond the limits of doubt, is that 
the parasite factors are an important element in both conditions. However, for living 
organisms including malaria, the control of the vital functions and the phenotypic 
characteristics can be mirrored through the information centre, which is the DNA. In this 
study we are aiming to deploy the polymerase chain reaction (PCR) for exploration at 
molecular level of the parasites that cause the severe disease in general and the individual 
complications in specific. Further more, in Eastern Sudan, the semi-immune populations are 
exposed during the annual short window of malaria transmission to markedly variable 
degrees of malaria infections but on average were less than one infectious bite per person per 
season. That have many consequences including: a. the low complexity of infection in the 
area, with minimal overlap of infections, which generate a favorable condition for studying 
the parasite dynamics in relation to the clinical outcome of the malaria infection b. very low 
parasitemia (sub-microscopic) could result in symptomatic or even severe and fatal malaria, 
that creates a dilemma with regard to malaria diagnosis with critical consequences. Again 
molecular techniques can ideally be used in this setting and can reveal very valuable clinical 
information. The above is also applied; if we want to study the molecular aspects of drug 
resistance.         
 
 
 
 
 
1.16 The overall objective of this study:  
This study was done to validate the use of modern molecular techniques in diagnosis and 
determination of the parasite factors associated with severe malaria morbidity and mortality. 
Furthermore, to deploy these techniques in; evaluation of the anti-malarial drug efficacy and 
study of the molecular marker of parasite resistance, with special reference to chloroquine 
and sulfadoxine/pyrimethamine combination therapy.    
1.16.1 Detailed objectives: 
1. To study the molecular characterization of severe malarial parasitemia in terms of 
parasite genotypes and multiplicity of infection.                        
2. To validate the use of molecular techniques (PCR) in detection of submicroscopic 
parasitemia in severe malaria and pregnancy associated malaria.  
3. To estimate the frequency of drug-resistance associated mutations in severe and 
uncomplicated malaria in the study area. 
4. To validate the use of the new molecular techniques, PCR-ELISA, in detection of 
single nucleotide polymorphisms (SNPs) in P. falciparum chloroquine resistant 
transporter, dihydrofolate reductase and dihydropetroate synthase genes. 
 
 
 
 
 
 
 
 
 
 
 
Chapter two 
Materials and Methods 
2.1 Study area: 
2.1.1 Gedarif area: 
The severe malaria study was carried out in Gedarif Teaching Hospital, Gedarif state/ town in 
Eastern Sudan (350 to 400 thousand inhabitants) during two consecutive malaria seasons 
(September to January) over the years 2000 to 2002. Gedarif town is situated on the Sudanese 
savannah, at an altitude of about 600 meters above sea level; it is 450 Km from the Capital, 
Khartoum (fig. 2.1). The epidemiology of febrile uncomplicated malaria episodes in the area 
has been reported before16. Malaria in this area is highly seasonal, and follows the annual 
June - October rains and accordingly the incidence of malaria varies considerably from year 
to year282. The Plasmodium falciparum is the predominant species (98%), and the Anophiles 
arabiensis is the sole malaria vector in this area. The entomological inoculation rate (EIR) in 
Gedarif has not been measured, but was found to be very low and difficult to measure by 
conventional methods in the surrounding villages115,276.  
For anti-malarial drugs study, samples were collected from the Daraweesh and Kajara 
villages, 16 km from Gedarif town, from October 2003 to December 2003. Daraweesh is 
inhabited by approximately 550 individuals, of a Fulani origin who settled in Sudan a century 
ago. Kajara inhabited by approximately 2000 individuals including different ethnic groups; it 
is one or two km from Daraweesh. The villages’ economy is based on subsistence agriculture 
of sesame and dura.  
2.1.2 New Halfa area: 
Data and samples were also collected from New Halfa Teaching Hospital, the Sugar Cane 
Health Center and Alhara Aloula Health Center, New Halfa town, Kassala state, Eastern 
Sudan, about 550 Km from Khartoum (fig. 2.1). New Halfa is 450 m above sea level, located 
between 15-19 Latitude, North and 35-36 Longitude, East. It is characterized by average 
annual rainfall of 238 mm and average annual relative humidity of 35%. New Halfa is a 
relatively large town center surrounded by more than 100 small villages on the outskirts of 
the town; it is inhabited by around 250000 individuals with approximately 2000-3000 
individuals in each village. Several ethnic groups including Afroarab tribes were settled in the 
area in 1964. A large sugar cane industry and associated agricultural schemes represent the 
backbone of the economy in the area. The agriculture depends on rainfall and permanent 
irrigation system from Atabra River and many water canals found around and between the 
villages. 
 
Figure (2.1): Map for the study area 
The malaria infections in New Halfa region are predominantly (95%) caused by Plasmodium 
falciparum and the transmission is seasonal and unstable. Although malaria is mesoendemic 
in this area, with the peak of transmission occurs between September-January following the 
rainy season, severe epidemics are occasionally recognized. The health facilities of the area 
constitute of one referral hospital, where severely ill patients are brought, one single-doctor 
hospital and twenty dispensaries. 
2.2 Study design: 
This study is part of a large project funded by the Multilateral Initiative on Malaria in Africa 
(MIM/TDR/WHO) about pathogenesis of severe malaria in Eastern Sudan. Collaborators 
from different disciplines (physicians, scientists, technicians and others) and from different 
countries (Sudan, Denmark and Sweden) were involved in this study. The study received 
ethical clearance and national endorsement by the Sudan Ministry of Health. 
We aimed in part of the project to deploy the molecular techniques to study the malaria 
parasite at a molecular level in relation to: a/ severe malaria development b/ sub-patent 
malaria in clinically diagnosed cases of severe malaria or pregnancy associated malaria with 
negative blood smears. c/ drug resistant parasites. Each of these studies was conducted in a 
separate cohort of patients for variable period of times. Each cohort was selected based on 
specific criteria       
Gedarif 
a. For severe malaria in Gedarif: The selection of severe malaria patient was based on the 
WHO criteria for severe malaria, which includes; 1. Cerebral malaria, an unarousable coma 
persisting for at least 30 minutes, it should be differentiated from transient postictal 
phenomenon 2. Severe malarial anemia, normocytic anemia with haematocrit <15% or 
hemoglobin <5g/dl, in presence of parasitemia 3. Respiratory distress 4. Hypoglycemia, 
whole blood glucose concentration of <2.2mmol/1 (40mg/dl) 5. Circulatory collapse or 
shock, hypotension (systolic blood pressure <50 mmHg in children (1-5 years) or <70mmHg 
in adults), with cold clammy skin. 6. Renal failure, urine output of <400ml/24 hours in adults 
or 12ml/kg in children inspite of rehydration, and elevated serum creatinine level, 
>265µmol/1 (>3mg/dl) 7. Spontaneous bleeding from gums, nose, gastrointestinal tract, etc. 
and/or laboratory evidence of desiminated intravascular coagulation (DIC) 8. Repeated 
generalized convulsions at least two per 24 hours despite cooling; febrile convulsions in 
children should be considered 9. Acidosis, an arterial pH <7.25 or a plasma bicarbonate 
concentration <15 mmol/l 10. Macroscopic hemoglobinuria. Other supportive (non-defining) 
manifestations of severe malaria include: a) Impairment of consciousness. b) Jaundice. c) 
Prostration or weakness. d) Hyperpyrexia and e) Hyperparasitaemia. Patients will be 
characterized clinically and grouped11.  
A matched control group (age, sex, tribe and etc.), which included; patients presenting with 
mild uncomplicated falciparum malaria, and malaria free individuals, were enrolled as 
positive and negative controls, respectively. This control group case was selected mostly 
from among the severe malaria patient’s relatives or from the same area. Full history and 
detailed symptoms of illness were obtained from the malaria patients or their accompanying 
relatives. (questionnaire and informed consent are attached as annex).  
b. For severe malaria in New-Halfa: The data was obtained in the period from November 
2000 to February 2001. A medical doctor examined patients presenting with malaria-like 
symptoms in New-Halfa Hospital, in an outpatient malaria clinic. The malaria diagnosis was 
done by examination of thick and thin blood smears under light microscopy. Patients with 
confirmed malaria infection were treated with chloroquine, fansidar or quinine, as mentioned 
before. During the study period, all patients admitted to hospital in coma and clinically 
suspected to have cerebral malaria (CSCM), but with negative blood smear for malaria 
parasites, were included in the study after the consent of their guardians was obtained. The 
enrolled patients were treated according to the health policy and management protocol 
adopted by the local health authorities. They were treated initially by quinine infusion and, 
after suitable clinical improvement, by quinine tablets (10mg/kg body weight, 8-hourly, for a 
total duration of 7 days). Two patients were further treated with benzyl penicillin (106 IU/6-
hourly, for 5 days) and one of them was in addition given gentamycin (80mg/8-hourly for 5 
days) all were given in parallel with quinine from the first day. Only a small fraction from 
other groups of individuals with and without microscopically confirmed P. falciparum 
malaria were included in the study, as controls in addition to apparently healthy donors.    
c. For drug resistance in Daraweesh/Kajara (Gedarif area): A clinic was set in each village, 
and inhabitants were informed to come to the clinic if they or their relatives had fever or 
other malaria like symptoms. A health team consisting of; a medical doctor, nurse, 
microscopist and the investigator were informed to cover both villages. They were available 
in the villages on daily basis. Most of the patients who had malaria were included in the 
study, and only small number of patients were excluded from the study based on the 
exclusion criteria mentioned before. However, other remaining patients were examined, and 
were either treated or prescribed a drug not available in the clinic or referred to Gedarif 
Hospital.   
In this study the 28-days in-vivo drug efficacy protocols of the WHO196 which are used in 
malaria hyperendemic regions was modefied. The main modification was that malaria 
diagnosis does not depend on parasite in this setting i.e. malaria was diagnosed when 
parasitemia of any count was detected in a febrile (≥ 37.5°C) patient or a patient had a recent 
history of fever. The SP was given as a single dose of 1.25 mg P/kg body weight, and CQ 
was given in a dose of; 10-10-5 mg/Kg/day, over 3 days. The treatment was supervised; in 
the first day (D0), the patient was given SP alone or with CQ simultaneously in the clinic and  
the dose is repeated if the patient vomited during his/her stay (half an hour), then, CQ was 
given in D2 and D3 in the clinic as in D0. Patients were examined clinically and 
parasitologically by taking blood smears and blood in filter paper for parasite detection, 
during the follow up on days;  3, 7, 14, 21 and 28. Finally, the treatment outcome was to be 
classified as; early treatment failure (ETF), late treatment failure (LTF), and adequate clinical 
and parasitological response (ACPR).  
The alternative treatment (quinine) was given to patients in D3 if they developed severe 
malaria, and was given thereafter if parasitemia associated with symptoms was detected.  
Parasite genotyping was done to distinguish recrudescence and re-infection and molecular 
markers were used to investigate the relationship between in-vivo drug resistance and the 
mutations in drug resistance genes  
d. For preganacy associated malaria in New-Halfa: All the pregnant women visiting the 
center’s antenatal clinic for the first time were enrolled. After verbal consent was obtained, 
each woman’s obstetric history was recorded in details, including the date of her last 
menstrual period, gravidity, and parity. Each woman was then asked specifically if she had 
any symptoms indicative of malaria: fever, headache, sweating, joint pain and/or vomiting. 
Body temperature was recorded, obstetric and physical examinations were conducted, and 
blood pressure, pallor and fundal level were recorded. Pregnancy was confirmed by 
ultrasound and its duration was calculated from the date of the last menstrual period. The 
blood concentration of hemoglobin was estimated using a colorimetric method. The main 
aims were to assess the prevalences of submicroscopic and multiple P.  falciparum infections 
in pregnant women (using the P. falciparum merozoite surface protein-2 as a polymorphic 
marker in PCR-based assays) and to determine the effects of such infections on anemia 
during pregnancy. 
2.3 Study population: 
a. Severe malaria in Gedarif Hospital: All patients in all age groups with a primary diagnosis 
of malaria confirmed by a positive blood smear for P. falciparum and no other cause for the 
clinical presentation, in Gedarif Hospital during the malaria seasons of 2000 to 2002, were 
enrolled in this study after informed consent from the patient or guardians. 
More than 16600 patients were screened for malaria infection, 2488 were slide positive and 
among them 103 individuals had fulfilled the WHO (2000) criteria of severe malaria and 
were enrolled in a longitudinal study. Samples were taken at day0 (D0) before treatment, D3, 
D7 (during treatment) and D28 (after treatment). Blood spots were taken onto filter paper 
(Whatman 3MM chromatography paper) from finger prick, allowed to air-dry, then placed 
individually in plastic bags and stored in refrigerator for further analysis. All severe patients 
were treated with quinine infusion for 48 hours followed by quinine tablets (10mg/kg) for 
total of seven days. For uncomplicated falciparum malaria, adults and older children were 
treated with chloroquine tablets, and for children chloroquine syrup was used (10, 10 & 
5mg/kg body weight for three days). In case of treatment failure, patients were given fansidar 
tablets.  
Follow-up: The patients were discharged from hospital after clinical improvement and the 
ability to continue the treatment orally at home under medical supervision. Patients were 
followed up, clinically and parasitologically up to day 28 after diagnosis, and were advised to 
visit our malaria clinic if symptoms recurred thereafter.  
b. Severe malaria in New-Halfa: For the study of the sub-patent severe malaria in New-
Halfa, patients with malaria symptoms with and without microscopically detectable 
parasitemia were included. The case definition for severe malaria was mentioned previously. 
Patients clinically suspected to have severe malaria (CSSM) had the above symptoms, but 
parasitemia was not detectable by microscopy, and the other possible diagnoses were 
excluded. The latter was done by meticulous clinical examination, clinical consultancy of the 
clinical experts and by doing basic routine investigations like; urine/stool general, complete 
hemogram, chest x-ray, lumber puncture and etc. The details about the patients included in 
the study and their characteristics are shown in the result section.  
c. Drug combination in Daraweesh/Kajara: In this total population study, all individuals in 
Daraweesh and Kajara villages during 2003 malaria transmission season, who had confirmed 
malaria infection (clinical and parasitological) and accepted to be seen and examined during 
the follow up, were included in study of efficacy of sulphadoxine/pyrimethamine (SP) alone 
and in combination with chloroquine (CQ) in treatment of uncomplicated P. falciparum 
malaria. The total villagers were estimated to be more than 2500 individuals, of them one 
quarter were living in Daraweesh. The estimated sample size was between 50 and 100 
individuals for each of the treatment arms respectively. All individuals in both villages, who 
had confirmed malaria infection (clinical and parasitological) and accepted to be seen and 
examined during the follow up, were included in the study. Pregnant women, severely ill 
patients, patients co-infected with other organism, children too small to swallow tablets 
(mostly less than 4 years), or patients known to be allergic to the antimalarial drugs were 
excluded from the study. In addition, patients with severe malaria11 or with mixed malaria 
infections were also excluded. Patients and/or their guardian's verbal consent were obtained, 
as well as both village leaders and patients were informed about the study and the objectives.        
d. Pregnancy associated malaria in New-Halfa: A third group in New 
Halfa city including the pregnant women attending Alhara Aloula health 
center from August 2003 to July 2004 were enrolled in a separate study.  
142 pregnant women were enrolled as they attended antenatal clinic for the 
first time. 
2.4 Blood sampling: 
Venous blood samples (5-10ml) were taken into EDTA or heparinised vacutainer at D0 and 
D28. Red blood cells were separated by centrifugation of the blood samples, re-suspended 
with glycerol freezing solution and stored in liquid nitrogen until used (mainly for 
immunological studies). The buffy coats (mainly leucocytes) were removed and plasma was 
transformed into cryotubes and stored at -20oC, also plasma was used mainly for 
immunological studies. Few drops were used for preparation of blood smears and parasite 
DNA. Finger pricks were used to obtain few drops of blood to be used for preparation of 
blood smears for parasite detection and to be blotted in filter paper for parasite DNA 
extraction. The finger prick samples were collected during the follow up days; D3, D7, D14, 
D21 and D28. 
2.5 Malaria diagnosis and parasite count:  
The malaria diagnosis was carried out as described by the WHO, in brief; thick and thin 
blood smears were prepared, stained with Giemsa and examined under light microscopy at a 
magnification of x1000, by an expert malaria technician. Films were considered negative 
after examination of 200 thick smear fields without detection of parasites. Another two expert 
malaria microscopists using quality control-evaluated microscopes at the reference malaria 
laboratory rechecked all slides. Parasites were counted per 200 leukocytes and standardized 
to 1 micro liter of blood21,283 assuming that the number of WBCs in Sudanese individuals 
6000/µl of blood.  
2.6 Other investigations:   
General routine investigations were done for severe malaria patients such as: complete 
hemogram (Hematocrit, reticulocytes, total and differential white blood cell count-TWBC- 
thrombocyte count, ESR-1hour) and urine general. Other investigations were done on special 
condition and upon request from the clinician e.g. blood glucose level (electronic glucometer, 
accu trend™), blood insulin measured by radioimmunoassay-kit IMK-414, Beijing, China, 
and renal function test (blood urea, serum creatinine, plasma bicarbonate). However, other 
investigations were done for exclusion of other febrile conditions e.g. Widal test for typhoid 
and brucellosis, sickling test, spinal fluid culture and Chest X-ray. Then the results and the 
clinical data were entered into a data base program, Microsoft Access.  
2. 7 In vivo study: 
Patients were allocated randomly to either of the two treatment regime (SP alone and SP plus 
CQ) with consideration of the possible similarity between the two groups with regard to age, 
gender and village. The first treatment group was given SP single dose of 1.25 mg P/kg body 
weight, and the second treatment group (SP plus CQ) was given SP single dose of 1.25 mg 
P/kg body weight and CQ (dose; 10-10-5 mg/Kg/day) over 3 days. All patients were first 
weighed, the two drugs in the first treatment group were administered simultaneously under 
our supervision, and repeated if vomiting occurred within half an hour, and the same was 
applied for SP treatment. 
During the follow up, patients were seen and investigated for malaria (clinical and 
parasitological) on day 0,  3, 7, 14, 21 and 28,  guided by the major steps of the WHO 
protocols for in-vivo studies, with some modifications which were mentioned before. Clinical 
information was recorded in follow up sheets and later entered into data base programme; in 
addition blood smears and blood in filter papers were taken in all the days of the follow up.    
Classification of treatment outcome: After the in-vivo test was performed, the treatment 
outcome had been classified into three categories; early treatment failure (ETF), late 
treatment failure (LTF) both clinical and parasitological failure, and adequate clinical and 
parasitological response (ACPR)196. However, a number of patients had parasitemia at day 3 
with or without symptoms, resolved by D7, those were categorized as having delayed 
parasitological response (DPR).  
2.8 Polymerase chain reaction – PCR: 
The polymerase chain reaction (PCR) was used for; a. parasite detection b. parasite 
genotyping c. and detection of single nucleotide polymorphism (SNP), the mutations 
associated with chloroquine resistance and sulphadoxine/pyrimethamine resistance     
 
 
2.8.1 DNA extraction:  
Extraction of DNA from bloodspots on filter papers was carried out by the chelex-100 
method described by Wooden et al.284 with some modifications described by Pearce et al.285. 
DNA extraction from bloodspots on filter paper was carried out in a 96-well plate format. A 
segment of the bloodspot was first soaked in 0.5% saponin–1X phosphate-buffered saline 
overnight and was then washed twice in 1 ml of 1X phosphate-buffered saline. The segment 
was then boiled for 8 min in 100 µl of PCR-quality water–50 µl of 20% Chelex suspension in 
distilled water (pH 9.5)285. 
Another approach was also used for DNA extraction by using also chelex-100. Samples were 
extracted as follows: 50µl of 10% saponin as a detergent were added to the sector of 10–
30µm of the blood spotted on filter paper and 1ml phosphate buffer saline (PBS) pH 7.4 was 
added, and incubated at 4oC for 4-6 hours or overnight, spined for 1 minute at 13000 rpm., 
the supernatant was aspirated from the tube and washed with 1ml 1x PBS, incubate for 1-2h 
in 4oC, spined for 1 minute at 13000 rpm and the supernatant was removed. The filter paper 
was boiled at 95oC with 100µl highly qualified distilled water and 50µl 20% chelex-100 
solution for 10 minutes, vortexed vigorously at least twice during boiling time. The DNA was 
separated after centrifugation and stored in -20oC till used286. 
2.8.2 PCR amplification:  
The polymerase chain reaction (PCR) was used to complement microscopical monitoring, for 
the detection of low level parasitemia and for genotyping. From the extracted DNA 2µl were 
amplified in a 20µl reaction volume containing 0.2mM of each dNTP (0.4µl), 50mM Mgcl2  
(0.6µl), 10µM of each primer (0.4µl), 1U Taq (DNA polymerase enzyme), 2µl of 10X PCR 
buffer, and the volume was completed to 20µl using autoclaved or highly qualified distilled 
water. 
Positive and negative controls were run parallel to each test sample (positive controls; 3D7 
and HB3 for IC1 and Fc27 MSP2 allelic families respectively) and negative control 
containing no target DNA. 
2.8.3 Parasite genotyping: 
The parasite isolates were genotyped at the allelic variants in the polymorphic regions of 
MSP2 and GLURP marker genes 
2.8.3.1 Genotyping at the MSP2 locus: 
The amplification at the MSP2 locus was carried out as a nested reaction. The outer PCR 
primers were used in the initial amplification reaction for 30 cycles at 94oC for 25sec., 42oC 
for 1min., and 65oC for 2min106. One µl of the outer reaction was then used as template for a 
second inner reaction for amplification using the primers (Table 2.1) and conditions 
of106,287,288. All inner reactions were carried out with cycling parameters of 94oC for 25sec., 
55oC for 1min., and 70oC for 1min., for 30 cycles for IC1 and FC27 alleles. Both alleles were 
amplified using S1 primer and either Fc27 or IC1 primers (Table 2.1). 
2.8.3.2 Genotyping at the GLURP locus:  
Alleles at the GLURP gene locus were detected in nested PCR reactions using outer and 
inner primers derived from the published gene sequence86. Outer primers, G4 and G5 (see 
Table 2.1 for sequence), were used for initial amplification105 for 30 cycles under the 
following conditions; 94oC for 25sec., 45oC for 1min. and 68oC for 2min. One µl of the outer 
reaction was used as template in an inner reaction using primers G1 and G3 (Table 2.1)72 in a 
reaction of 30 cycles with parameters of 94oC for 1min., 55oC for 2min. and 70oC for 2min. 
2.8.4 Detection of PCR products using Electrophoresis Techniques: 
The PCR products were analyzed by gel electrophoresis, 8µl of PCR products were loaded 
onto 1.5% agarose gel (Sigma agarose type II: Medium EEO) in 1X Tris-borate EDTA (TBE) 
buffer (pH 8.3), then were visualized using UV transillumination after staining with 0.5 µg 
/ml ethidium bromide. 
2.9 PCR-ELISA for detection of drug-resistance-associated mutations: 
This new approach is used for detection of SNP (mutations) of genes associated with drug 
resistance; in this study we used it for detection of chloroquine and sulphadoxine/ 
pyrimethamine resistance genes. It is characterized as being a fast and reliable approach by 
combining the advantages of both PCR and ELISA in sensitivity and amplification. This 
method was carried out in several steps289. 
2.9.1 Plasmodium falciparum clones and field isolates, as control: 
Five P. falciparum laboratory clones (3D7, FCR3, 7G8, K1, and DD2) were used to verify 
the specificity of PCR-ELISA technique and were used as a standard control panel in 
subsequent experiments. In addition three P. falciparum parasite isolates from 
Daraweesh/Kajara, were used in the control panel since they were found to expressing the 
436/437AA, 436/437AG and 540E genotypes of dhps. Almost all known SNPs of dhfr, dhps, 
and pfcrt (codons 72-76) are represented in this panel of parasites. 
Table 2.1: Sequences of P. falciparum allele specific primers used in genotyping 
Primer used Primer sequence (5´ to 3´ direction) Position 
MSP-2 S2 GAGGGATGTTGCTGCTCCACAG  MSP-2 Outer 
MSP-2 S3 GAAGGTAATTAAAACATTGTC MSP-2 Outer 
IC1/3D7 S1 GAGTATAAGGAGAAGTATG MSP-2 IC1 allele specific 
IC1/3D7-2 CAGGTTGAGCAGTAGGAC MSP-2 IC1 allele specific 
FC27 S1 GAGTATAAGGAGAAGTATG MSP-2 FC27 allele specific 
FC27-2 TTGAGGTTCTTGTGGAGCT MSP-2 FC27 allele specific 
GLURP-G4 ACATGCAAGTGTTGATCC  GLURP-Outer 
GLURP-G5 GATGGTTTGGGAGTAACG GLURP-Outer 
GLURP-G-1 TGAATTTGAAGATGTTCACACTGAAC GLURP-Size specific 
GLURP-G-3 GTAGGTACCACGGGTTCTTGTGG GLURP-Size specific 
 
2.9.2 Polymerase chain reactions for dhfr/dhps and pfcrt:  
A nested PCR described by Pearce et al.285 was used to amplify fragments of the dhfr and 
dhps genes. A nested PCR described by Djimde et al.187 was used to amplify fragments of the 
pfcrt gene (described in details at http://medschool.umaryland.edu/CVD/nejm2001djimde. 
htm). The only modification in our procedure was that, the M9, R/ and TCRD2 primers for 
the dhfr, dhps, and pfcrt nested PCRs were biotinylated at the 5´-end by the supplier (MWG 
Biotech, Riskov, Denmark). We used 20-µL dhfr/dhps outer PCR mixture consisted of 0.3 
mM of each dNTP, 0.25 µM of either primer set M1/M7 (dhfr) or N1/N2 (dhps), one unit of 
DNA HotStart polymerase (Qiagen, Albertslund, Denmark), buffer containing 1.5 mM 
MgCl2 and 1 µL of extracted DNA. 
1 µL of the outer dhps and dhfr PCR products were used in the nested PCRs. The nested dhfr 
and dhps PCR reaction mixture was the same as the outer PCR mixture using primer sets 
M3b/M9 and R2/R/ for the dhfr and dhps PCR, respectively. The outer and nested dhfr/dhps 
PCR conditions were as previously described285. We used 20-µL pfcrt outer PCR mixture 
consisted of 0.2 mM of each dNTP, 1 µM of the primer set TCRP1/TCRP2, 1.25 units of 
DNA Qiagen HotStart polymerase, buffer containing 2.5 mM MgCl2, and 1µL of extracted 
DNA. The reaction mixture of the nested pfcrt PCR was identical to that of the outer PCR 
and the primer set TCRD1/TCRD2 was used. The conditions of the outer and nested pfcrt 
PCR were as previously described187. 
Amplifications were performed in 96-well PCR plates. The nested PCR products were 
confirmed by electrophoresis on a 1.5% agarose gel along with a set of controls. 
2.9.3 SSOP-ELISA: 
Single nucleotide polymorphism (SNP) in the SP resistance associated genes; dhfr and dhps 
for (SP), and pfcrt for chloroquine were analysed by a recently developed method, the PCR-
ELISA289. The ELISA plates (Maxisorp; Nunc, Roskilde, Denmark) were coated with 
streptavidin in phosphate buffered saline (PBS) (1µg/mL), covered, and left overnight at 4°C. 
The plates could be kept for at least two weeks at 4°C without loss of reactivity. Prior to use, 
the plates were washed three times in washing buffer (1× PBS containing 0.05% Tween 20). 
The nested PCR products were diluted 1:10 in water in a 96-well PCR plate, denatured at 
95°C for 5 minutes, and thereafter cooled to 4°C, until used. One hundred microliters of cold 
dilution buffer (1× PBS with 0.05% Tween 20) and 2 µL of the diluted PCR products were 
then added to each well of the ELISA plate. Replicate ELISA plates were made to enable 
simultaneous probing with sequence specific oligonucleotide probes (SSOPs) targeting the 
full panel of dhfr, dhps, and pfcrt SNP/haplotypes. The plates were incubated at room 
temperature for one hour and washed three times in washing buffer (1× PBS with 0.05% 
Tween 20). The 3´-end digoxigenin- conjugated SSOPs (MWG Biotech) were diluted in 
tetramethyl ammonium chloride (TMAC; Sigma Aldrich Chemie, Seelze, Germany) solution 
(3 M TMAC, 50 mM Tris, pH 8.0, 0.1% sodium dodecyl sulfate, 2 mM EDTA, pH 8.0), 
heated to 53°C, and 100 µL was then added to each well at the concentrations indicated in 
Table 2.2. The plates were then incubated in a hybridization oven (AH Diagnostics, Aarhus, 
Denmark) at 53°C on a shaking device for one hour and washed three times in washing 
buffer. This was followed by two rounds of washing and incubation (12 minutes per round) in 
TMAC solution at the temperatures indicated in Table 2.2. To remove TMAC, the plates 
were then washed three times in washing buffer and peroxidase-conjugated anti-digoxigenin 
antibody in dilution buffer (1:1,000) (Roche Diagnostics, Mannheim, Germany) was added to 
each well. After incubation for one hour at room temperature, the plates were washed three 
times in washing buffer and an o-phenylenediamine solution of 1.5 mg/mL of 1,2-
phenyldiamine dihydrochloride (Dako, Glostrup, Denmark) dissolved in water containing 
0.015% H2O2 was added to the plates. After 30 minutes, the reaction was stopped by adding 
1.25 M H2SO4 and the optical density (OD) at 492 nm was measured in an ELISA reader. A 
flow chart of the method is shown in Figure 2.3. 
Figure 2.3: Flow chart of the dihydrofolate reductase, dihydropteroate synthase, and 
Plasmodium falciparum chloroquine resistance transporter sequence-specific 
oligonucleotide probe–enzymelinked immunosorbent assay (SSOP-ELISA) method.          
TABLE 2.2: Distribution of the probes used for the dhfr, dhps, and pfcrt ELISA haplotyping 
assay* SSOP sequence† Probe 
SSOP SSOP sequence† Probe Conct.‡ Washing Temp.§ Isolate(s) )¶ 
dhfr 
50/51CN 
50/51CI 
50/51CN2 
50/51RN 
50/51RN2 
50/51RI 
 
TGG AAA TGT AAT TCC CTA 
TGG AAA TGT ATT TCC CTA 
TGG AAA TGT AAC TCC CTA 
TGG AAA CGT AAT TCC CTA 
TGG AAA CGT AAC TCC CTA 
TGG AAA CGT ATT TCC CTA 
nM 
 
20 
 
 
(C°) 
 
58 
 
3D7, FCR3, K1 
DD2 
– 
– 
– 
– 
59C 
59R 
AAT ATT TTT GTG CAG TTA 
AAT ATT TTC GTG CAG TTA 
4 60 3D7, FCR3 
DD2, K1 
108S 
108N 
108T 
A AGA ACA AGC TGG GAA AG 
A AGA ACA AAC TGG GAA AG 
A AGA ACA ACC TGG GAA AG 
 
4 
 
62 
3D7 
DD2, K1 
FCR3 
164I 
164L 
GT TTT ATT ATA GGA GGT T 
GT TTT ATT TTA GGA GGT T 
4 60 – 
– 
dhps 
436/437AA 
436/437AG 
436/437SA 
436/437SG 
436/437FA 
436/437FG 
436/437CA 
 
GAA TCC GCT GCT CCT TTT 
GAA TCC GCT GGT CCT TTT 
GAA TCC TCT GCT CCT TTT 
GAA TCC TCT GGT CCT TTT 
GAA TCC TTT GCT CCT TTT 
GAA TCC TTT GGT CCT TTT 
GAA TCC TGT GCT CCT TTT 
 
 
 
4 
 
 
 
60 
 
DK1 
DK4 
FCR3 
3D7, K1 
– 
DD2 
– 
540K 
 
540E 
ACA ATG GAT AAA CTA ACA 
 
ACA ATG GAT GAA CTA ACA 
 
4 
 
60 
3D7, FCR3, DD2, K1, 
DK1, DK4 
SP70 
581A 
 
581G 
A GGA TTT GCG AAG AAA CA 
 
A GGA TTT GGG AAG AAA CA 
 
4 
 
60 
3D7, FCR3, DD2, DK1, 
DK4, SP70 
K1 
613A 
 
613S 
613T 
GA TTT ATT GCC CAT TGC 
 
GA TTT ATT TCC CAT TGC 
GA TTT ATT ACC CAT TGC 
 
4 
 
60 
3D7, FCR3, K1, DK1, 
DK4, SP70 
DD2 
– 
Pfcrt c72-76 
CVMNK 
CVIET 
SVMNT 
CVIEK 
S2VMNT 
 
TA TGT GTA ATG AAT AAAA 
TA TGT GTA ATT GAA ACA A 
TA AGT GTA ATG AAT ACA A 
TA TGT GTA ATT GAA AAA A 
TA TCT GTA ATG AAT ACA A 
 
 
4 
 
 
60 
 
3D7 
FCR3 
7G8 
– 
– 
 
 
 
2.10 Measurement of Antibodies against MSP Antigens by ELISA:  
The measurement of antibodies (Abs) against MSP1 antigens (Ags) in some of the samples 
used in this study was done. However, hereunder there was a brief description for the 
methodology.   
Anti-MSP1 antibodies were measured by indirect enzyme linked immunosorbent assay 
(ELISA), using a protocol described by Cavanagh et al.277. In brief, 96-well, microtitre plates 
were coated at 4°C for 3 days with MSP119 (fused with Glutathione-S Transferase, GST) or 
with GST (50ng, pH 9.4). Plates were washed with washing buffer (PBS-Tween), and were 
blocked by skimmed milk. One hundred µl of diluted plasma (1:500) was added in duplicates 
to coated plates and the latter incubated overnight at 4°C. After washings, plates were 
incubated sequentially with; 100µl horseradish peroxidase-conjugated rabbit antihuman IgG 
Abs (1:5000 dilution) and 100µl substrate buffer, then the reaction was stopped with 2M 
H2SO4. The optical density (OD) was measured using an ELISA reader at 492nm, and the 
mean value of each pair of wells (after subtraction of that of GST), was calculated. A pool of 
adult African hyperimmune sera and sera obtained from 17 Danish blood donors known not 
to have been exposed to malaria, were used as positive and negative controls in each plate. 
The same steps were followed for measurement of Abs against MSP2 Ags, GF and T9290. 
The cut-off level for positive plasma was considered as the mean plus 3xSD of OD readings 
of the Danish blood donors. The OD readings of serial dilution of the hyperimmune sera were 
used as a reference for grading of Ab levels into; high, intermediate and low levels. 
2.11 Statistical Analysis:  
For statistical analysis we used the Statistical Package for Social Sciences (SPSS) software. 
For comparison of groups, first the distribution of data was tested for normality by 
descriptive statistics, normally distributed data analyzed by independent samples T-test, and 
when normal distribution was violated data transformed by computing, and then analyzed. 
Uncorrected distributions were analyzed using non-parametric tests. Kruskal-Wallis test was 
used for comparison between clinical subgroups of severe malaria. The quoted levels of 
significance allow for post-hoc testing using Scheffe's method (comparison of age, 
hemoglobin and blood glucose level between individual complications) or the Least 
Significant Difference (LSD) method (parasite count between individual complications). 
SigmaStat software was used also for the statistical analysis. For example when comparing 
between any two sub-groups we used Mann Whitney Rank Sum Test. The Fisher Exact Test 
was used for comparison of proportions of antibody responders and prevalence of MSP 
alleles between the study groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Three 
Results 
3.1 Severe malaria: 
3.1.1 Gedarif Hospital, 2000-2002  
3.1.1.1 Clinical pattern of severe Plasmodium falciparum malaria: 
3.1.1.1.1 The frequency of acute uncomplicated and complicated malaria:  
The total number of patients clinically suspected to have malaria and for whom blood smears 
was taken and examined was 16606; among them 2488 patients (15%) were found to be 
parasitemic (Table 3.1). P. falciparum was the causative agent in 98.88% (2460/2488), while 
P. vivax accounted for 0.64% (16/2488), P. malariae 0.44% (11/2488) and P. ovale 0.04% 
(1/2488) of all malaria infections. No mixed infections were detected. Based on the 
clinician’s decision 252 malaria patients were hospitalized, and 110 (4.4%) fulfilled the 
WHO criteria for severe malaria were included in the study. The remaining hospitalized 
patients were admitted, because they had early treatment failure (chloroquine or fansidar), 
were vomiting or prostrated. The mean admission period was 2.8 days (min 0.5, max 4). 
Seven patients died, all had cerebral malaria. The mortality rate was 0.3% of all malaria 
infections. 
Table 3.1: Clinical categorization of patients presented with malaria-like symptoms to the 
malaria clinic at Gedarif Hospital  
 
3.1.1.1.2 The frequency of the different types of severe complications: 
The WHO criteria for severe malaria (SM) were used to classify malaria patients as 
uncomplicated and severe. The clinical presentation of patients categorized as having SM is 
shown in figure 3.1. Severe malarial anemia (SMA) was the most commonly recognized 
complication as it accounted for 45.46% of all severe malaria cases. Cerebral malaria was 
found in 16.36% of the patients. The rest had convulsions (20.91%), hypotension (11.82%), 
or a mixture of above manifestations (5.45%),. There was a tendency that a higher percentage 
of patients had anemia during the second malaria season, but the difference between clinical 
presentations in the two years was not statistically significant. 
  
 
 
First malaria season
Anemia
Convulsions
Cerebral Malaria 
Hypotension
Mixed complications 
Second malaria season 
(26.4%; 14)
(26.4%; 14)
(20.8%; 11)
(17%; 9)
(63.1%; 36)
(15.8%; 9)
(12.3%; 7)
(7%; 4)
(1.8%; 1)
(9.4%; 5)
 
  
Fig. 3.1: Symptoms in the 110 patients admitted to Gedarif Hospital, and fulfilling the WHO 
criteria for severe malaria, the patients were admitted over a period of two years.    
 
The six patients who had more than one type of complication were; two patients with cerebral 
malaria were also anemic, while four severely anemic patients also presented with 
convulsions. Other complications, like respiratory distress syndrome, renal failure, and 
bleeding abnormalities (thrombocytopenia) were not recognized during the study. There was 
no difference in the clinical presentations of females and males. 
3.1.1.1.3 Comparison between the age distribution of severe and mild 
malaria: 
Uncomplicated and severe malaria affected both children and adults, while small children 
between two and four years constituted a much higher percentage among patients with severe 
malaria compared to patients with uncomplicated disease. Of the 110 severe malaria patients 
27 (14 females and 13 males) were above 12 years of age. The incidence of severe malaria in 
males and females was (1:1) (figure 3.2). 
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Figure 3.2: The age distribution of patients with severe malaria and uncomplicated 
malaria in Gedarif Hospital (period 2000 – 2002). 
 
3.1.1.1.4 Characterisation of patients in the different categories of severe 
malaria: 
The mean age varied markedly between the different categories of patients with severe 
malaria. Patients with anemia or convulsions were infants and small children, patients with 
cerebral malaria were older children and young adults, whereas hypotension was found in the 
adults (figure 3.3a).  
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Figure 3.3: Comparison between four groups of patients with severe malaria       
The mean parasite count was highest in patients with convulsions and in this group the 
parasitemia was significantly higher than in patients with hypotension or anemia (figure 
3.3b). The group of patients with severe anemia by definition had low levels of haemoglobin, 
but the other groups did differ with respect to this parameter (figure 3.3c). The mean blood 
glucose levels at diagnosis and before treatment, was higher in patients with cerebral malaria 
than in patients with anemia (figure 3.3d), but did not differ significantly between the other 
groups.  The white blood cell (WBC) count was highest in patients with cerebral malaria 
(6876.5± 4 556, mean ± SD), but the differences between the groups were not significant. 
3.1.1.1.5 Comparison between fatal and non-fatal severe malaria:  
Seven patients with cerebral malaria died despite treatment. The characteristics of these 
patients are shown in (Table 3.2). Two of the patients were adults and the remaining were 
children between 5-11 years.  
Table 3.2: Shows levels of variable blood parameters in individuals who died of severe 
malaria, and comparison of the mean values of these parameters between fatal and non-fatal 
severe malaria groups   
Age (years)
/sex 
Symptoms 
duration (BA) 
Parasite count
(parasite/µl) 
Hb 
level (%) 
TWBC 
(cell/µl)
Blood glucose 
(mg/dl) 
Insulin level
(mIU/L) 
11/male 3 days 4350 ND ND 219.6 32.6 
35/male UK 180000 92 1900 122.0 9.0 
09/female∗ 4 days 96000 60 4000 246.6 20.3 
05/male 3 days 114000 65 11600 102.6 4.1 
55/male 5 days 4800 46 4600 311.0 25.0 
10/male 7 days 3150 ND 3500 149.4 ND 
06/female 2 days 42000 40 11000 111.6 ND 
RI 18.7 
 
 63471± 
68590 
60.6± 
20.3 
6100± 
4131 
180.4± 
79.7 
18.2± 
11.6 
RII 10.5 
 
 37940± 
66741 
42.18± 
18.3 
5790± 
2962 
94.3± 
29.9 
13.8± 
12.7 
P-value  0.226 0.035 0.885 0.000 0.406 
The duration of symptoms before admission varied between two to seven days. The mean 
(±SD) hemoglobin and the mean blood glucose levels were higher in patients who died of 
severe malaria than in the survivors (p=0.035 and p<0.001, respectively, T-test).  
The difference in glucose levels were not reflected in the insulin levels, which were 
comparable between the groups, although insulin level in fatal malaria was above the normal 
physiological range (4.0 to 16.8 mIU/L), 
3.1.1.2 Allelic polymorphism of MSP2 gene in severe P. falciparum malaria: 
3.1.1.2.1 Clinical groups and samples: 
A total of 616 blood samples were obtained from 325 donors; 116 were apparently healthy 
malaria-free (MF) volunteers, 106 patients with UM and 103 patients with SM. The patients 
with SM were had; SMA (48), CAM (23), CM (17), HTN (9) or multiple complications (6). 
From patients with SM blood samples were taken at D0 (n=103), D3 (n=97), D7 (n=97) and 
D28 (n=97). All blood samples were screened by PCR for P. falciparum parasite detection 
and genotyping into IC1 and FC27 families of MSP2 locus. At the time of malaria diagnosis 
and before treatment (D0), the parasite DNA was detected in all samples obtained from 
malaria patients (UM and SM) and 22 of the MF donors (n=231), see Table (3.3). The group 
of MF donors who had PCR detectable parasitemia (n=22) in fact had asymptomatic sub-
microscopic (ASUM) infection. The number of clones in the bloods obtained at diagnosis and 
before treatment (D0) in individual infections was not correlated with the initial parasite 
count (CC=0.051, P=0.48, Pearson Product Moment Correlation). Similarly, when we 
correlated the clone number in individual infections with age in all study groups (SM, UM, 
and MF) there was no correlation neither (CC=-0.016, p=0. 818, Pearson Product Moment 
Correlation). 
3.1.1.2.2 Prevalence of single clone and multi-clone malaria infections:  
As seen in Table 3.3, the single clone infections in SM accounts for 61.2% [63/103], which 
was not significantly different from UM, 54.7% [56/106], neither in the frequency nor in the 
genotypes (IC1, 45.6%; FC27, 15.5%) and (IC1, 33%; FC27, 21.7%), respectively. In all 
clinical malaria infections (UM and SM) the multi-clone infections (MCI) accounted for 
42.1% (88/209). The MCI in SM (38.8%, 40/103) and UM (45.3%, 48/106) was similar and 
basically of two types; either composed of clones of one allele family, IC1 or FC27 
(homogenic), or of both allele families, IC1 and FC27 (heterogenic). Interestingly, while only 
6 SM (5 IC1 and 1 FC27) and 7 UM (5 IC1 and 2 FC27) infections were homogenic, 34 SM 
and 41 UM infections, were heterogenic. 
Table 3.3: The frequency of single clone and multi-clone infections in patients with severe 
malaria (SM), uncomplicated malaria (UM) and malaria free donors (MF) 
Single clone 
infection 
Multi-clone infection 
HO-MTCI HE-MTCI Donors 
IC1 FC27 
IC1 FC27 IC1 FC27 
Total CN 
IC1/FC27 
6 34 SM 
(n=103) 
47 
(45.6%) 
16 
(15.5%) 3x2, 2x3 1x2 29 + 5x2 29 +5x2 
155 
(98/57) 
7 41 UM 
(n=106) 
35 
(33%) 
23 
(21.7%) 5x2 2x2 39 +2x3 36 +5x2 
162 
(89/73) 
MF 
(n=22) 
7 
(31.8) 
15 
(68.2%) 
0 
 
0 
 
0 
 
0 
 
22 
(7/15) 
Total 
(231) 
89 54 13 75 
339 
(194/145) 
 
The proportion of homogenic infections was significantly lower than that of heterogenic 
infection (P=0.009, Fisher Exact Test) whether or not SM and UM were considered together. 
The maximum number of clones in an individual infection was four in SM and five in UM. 
3.1.1.2.3 Multiplicity of infection (MOI) in different clinical grades of 
malaria infection: 
The total number of clones of parasites isolated from the 231 P. falciparum infected 
individuals at D0 was 339, giving an overall MOI of 1.5 (339/231). The MOI in parasite 
carriers with ASUM was 1.0, which was significantly lower than in patients with clinical 
malaria infection (UM and SM) who had MOI of 1.52 (P=0.001, Mann-Whitney Rank Sum 
Test). However, when we compared the MOI in UM (1.53) and SM (1.5) patients, the 
difference was not significant. Furthermore, when the individual complications of SM were 
considered separately, there was no significant difference in MOI between patients with HTN 
(1.56), SMA (1.52), CAM (1.52) and CM (1.47) (Table 3.4). But the MOI was significantly 
higher in patients with SMA and non-fatal CM (1.7) when compared with patients with 
ASUM infection. Patients died of SM (all had CM, fatal-CM, [n=7]), had less complex 
infections, with MOI of 1.14.     
Table 3.4:. Mean clone number and the frequency of infection with FC27 allele family 
alone in; MF donors (asymptomatic-sub-microscopic infection) and individual complications 
of SM, including fatal and non-fatal CM.                                                      
CM                  Molecular  
Parameters  
  
ASUM 
Malaria 
(n=22) Fatal  
(n=7) 
Non-fatal  
(n=10) 
SMA 
(n=48) 
CAM 
(n=23) 
HTN 
(n=9) 
UM 
(n=106) 
MOI 
(range)  
1 
(1 – 1) 
1.14 
(1 – 2)  
1.70∗ 
(1 – 4) 
1.52∗ 
(1 – 3) 
1.52 
(1 – 4) 
1.56 
(1 – 4)
1.53∗ 
(1 – 5) 
        
FC27 only 
(frequency)  
 
68.2% 
 
00% 
 
20% 
 
20.1% 
 
8.7% 
 
22.2% 
 
23.6% 
  
 
3.1.1.2.4 The frequency of IC1 and FC27 genotype families and allele size in 
different types of malaria infection: 
Based on MSP2 locus analysis, the parasites were either belonging to IC1 or FC27 allele 
family. The overall frequency of IC1 and FC27 alleles in all malaria infections was; 57.2% 
(194/339) and 42.8% (145/339), respectively.  
However, within each allelic family there were considerable degree of polymorphism based 
on allele size, the later was measured by the number of base-pairs (bp) in each allele. 
Accordingly, we found that the total number of alleles in the IC1and FC27 families were 30 
and 23 allele types, respectively. 
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Figure (3.4) The MSP2 allele-size polymorphism in uncomplicated (black circles) and severe 
(open circles) malaria, each circle points to the number of parasites with specific allele size  
 
Not only the number of IC1 alleles in UM (24 type) and SM (26 type) were similar but also 
the frequency of the different allele sizes were comparable, (CC=0.594, p<0.001, Pearson 
Product Moment Correlation), (Figure 3.4A). Although, the number and types of FC27 alleles 
were less common in SM (n=57, types=13) compared with UM (n=73, types=23), their 
distribution was comparable between SM and UM (CC=0.718, p<0.001, Pearson Product 
Moment Correlation, see Figure (3.4B). The most commonly recognized alleles, based on 
size typing, were IC1-420-bp and FC27-420-bp in both SM (18 & 14 times, respectively) and 
UM (14 & 9 times, respectively), See Figure (3.4).  The prevalence of the genotype FC27 
alone as a cause of infection was similar in patients with UM (23.6%, 25/106) and SM 
(16.5%, 17/103), and between the individual complications of SM; CAM (8.7%), CM 
(11.8%) SMA (20.1%) and HTN (22.2%), see Table (3.4). However, in patients with ASUM 
infection the prevalence of FC27 infection was 68.2% (15/22), while no patient died of CM 
(fatal-CM) carried the FC27 genotype as a single clone (0/7), the prevalence of FC27 in the 
two groups was significantly different (P=0.012, Fisher Exact Test). Only one fatal-CM 
infection was found to be IC1/FC27 mixed infection.        
3.1.1.2.5 Dynamic of parasite clone numbers and types in persistent SM 
infections after quinine treatment:  
After quinine treatment, twelve patients with SM had persistent parasitemia, the later was 
revealed by PCR after analysis of blood samples collected during the days of follow up (D0, D3, 
D7 and D28). All forty eight parasite DNA samples were genotyped. Seven patients were found 
to have had an initial single clone infection, 3 patients had 2 clones and 2 patients had 3 clones. 
As seen in Fig. (3.5), there was marked vertical heterogeneity indicating the genetic diversity of 
SM parasites that were resistant to quinine treatment in this sub-group of patients, only 2 out of 
12 (16.7%) patients had similar parasite genotypes (IC1-330) at diagnosis (D0). However, there 
was a clear horizontal homogeneity, 3 patients had novel genotype at D28, while only 1 patient 
had carried new genotype in D7, but no other patient had novel genotype in the other follow up 
days. None of the patients infected with more than a single clone had maintained all the infecting 
clones during the follow up, they all had only one clone at D28. Generally, only 6 out of 39 
(15.4%) clones identified during the follow up of this subgroup of SM patients were found to be 
novel (were not detected at diagnosis, D0).      
 
 
 
 
 
 
 
 
 
Did 
Clone 
No  
Allele type  
at diagnosis 
D3-allele D7-allele D28-allele 
SG038 1 FC27-350 FC27-350 FC27-350 FC27-700 
SG042 1 IC1- 390 IC1- 390 IC1- 390 IC1- 390 
SG101 1 IC1- 330 IC1- 330 IC1- 330 IC1- 330 
SG096 1 IC1- 330 IC1- 330 IC1- 330 IC1- 330 
SG098 1 FC27-480 FC27-480 FC27-480 FC27-480 
SG104 1 FC27-420 FC27-420 FC27-420 FC27-420 
SG047 1 FC27-517 FC27-517 FC27-580 FC27-517 
SG037 2 IC1- 340  IC1- 340  
  FC27-517 FC27-517  FC27-517 
SG066 2 IC1-420 0 0 0 
  FC27-650 FC27-650 FC27-580 FC27-580 
 SG95 2 IC1-420 IC1-420 IC1-420 IC1-420 
  FC27-450 0 0 0 
SG010 3 IC1-350 IC1-350 IC1-350 0 
  IC1-450 IC1-450 IC1-450 0 
  IC1-550 0 FC27-517 FC27-517 
SG065 3 IC1-430 0 0 0 
  IC1-520 0 0 0 
  FC27-420 FC27-420 FC27-420 FC27-420 
      
 
Figure (3.5): The genetic diversity of infection in different severe malaria patients at the time 
of malaria diagnosis 
 
3.1.1.2.6 Differential clearance of IC1 genotype in multi-clone SM infections 
after treatment:  
The total number of SM patients who had heterogenic multi-clonal infection (mixed IC1/FC27) 
at the time of malaria diagnosis was 34 patients (33%). After initiation of quinine treatment, 
significantly more parasites of IC1 (28/34) genotype were cleared compared to the FC27 (15/34) 
parasites at D3, P=0.002, Fisher Exact Test (fig. 3.6). The same trend was also recognized in the 
other follow up days, where the prevalence of FC27 exceed that of IC1 at D7 (12/34 and 4/34, 
respectively) and D28 (8/34 and 4/34, respectively), P= 0.026 and P=0.34, respectively.  
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Figure (3.6): The differential and faster clearance of IC1 genotypes in multi-clone infections 
with IC1 and FC27 parasite clones, in SM patients.  
 
3.1.1.3 Genetic fingerprints of parasites causing severe malaria in a setting 
of low transmission “one strain one patient”: 
3.1.1.3.1 Clinical data: 
Among the 943 microscopically confirmed clinical P. falciparum malaria infections, only 53 
(5.6%) patients were found to have severe malaria, these included 11 (1.2%) patients with 
cerebral malaria, and among the later 5 (0.5%) patients died. Other severe malaria patients 
had; convulsions (n=14), severe malaria anemia (n=14), hypotension (n=9) and multiple 
complications (n=5), the details were presented before. From the patients with SM, parasite 
DNA was obtained from 47 patients.  
3.1.1.3.2 Diversity of infection (DOI): 
The diversity of infection (DOI), is the parameter for quantitative estimation of the parasite 
genetic variations, it is based on our hypothesis that; each infection is caused by a parasite of 
a unique genetic make up; however; the DOI value depends on the molecular marker used. 
The maximal number of parasite gentotypes which can be detected by using any of the four 
molecular markers; the pfcrtK76T, pfmdr1N86Y, GLURP allele size, MSP2 family types and 
allele sizes were; 3, 3, OPEN (depends on number of test samples), 3 and OPEN, 
respectively. Accordingly, the maximal DOI which can be obtained if we used any of the 
above molecular markers would be; 0.064 (3/47) for pfcrt, pfmdr1 or MSP2 allele families, 
while if we used GLURP or MSP2 allele size typing, the maximal DOI should be 1.00 
(47/47), see Table (3.5).        
Table (3.5): Estimation of the diversity of infection in severe and uncomplicated  
malaria, by using different molecular markers (pfcrt, pfmdr1, msp2 and glurp) 
 and by compiling all markers together 
   
Diversity of infection (DOI) 
in clinical malaria 
Molecular markers 
(MM) 
SM UM 
Max. No of 
Allele-type for 
each MM 
pfcrt 76 
(T, K, T/K) 
0.043 
(2/47) 
0.057 
(3/53) 
3 
pfmdr1 86 
(Y, N, Y/N) 
0.064 
(3/47) 
0.058 
(3/52) 
3 
 
MSP2 families 
(IC1, FC27, Mixed) 
0.064 
(3/47) 
0.057 
(3/51) 
3 
 
MSP2 
Allele size 
0.553 
(26/47) 
0.804 
(41/51) 
3 
 
glurp 
Allele size 
0.435 
(20/46) 
ND Open 
Overall 0.936 
(44/47) 
0.868 
(46/53) 
Open 
  
 
3.1.1.3.3 Genetic diversity of parasite isolates in patients with severe 
malaria, based on use of a single molecular marker: 
In the 47 SM parasite isolates, only two pfcrt76 (T and K), 3 pfmdr1 86 (N, Y and N/Y), and 
3 MSP2 families (IC1, FC27 and IC1/FC27) allele-types were detected. However, the glurp 
locus analysis revealed 20 allele-types; accounting for (20/46) 43.5% of all SM infections, 
indicating that at least 43.6% of all infections were precipitated by parasites of unique allele-
type. While number of parasites with unique allele-type based on MSP2-allele size typing 
was 26, giving a DOI of (26/47) 55%, as seen in table (3.5).  
3.1.1.3.4 Genetic diversity of parasite isolates obtained from patients with 
uncomplicated malaria, based on use of a single molecular marker: 
For parasite isolates obtained from patients with UM (n=53), 3 allele types were revealed by 
each of the three markers; pfcrt76 (T, K and T/K), pfmdr1 86 (N, Y and N/Y), and MSP2 
families (IC1, FC27 and IC1/FC27), and that was the maximum allele-type could be detected. 
Interestingly, the allele-size-based MSP2 typing revealed 41 allele-types in UM, giving a DOI 
of (41/51) 0.804, which was higher than the DOI in SM when MSP2 allele size typing was 
used. The GLURP locus analysis was not done for UM samples, and not all samples were 
analyzed for the other three molecular markers, as seen in Table (3.5).    
3.1.1.3.5 Genetic diversity of parasite isolates obtained from malaria 
patients, based on use of multiple molecular markers: 
In severe malaria, the genetic profile of the individual parasite isolates in all tested loci; pfcrt, 
pfmdr1, glurp and msp2 (allele family and size), is shown in the figure (3.7). This multi-locus 
genetic profile of parasites had revealed an extreme diversity between the isolates, DOI of 
0.936 (44/47), which was statistically significantly higher compared with the DOI when any 
of the individual molecular markers was used alone (range 3/47 to 26/47), P value < 0.001, 
Fisher’s exact test, see Table (3.5) and the Figure (3.7). Although, glurp analysis was not 
carried out for parasite isolates obtained from patients with uncomplicated malaria, the multi-
locus genetic profile revealed a large degree of diversity, DOI 0.902, which was also 
significantly higher than the DOI for individual markers (range 3/53 to 41/51)(P=<0.001 to 
0.269, Fisher’s exact test), see Table (3.5) and figure (3.7). 
 
 Figure (3.7): The mult-locus genetic profiles of parasites isolates from patients with 
severe malaria 
3.1.1.3.6 Homogeneity of parasite isolates in patients with severe malaria: 
In figure (3.7), three pairs of patients were found to carry parasites of identical multi-locus 
genetic profile within each pair which differ between the pairs; (SG19 & SG20), (SG25 & 
SG42) and (SG49 & SG51). The history, clinical description and laboratory data of these 
patients shown in table (3.6). Depending on this data, the probability that the parasites of each 
pair will remain identical if genetic profile testing was extended to involve more genes is 
high for one pair (SG19 & SG20), intermediate for another pair (SG25 & SG42) and unlikely 
for the third pair (SG49 & SG51). 
Table (3.6): Characteristics of three pairs of patients infected with parasites of the same 
multi-locus genetic profile in each pair, but differ between pairs    
Pair 1 Pair 2 Pair 3   
Parameters  SG19 SG20 SG 25 SG 42 SG 49 SG 51 
Complication  SMA plus SMA SMA CAM SMA SMA 
Gender M F M F M M 
Age 4 6 8 9 14 50 
Hospital 
admission  
27-30 
Oct/2000 
27-30 
Oct/2000 
5 – 8 
Nov/2000 
21 – 24 
Nov/2000 
4 – 7 
Dec/2000 
18-21 
Dec/2000 
Ethnic group  The same  The same  Different  
Village   The same  The same The same 
House The same  The same Different  
Hemoglobin (%) 30% 35% 55% 51% 30% 30% 
TWBC 5100 4000 3600 5700 1300 5700 
Parasite count  144600 108600 8040 45000 41400 6300 
Ab response 
MSP119 
MSP2A 
MSP2B 
 
0.610 
0.547 
0.849 
 
0.721 
0.717 
0.074 (-ve) 
 
0.65 
0.33 
ND 
 
0.637 
0.282 
0.317 
 
0.723 
ND 
1.88 
 
1.162 
ND 
0.911 
 
In the first pair, the patients are brothers, close in age and both brought to the hospital at the 
same time, both had SMA, admitted and discharged from the hospital on the same dates. For 
the second pair of patients, they were of the same ethnic group, living in the same quarter 
(may be neighbors) and most probably they were relatives and may be living in the same 
house. In the third pair the patients different in most of the available data, but they were 
living in the same town and may be the same quarter. 
3.1.2 Severe malaria in New-Halfa Hospital (November 2000 to February 
2001): 
3.1.2.1 Clinical and parasitological categorization of patients:  
From the patients seen in the malaria clinic, 120 individuals were recruited to the study.  
Three study groups were identified based on clinical and parasitological data; 52 febrile 
patients were clinically suspected to have malaria but were found to have negative blood 
smears, 40 febrile patients with microscopically confirmed malaria and the 28 apparently 
malaria free (MF) donors (Table 3.7). In the former two groups of patients there were three 
clinically diverse subgroups of patients; patients with or suspected to have uncomplicated 
malaria (UM), severe malarial anemia (SMA) or cerebral malaria (CM).  
Table 3.7: Number of individuals, number of patients with coma and  
Mortality rate of comatose patients in the three study groups 
 
The cerebral malaria patients: Among the clinically suspected group of malaria patients, 24 
patients were brought to hospital in coma, suspected to have cerebral malaria (CSCM), the 
microscopic examinations failed to confirm the clinical diagnosis. The age of CSCM patients 
(age data is available for 21 out of 24 patients) fall between 1 and 70 years included one 
child, 3 adolescents and the others were adults, with an overall mean ± (SD) age of 31.2 ± 
Study groups Confirmed Malaria  
(+ve blood smear) 
       CSMalaria 
(-ve blood smear) 
Apparently healthy 
     (MF donors)      
Number of individuals 
(male/female ratio) 
40 
(27/13) 
52 
(24/28) 
28 
(17/11) 
Number of comatose 
Patients  
10 24 
 
0 
Mortality among 
comatose patients  
20% 
(2/10) 
20.8% 
(5/24) 
0% 
(0/28) 
21.8 years. Half of the patients were males. All the comatose patients were treated initially 
with quinine infusion; in addition injectable antibiotics were given to two patients. Nineteen 
patients (79.2%) fully recovered, and five (20.8%) patients died (mean age was 46.2 ± 22.4 
years). 
The other clinically diagnosed malaria patients with negative blood smear included 14 
patients suspected to have severe malarial anemia (CSSMA; hemoglobin - mean ± SD of 24.3 
[± 4.5] %). They had a mean age of 18.6 ± 19.3 (range 1-58) years (age data is available for 9 
out of 14 patients). Fourteen patients with a mean age of 4.1 ± 3.4 (range 1-12) years, had 
symptoms suggestive of uncomplicated malaria (CSUM). 
The control groups were patients with microscopically confirmed malaria and malaria-free 
donors; the former group included 40 patients, 17 had uncomplicated malaria (UM) and 23 
patients with severe malaria (10 patients had CM and 13 had SMA). The mean age ± SD 
(range) of the patients with UM, CM and SMA were; 8.2 ± 9.4 (1-30), 8.4 ± 9.1 (2-33) and 
1.6±1.1 (0.3-4). In addition, a group of 28 apparently healthy donors (MF) was included in 
the study; they had a mean age of 6.8 ± 4.8 (1-21) years [± SD (range)].  
The clinically suspected severe malaria group (CSCM and CSSMA) had a mean age much 
greater than that of the corresponding representative group of the confirmed severe malaria, 
CM and SMA. However, the mean age for all selected groups, represented the overall age 
pattern of malaria prevalence in the area16. 
3.1.2.2 Parasite prevalence by PCR: 
P. falciparum parasites were detected by PCR in 17 out of 24 (70.8%) blood samples 
obtained from the csCM patients (Table 3.8). All the 5 comatose patients who died had 
parasitemia revealed by PCR (Fig. 3.7A). For the 14 csSMA, the parasite rate as detected by 
PCR was 42.8% (6/14). The detection rate of parasites by PCR was 100% for the 14 patients 
who had negative blood smears and clinical features suggestive of uncomplicated malaria 
(CSUM). Parasitemia was also detected by PCR in patients with microscopically confirmed 
SMA, CM and UM, except for one patient with UM (PH08), for whom repeated PCR did not 
reveal any visible band. On the other hand parasitemia was detected by PCR in only 5 of the 
28 asymptomatic (MF) donors (17.8%) and two of them had parasitemia detected also by 
microscopy (7%). As shown in table 3.6, the differences were statistically significant between 
the prevalence of parasitemia as detected by PCR between malaria-symptom-free donors 
(MF) and the other malaria patient categories; UM, CSUM, CM, CSCM and SMA, CSSMA 
(17.8 % for MF versus 94.1, 100, 100, 100, 70.8 or 42.8, respectively), p < 0.05 for all 
comparisons.  
3.1.2.3 Molecular characterization of the parasite isolates: 
The predominant sub-patent malaria infections of the comatose patients (CSCM) were single 
clone infections (82.4%, 14/17), with a mean clonal number (MCN) of 1.23 ± 0.56 while only 
50% of the CM infections with patent parasitemia, were single clone infections, with a MCN 
of 1.70 ± 0.82 (Table 3.8, Fig. 3.8). 
Table 3.8 Parasitemia detected by microscopy and by polymerase chain reaction and the 
mean number of clones, in different study groups or subgroups in New Halfa area 
Patients with +ve BF Patients with -ve BF  
Parasitemia    UM 
(n=17) 
  CM 
(n=10) 
 SMA 
(n=13) 
CSUM 
(n=14) 
CSCM 
(n=24) 
CSSMA 
(n=14) 
Apparently 
Healthy,MF     
Donors (n=28) 
Parasite rate by 
microscopy 
100% 100% 100% 0% 0% 0% 7.1% 
Parasite rate by 
PCR 
94.1% 100% 100% 100% 70.8% 42.8% ¤17.8% 
Mean clone 
number  
1.69± 
0.70 
1.70± 
0.82 
1.62± 
0.77 
1.86± 
0.66* 
1.23± 
0.56* 
1.17± 
0.41 
1.20± 
0.45 
 
The uncomplicated malaria infections were relatively more commonly multiclonal, both 
patent UM (56.3%, 9/16; with a MCN of 1.69 ± 0.70), and sub-patent CSUM (71.4%, 10/14; 
with a MCN of 1.86 ± 0.66). Although there were great variations in clone number between 
the groups, the mean clonal number was not statistically significantly different between all 
the groups taken together (p=0.060, Kruskal-Wallis one way analysis of variance on rank). 
However, when comparing CSCM with CSUM the difference was statistically significant (1.23 
± 0.56 versus 1.86 ± 0.66, p=0.014, Mann Whitney Rank Sum Test). The genotype IC1 was 
detected in all PCR-detectable infections except in seven patients (7/81). The genotype FC27, 
was recognized in only 3 infections in CSCM (17.6%, 3/17), while it was recognized in 7/10, 
9/14, and 8/17 parasite isolates obtained from CM, CSUM and UM patients, respectively. The 
differences were statistically significant when comparing CSCM to CM or CSUM, (p=0.013 & 
0.012, respectively, Fisher Exact Test).  
3.1.2.4 Prevalence of antibodies against MSP Antigens:  
The prevalence of antibodies against any or all the three MSP fragments (MSP119, MSP2GF, 
MSP2T9), in plasma collected at diagnosis and before treatment, was calculated for the 3 
major groups of donors. Plasma from the CSSMA subgroup was not obtained.  
 
Figure 3.8:  The proportions of antibody responders to any of the MSP fragments 
(MSP119, MSP2GF and MSP2T9), in the different study groups. 
    
As seen in figure 3.8, the positivity rate of anti-MSP antibodies was; 84.2% (16/19), 68.4% 
(26/38), 36.4% (8/22), and 14.3% (2/14) in the groups of the patients; the CSCM, 
microscopically confirmed malaria, MF and CSUM groups, respectively. The difference in the 
proportion of responders between the CSCM and microscopically confirmed malaria group 
(UM & SM) was not significant (p=0.339, Fisher Exact Test). But the difference between 
CSCM and MF or CSUM donors was statistically significant (p=0.004 and 0.001, respectively), 
as was the difference between the confirmed malaria group and MF or CSUM (p=0.029 and 
0.001, respectively). When considering the clinical subgroups; the Ab prevalence rate in 
comatose patients, with negative blood smear and negative PCR, was 85.7% (6/7), while it 
was 100% (5/5) in comatose patients who died thereafter. While the prevalence of anti-MSP1 
Abs was low in the MF donors, most of the responders (80%) had the highest level of Abs 
compared with the other groups as seen in the semi-quantitative estimation of antibody levels 
(Fig. 3.9A & B). 
           
                                             (3.9A)                                                                             (3.9B) 
Figure 3.9 Comparison between; CSSM, UM and MF donors. Test parameters are; a. parasite genotype (CN; light shade =1 clone, dark 
shade=2 clones) b. level of MSP Ab (blank, light, medium or dark shaded boxes for; no response, low, intermediate and high level of Abs, 
respectively). Panel (A), patients with malaria symptoms (CSSM and UM); Panel (B), apparently MF donors. ID bolded given quinine and 
benzyl penicillin, ID italic given in addition gentamycin
Genotype Patient 
ID 
Age 
year IC1   FC27 CN 
Anti-MSP 
Ab level 
Clinical 
category 
CH01 60     csCM 
CH02 NK     csCM 
CH04 35    0 csCM 
CH05 32     csCM 
CH06 NK     csCM 
CH07 NK     csCM 
CH08 65     csCM 
CH03 5   1  csCM 
CH09 4   1  csCM 
CH10 50   1  csCM 
CH13 25   1 0 csCM 
CH15 1   1 ND csCM 
CH16 33   1 0 csCM 
CH17 40   1  csCM 
CH20 17   1  csCM 
CH19 13   2  csCM 
CH18 13   2  csCM 
SH13 5.5   1  csCM 
SH19 26   1  csCM  
CH12 30   1  csCM died 
CH14 70   1  csCM died 
CH22 55   1  csCM died 
SH01 16   1  csCM died 
CH11 60   3  csCM died 
PH08 2   0  UM 
PH02 4   1  UM 
PH03 30   1 0 UM 
PH09 2   1  UM 
PH10 5   1  UM 
PH15 2   1 0 UM 
PH18 7   1  UM 
PH21 1   1 0 UM 
PH13 28   2  UM 
PH04 5.5   2  UM 
PH05 2   2 0 UM 
PH06 14   2  UM 
PH29 1.5   2  UM 
PH30 22   2  UM 
PH31 5   2  UM 
PH14 5   3  UM 
PH07 4   3 0 UM 
Patient 
ID 
Age 
Year 
Anti-MSP 
Ab level 
NH02 21 0 
NH04 20  
NH17 11 0 
∗NH01 9  
NH09 9 0 
NH13 9 0 
NH14 9  
NH22 9 0 
NH16 8 0 
NH29 8  
NH10 7 0 
NH11 7  
NH18 7 0 
NH24 7  
∗NH26 7 0 
NH23 6  
NH28 6 0 
+NH19 5 0 
NH27 5 0 
NH06 4  
NH21 3.5 0 
NH25 2.5 0 
NH03 2 0 
NH05 2 0 
NH20 2 0 
∗NH15 1.5 0 
+NH08 1 0 
NH12 1 0 
 + Blood film & PCR positive 
 ∗ Only PCR positive  
CN = clone number 
Ab = antibodies  
ND = not done 
CS  = clinically suspected 
CM= cerebral malaria  
UM= uncomplicated malaria 
NK= not known  
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3.2 Estimation of antimalarial drugs efficacy in Eastern Sudan: 
3.2.1 Gedarif area (October-December 2003): 
3.2.1.1 The efficacy of sulfadoxine-pyrimethamine alone and in 
combination with chloroquine: 
3.2.1.1.1. Characteristics of the treatment groups: 
The two treatment groups, the sulfadoxine/pyrimethamine (SP) and SP plus chloroquine (CQ) 
groups were similar with regard to age (22.9±15.5 and 22.5±16.4, respectively), weight (42.4 
± 15.4 and 40.9 ± 16.3 Kg, respectively), residence (Daraweesh / Kajara; 16/45 and 65/134) 
and time of study. However, the proportion of females was higher in SP treatment group 
(M/F, 26/35 [57.4%] and 97/102 [51.3%]), but the difference was not significant (p=0.490, 
Chi-square), Table (3.9). 
The table 3.9 Characteristics of the two treatment groups   
Age Village Treatment 
Arms 
Total 
patients 
Gender 
(M/F) Mean ±SD Median 
Weight 
(Kg) Daraweesh Kajara 
SP alone 61 26/35 22.9 ± 15.5 15 42.4 ± 15.4 16 45 
CQ & SP 199 97/102 22.5 ± 16.4 18 40.9 ± 16.3 65 134 
 
3.2.1.1.2. Clinical and parasitological response 
3.2.1.1.2(a) Efficacy of SP and SP plus CQ: 
The effectiveness of the two arms of treatment, SP and SP plus CQ was not statistically 
significantly different. Before PCR correction the proportion of patients achieved adequate 
and clinical response (ACR) following the treatment with SP alone or with SP plus CQ was; 
68.3% (41/60) and 63.4% (123/194), respectively. Typing the polymorphic regions of msp2 
revealed that 3.6% (7/194) were re-infections rather than recrudescence in the SP+CQ group 
only,  resulting in a PCR adjusted ACR of SP  plus CQ of 67.01% (130/194) the ACR in SP 
alone is remaining un changed 68.3% (41/60). The treatment failure (TF) inclusive was 
31.7% (19/60) for SP alone and 32.99% (64/194) for SP+CQ group. The overall treatment 
failure was estimated to be (83/254=32.68%). Both early and late TF (ETF & LTF) were 
recognized in the two arms of treatment ،see Fig (3.10). 
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Figure 3.10: The clinical and parasitological response of 260 P. falciparum malaria patients 
treated with CQ plus SP or SP alone using a modified WHO (1996) protocol. 
In early treatment failure, all patients with parasitemia detectable at D3 of follow-up, were 
not given alternative treatment, but were observed up to D7; none of them developed severe 
symptoms or marked hyperparasitemia. Based on clinical and parasitological findings 
(between D3 and D7 or after), patients can be categorized into two groups, a. patient without 
symptoms and undetectable parasitemia at D7 (delayed parasitological response, DPR). b. 
Patients maintained parasitemia and still had or had no symptoms at D7, that continued for 
variable periods after D7 (actual early treatment failure, AETF). None of those patients 
developed severe symptoms, and most of them were given alternative treatment either at D7 
or later. The frequency of DPR and AETF in the two treatment groups, SP and SP plus CQ; 
was 3.3% & 11.7% and 3.6% & 7.7%, respectively. The LTF was higher in SP plus CQ 
treatment group (25.3%, 49/194) than in SP treatment group (16.7%, 10/60), but the 
difference was not significant (P = 0.350, Chi-square).   
3.2.1.1.2(b) Prevalence of asexual parasitemia during follow-up:  
As shown in Fig. (3.11), the parasite clearance by D3 after treatment with SP and SP plus CQ 
treatment was 83.6% and 86.4%, respectively. Thereafter, the highest proportion of 
parasitemic patients was observed at D7 & D28 (13.1%), and at D21 (15.6%), in SP and SP 
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plus CQ treatment groups, respectively. The proportion of patients with parasitemia at D7 
were significantly higher in the SP treatment group, 13.1% versus 4%, (p=0.037, Chi-square). 
There was no correlation between initial parasitemia and treatment outcome over the 28-days 
of follow-up. Patients had ACR and TF had a median parasite count at D0 of 9130 and 10065 
parasites/µL of blood, respectively, the difference was not significant P=0.129 (Mann 
Whitney Rank Sum Test).     
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Figure 3.11 The proportion of patients who had microscopically 
detectable asexual parasitemia during the days of follow up 
 
3.2.1.1.3 Drug resistance and age: 
All patients (n=260), who were treated by SP (age, mean ± SD, 22.9±15.5 years) or SP plus 
CQ (22.5±16.4 years), had a median age of 17 years. The patients in both treatment groups, 
who had microscopically detectable parasitemia at D3, had a median age of 13 years, which 
was not significantly different from the age of all malaria patients at D0. However, malaria-
treated patients who had parasitemia after D3 (had drug resistant malaria) were statistically 
significantly younger in age, than all patients at the time of diagnosis (P = <0.001, Kruskal-
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Wallis One Way Analysis of Variance on Ranks, Dunn's Method). The median age of 
patients with ACR (21 Years) was statistically significantly greater than the median age of 
patients who had parasitemia at D7, D14, D21, and D28, which were; 9, 10, 10 and 10 years, 
respectively (Fig. 3.12A). Even, when we related treatment failure to age of patients in each 
treatment arm separately, a similar result was obtained, with few exceptions. For the SP 
treatment failure group, the patients with parasitemia at D28 had small median age of 9.5 
years (but the mean age was relatively high). While, for the SP plus CQ treatment failure 
group, the age of patients with parasitemia at D7 was not significantly different from the age 
of patients at D0 of the same treatment group. Since the two treatment regimes were 
comparable, we compared the age of all patients (both treatment groups) who achieved ACR 
(median & inter-quartile range; 21year & [13% – 35%]) and others who had TF (12 years & [ 
9% – 16%]), the difference was strongly significant (P=<0.001), Mann Whitney Rank Sum 
Test).           
3.2.1.1.4 Age and gametocyte carriage: 
The median age of the patients who didn’t had detectable gametocyte during the study period 
(n=117) was 22 Years (inter-quartile range, 13–35 Y). While patients had gametocytemia in 
the follow-up days; D0 (n=7), D3 (n=30), D7 (n=104), D14 (n=81), D21 (n=41), and D28 
(n=25), their median age were, 12 [9.25 - 16], 13 [9 - 17], 13 [9.5 - 22], 13 [10 - 21], 13 [9 - 
19] and 11[8.75 – 16.5] years, respectively, see (Fig. 3.12B). The age of patients without 
gametocytemia and with gametocytemia in the different days of follow up were significantly 
different P = < 0.001, Mann Whitney Rank Sum Test. But, even if the age of all patients with 
malaria at D0 was compared with age of patients who had gametocytemia in any of the 
follow up days the differences were all statistically significant (P = 0.01 - <0.001, t-test). 
Seven patients had gametocytes at the time of diagnosis (D0) in the two treatment groups, see 
Fig. (3.12). 
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Figure 3.12B 
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Figure (3.12): (A) The age of patients who had asexual parasitemia during the days of follow up, 
 after treatment with either SP alone or in combination with CQ. (B) The age of patients who  
never had microscopically detectable gametocytemia during the days of follow-up 
 
From the figure (D01) stands for D0 without detectable gametocytemia, and the others who 
had gametocytemia in the 6 days of the follow-up; D02, D3, D7, D14, D21, and D28. D02, 
stands for patients with gametocytemia in D0. The data was pooled from the two treatment 
groups since there was no significant difference between the two groups. The box span 
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between 25% and 75% percentile and crossed by the median value (heavy line within the 
box), the mean is represented by the light interrupted lines and the circles are outliers. 
However, during the follow-up, the gametocyte carriage in the two treatment groups was 
similar except for D3, while only 7% of the patients treated with SP plus CQ had 
microscopically detectable gametocytemia, 26.2% of the patients treated with SP alone had 
gametocytemia, the difference was significant (P = <0.001, Chi-square) . But at D7 the 
gametocyte carriage rate was equal between the two treatment groups, and reached the 
highest level of gametocyte carriage (39.3% and 40.2%, for SP and SP plus CQ, respectively) 
fig. (3.13). 
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Figure (3.13): The gametocyte carriage rate (%) during the days of the follow up, a comparison 
between two different treatment regime, SP alone (heavy line and closed circles) and SP plus 
CQ (interrupted line and open circles). 
 
3.2.1.1.5 Gametocytogenesis and drug response:  
Gametocyte production was estimated by microscopic detection and count of gametocytes in 
the blood smears taken during the six days of the follow-up (D 0, 3, 7, 14, 21, and 28). The 
parasite was considered as a potentially gametocyte producer, if gametocytes of any count 
were detected in any of the days of the follow up. Based on this definition, the proportion of 
the gametocytes producing parasites in patient with ACR (44.8%, 73/163) was significantly 
lower than in patients with TF (72.2%, 70/97), P=<0.001, Chi square test. However, the 
gametocyte count, in both treatment-outcome groups was comparable in D3 and D7, P=0.603 
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and P=0.414, respectively, but, it was higher in the TF group in D14, D21 and D28; P=0.024, 
P=0.002, and P=0.061, respectively, Mann Whitney Rank Sum Test. see Fig. (3.14).   
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Figure (3.14): The gametocytes count (median) in the different days of follow up, for 
patients achieved adequate clinical response and in patients with treatment failure 
Gametocyte longevity was estimated by the number of times in which gametocytes were 
detected, over the six times of the follow-up, it varied between zero and six. Accordingly, we 
found the longevity of gametocytes in patients with TF was significantly higher than in 
patients with ACR (median & inter-quartile range; 1 & 0 – 2 and zero & 0 – 2, respectively, 
P=<0.001, Mann Whitney Rank Sum Test). However, if we limited the comparison to the 
gametocyte producing parasites in both treatment outcome groups, the TF and ACR, there 
was no difference. 
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3.3 Implication of the dhfr/dhps/pfcrt molecular markers in the evolution of 
P. falciparum malaria parasite beyond the Sulfadoxine/pyrimethamine and 
chloroquine resistance: more relevance and mutual association   
 3.3.1 Prevalence of individual pfdhfr, pfdhps and pfcrt mutations;   
Of the 168 bloodspots that yielded PCR products, about 4.71% were mixed at dhfr, 3.57% 
were mixed at dhps and 1.19% were mixed at pfcrt, no majority haplotypes were found. The 
low number of mixed infections was a reflection of the low level of transmission in the area. 
The mutations single nucleotide polymorphism (SNP) of different codons of dhfr gene (c51-I, 
c59-R, c108-N, c164-L) and dhps gene (c436-F, c437-G, c540-E, c581-G and c613-S) that 
associates with SP resistance were estimated in blood samples obtained from patients 
(n=168) with UM. To attend the most accurate estimation for the prevalence of the mutations 
in the total population, we assumption that the un-typed ACR samples (n2=82) should 
mirrored the genotyped ones (n1=86) and we adjusted the mutation frequencies by 
multiplying by a correction factor of 1.953 (1+ n2/n1) see table (3.10). The prevalence of  dhfr 
mutant alleles; c51-I and c108-N, were 0.919 and 0.923, respectively, the mixed wild/mutant 
isolates, c51N/51I (n=7) were considered as mutant (fig. 3.16).  
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While only one isolate was found to carry the mutant allele 59-R (prevalence of 0.006), the 
c164L mutation was not recognized as major infection, but there were 2 patients have it as 
minor infection. On the other hand, the prevalence of dhps mutant alleles; c437-G and c540-E 
were 0.902 and 0.793, respectively, and that of c581-G was 0.13. The wild/mutant mixed 
mutations; c437A/G (n=6), c540K/E (n=6) and c581A/G(n=4) genotypes were considered as 
mutant (phenotype). While only one isolate (0.006) had c436F mutation as major infection, 6 
harboring it as minor infections and 3 harboring 436A also as minor infection, c613S 
mutation was not recognized as major infection, but there was only one patient harboring it as 
minor infection. 
For chloroquine resistant transporter gene (pfcrt) We found that the wild type (CVMNK) = 
11/168= 6.55%, the mutant type (CVIET) = 155/168 = 92.26%, mix infection wild/mutant 
type  = 2/168= 1.19%  and the mutant type (SVMNK) was not recognized.  
3.3.2 The linkage and the multiplicity of mutations: 
The linkage of mutant alleles associated with SP resistance was indicated by the high 
prevalence of multiple mutations. The prevalence of dhfr c51-I/c108N double mutation was 
80%, and that of dhps c437G/540E was 59%.     
Regardless of the loci of mutations (codon/gene), parasites were grouped into wild isolates 
and isolates with single, double, triple, quadruple and quintuple mutations. Some parasite 
DNA samples (n=23) didn’t show bands for all tested alleles, and they were excluded from 
the analysis, the included samples were 231. The frequency of isolates with the mutations 
from one to five were; 0.97, 0.93, 0.87, 0.72 and 0.12 respectively. While only 0.03 (n=4) of 
the isolates were found to carry the wild alleles of the tested genes.  
3.3.3 Association of dhfr/dhps mutations with sulfadoxine/pyrimethamine 
drug response   
In this sub-set of samples, the frequency of the mutant alleles; dhfr 51-I, 108-N and double 
mutant c51-I/108N (range 0.87–0.95; 0.88–0.92 and 0.68–0.84, respectively) was comparable 
between the different drug response groups, ACR (n=86), ETF (n= 19) and LTF (n= 63). 
Similarly was the frequency of dhps mutant alleles; c437-G, c540E, c581G and double 
mutant 437G/540E (range 0.85–0.94; 0.68–0.89; 0.11–0.26 and 0.37-0.59, respectively) was 
comparable between the above mentioned drug response groups. However, mostly, the 
prevalence of mutant alleles was higher in TF groups, but the differences always below the 
statistical significance.     
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3.3.4 Multiplicity of mutations, age and the immune factor:      
As seen in the Fig. (3.16A & B), patients infected with parasites with different number of 
mutations or with wild parasites were not different in age. However, the age of patients 
infected with parasites with the same number of multiple mutations (more than one mutation) 
was significantly different between those attended full recovery (ACR) and others who had 
treatment failure (ETF and LTF). Patients achieved ACR infected with parasites with 2, 3, 4, 
or 5 mutations, their mean ages were; 28.8, 24, 24, and 26.1 years, respectively, which were 
significantly higher than the ages of patients infected with parasites with a comparable 
number of mutations; 11.6, 17.5, 17, and 15.6 respectively. 
Figure 3.16 (A & B) 
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The term mutant-clearance immunity factor (MCIF) was introduced to estimate the impact of 
immunity in clearance of mutant (SP resistant) parasites; age was used as a marker for 
immunity. 
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In malaria endemic areas age is the single most reliable indicator for immunity unless other 
wise e.g. high prevalence of immune jeopardizing disorder in the area. It was calculated by 
dividing the prevalence of each individual dhfr/dhps mutant allele or that of the different 
scales of MOM, by the actual treatment failure (35.4%) (TF stands for parasite resistance 
grade I, II and III). The results as shown in table (3.10) varied between 0.34 and 2.74, 
depending on multiplicity of mutation of the infecting parasites, the higher parasite MOM the 
higher host immunity, the lower MCIF value. 
    Table 3.10: The prevelance of individual and multiple molecular markers of SP resistance 
 
3.3.5 Multiplicity of mutations and pre-treatment parasitemia:   
The parasite density at the time of malaria diagnosis and before treatment in patients infected 
with wild isolates and with isolates with single mutation, taken together, was significantly 
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higher than in patients infected with isolates with multiple dhfr/dhps gene mutations. The 
difference in parasite density abolished when wild isolates were considered separately, 
however, the number of wild isolates was too low (n=4). The parasite density was not 
different between patients infected with isolates had multiple mutations (more than one) 
irrespective of the number of mutations.  
3.3.6 Multiplicity of mutations and gametocytogenesis: 
We defined gametogenesis as the ability of the asexual parasitemia to produce gametocytes at 
least once during the 28-days of follow up (D0, 3, 7, 14, 21 and 28), while gametocytes 
longevity was considered as an index for gametocytogenesis and scaled from 0 (no 
gametocyte detected during follow up) to 5 (gametocytes detected in all days of follow up). 
On the other hand, parasites were grouped based on the number of dhfr/dhps genes mutations 
per parasite (0[wild], 1, 2, 3, 4 and 5). None of the wild isolates and isolates with single 
mutation (n=9) produced gametocytes during the follow up. Although, the gametogenesis rate 
of the parasite groups increased with the number of mutations per parasite, the difference was 
not significant, it was 60% in the group of isolates with double mutations (n=10) and 70% in 
isolates with quintuple mutation (n=20). On the other hand, there was no difference in the 
gametocytogenesis (gametogenesis and gametocyte longevity) among isolates with two or 
more mutations, that is to say, at least two mutations were needed for influencing the 
gametocytogenesis, and any further increase in number of mutations have no further effect, 
see Table (3.11).              
Table 3.11: The period prevalence of gametocytemia and gametocytogenesis 
Gametocytogenesis 
Gametocyte longevity 
No of 
mutations  
No gameto- 
genesis  Gameto- 
genesis  1 (min.) 2 3 4 5 (max.) 
*Wild (4) 1.0 0 0 0 0 0 0 
*Single (5) 1.0 0 0 0 0 0 0 
Double (10) 0.40 0.60 0.20 0.30 0.10 0 0 
Triple (21)  0.38 0.62 0.33 0.19 0.05 0 0.05 
Quadruple (93) 0.31 0.69 0.24 0.23 0.17 0.05 0 
Quintuple (20) 0.30 0.70 0.20 0.30 0.15 0.05 0 
3.4. Malaria during pregnancy in New Halfa (August 2003-July 2004): 
3.3.1 Submicroscopic Plasmodium falciparum infections during pregnancy: 
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Overall, 142 pregnant women were enrolled as they attended antenatal clinic for the first 
time. Only 17 (11.9%) were found smear-positive for malarial infection (all P. falciparum) 
but 40 (32%) of the 125 smear-negative women were found PCR positive and therefore had 
submicroscopic P. falciparum infections. Among the smear negatives, 14 (38.8%) of the 36 
primigravidae, five (22.7%) of the 22 secundigravidae and 21 (31.4%) of the 67 
multigravidae (i.e. those who had been pregnant more than once before) were found PCR-
positive (P>0.05). Twenty-one (37.5%) of the 56 smear-negative women investigated during 
the wet season and 19 (27.5%) of the 69 women smear-negative women investigated during 
the dry season had submicroscopic P. falciparum infections (P>0.05). 
In terms of age, parity, gestational age, hemoglobin concentration, and the frequencies of 
anemia (<11 g hemoglobin/dl) and severe anemia (<8 g hemoglobin/dl), the smear-negative 
pregnant women with submicroscopic P. falciparum infection were similar, when enrolled, to 
those without such infection (Table 3.12). 
                Table (3.12) some investigations for the pregnant women 
Variable With 
submicroscopic 
infections 
Without 
submicroscopic 
infections 
No. and (%) of women 
Investigated 
Primigravidae 
Secundigravidae 
Multigravidae 
With anemia 
With severe anemia 
 
40 
14(35%) 
5 (12.5%) 
21 (52.5%) 
29 (72.5%) 
2 (5%) 
 
85 
22 (25.8%) 
17 (20%) 
46 (54.1%) 
66 (77.6%) 
7 (8.2%) 
Mean value and (SD) 
Age (years) 
Gravidity 
Gestational age (weeks) 
Hemoglobin (g/dl) 
 
25.02 (6.0) 
2.01 (2.1) 
27.2 (6.8) 
9.97 (1.3) 
 
26.31 (5.1) 
2.50 (2.4) 
25.4 (7.7) 
9.90 (1.2) 
 
Blood samples from 32 (80%) of those with submicroscopic infections showed only the FC27 
allele (of merozoite surface protein-2), six (15%) showed only the ICI allele, and two (5%) 
showed both of these alleles. Each submicroscopic infection appeared to consist of just one or 
two clones of P. falciparum (mean=1.016; median=1). 
Chapter Four 
Discussion and conclusions 
4.1 Severe malaria: 
4.1.1 In Gedarif area during the two seasons 2000-2002: 
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4.1.1.1 Clinical pattern of severe falciparum malaria: 
In this study, we intended to execute the clinico-epidemiological description of severe 
malaria from a unique setting in an area of markedly unstable transmission. The malaria 
transmission in Gedarif area, as in most of central Sudan (∼ 70% of Sudan population), is 
confined to a short window of time, of two or three months a year, and sometimes is shorter 
or absent. Under such pattern of transmission, a partially protective immunity is acquired and 
the inhabitants are best described as semi-immune population16,282. 
The overall frequency of severe malaria among the confirmed cases of malaria was 4.4%, and 
the mortality rate among the severe malaria patients was 6.4% which accounts for 0.3% of all 
cases of malaria, this finding is coherent with a previously reported rate from other 
settings291. Only four types of complications were recognized during the study period, the 
severe malarial anemia (SMA) was the commonest (45.46%), followed by convulsions, 
cerebral malaria (CM) and hypotension, and only 5.45% of the patients had multiple 
complications. In general, the difference in the rate of severe malaria morbidity and mortality 
between the two seasons was not statistically significant, but, the frequency of the individual 
complications changed considerably. While the SMA represented 26.4% of all complications 
in the first season it was increased by 2.4 fold (63.2%) in the second season, the high 
frequency of SMA was not due to multiple visits of individual patients. But, whether or not 
the unstable transmission of malaria accelerates the change of parasite population and 
consequently the pattern of clinical complications is not known and worth prolonged 
observation. Some complications were not recognized during both malaria seasons e.g. 
respiratory distress syndrome, renal disorders and thrombocytopenia. These complications 
are commonly recognized in regions like South East Asia292,293. 
Previously Giha et al16. reported that uncomplicated malaria in the same area was recognized 
in all age groups, and individuals aged between 5 and 19 years had the highest risk. In this 
study, the highest proportion of patients with mild malaria was recognized in the same age 
group, 5–19 years, while that for severe malaria was in the age group of two to four years. 
The earlier protection from severe malaria compared with uncomplicated malaria is believed 
to be due to an earlier and faster acquisition of immunity against parasite strains causing non-
cerebral severe malaria55. However, due to the inherent limitations in urban hospital-based 
studies in general (not all malaria patients seen in hospital) it was difficult to calculate with 
accuracy the incidence and the age risk for both mild and severe malaria. 
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There is some evidence that malaria infection in the older age groups results in a different 
form of complications as compared to that seen in children, in areas of stable transmission294. 
In these areas, distinct age-specific patterns of infection and disease are seen295,296. This study 
showed that the different clinical groups of severe malaria (anemia, convulsions, cerebral 
malaria, and hypotension) differ from each other in critically important clinico-
epidemiological indices. We compared five parameters; the age, parasite count, hemoglobin 
level, blood glucose level, and mortality rate, among the groups. Taken together, the four 
clinical entities of severe malaria were found to be strongly statistically significantly different 
from each other in all the five tested parameters (p=0.022–0.000, Kruskal-Wallis test). 
However, when we compared each complication with other complications separately, we 
found the greatest difference was between CM and SMA, and the least difference was 
between CM and convulsions. The similarity between CM and convulsions (except for the 
age), and the dissimilarity between CM and SMA on clinical and epidemiological aspects, 
looks interesting, and possibly denote resemblance and disparity in pathogenesis of these 
complications, respectively. 
The difference in the age distribution of the different complications in this setting, and 
between this and other settings, was marked and of special importance. It is well known that, 
there are differences in the peak age for CM compared to SMA and also in the distribution of 
CM and SMA depending on the level of P. falciparum transmission in the area291,295. The 
SMA peaks at the age of 6 months to one year and CM at the age of two to three years in 
hyper endemic areas51,297,298, in this study, the mean age for SMA was around five years, 
while that for CM was approximately 14 years. The mean age for both complications, was  
three times higher in our study area, while the ratio of the peak age for the two complications 
in each site is constant, (a ratio of approximately 1:3). Hypotension was only recognized 
during adulthood with a mean age of 35 years; however, the outcome of treatment was good 
and fast, with the shortest duration of hospital admission. On the contrary, the mean age for 
malarial convulsions was similar to SMA, five years. In general more than 60% of patients 
with severe malaria were above five years of age, while all patients who died of severe 
malaria were above five years of age (with a mean age of 18 years), see table (3.2). 
As seen in (figure 3.3), the lowest parasite count was recognized in patients with SMA, the 
youngest group of patients, a low parasite count was also recognized in individuals with 
hypotension, the eldest group. The low parasite count in patients with hypotension could be 
due to the acquired anti-parasitic immunity which increases with age299. However, the role of 
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age-associated acquisition of immunity can not explain the low parasite count in patients with 
SMA. 
The blood glucose level was highest in patients with CM and lowest in patients with SMA, 
the difference was significant; also, hyperglycemia was very remarkable in the fatal cases of 
malaria. Generally, hypoglycemia, is one of the complications of P. falciparum malaria with 
a prevalence of 10% is ascribed to inhibition of gluconeogensis300, and is considered as 
independent risk of mortality in severe malaria301. In this study, hyperglycemia in fatal severe 
malaria was not due to quantitative deficiency of insulin, on the contrary insulin levels were 
extraordinary higher than in nonfatal severe malaria and above the upper physiological limits. 
The strong association between hyperglycaemia, hyperinsulinemia and cerebral malaria 
fatality, need further biochemical explanation. It is of interest to know, how hyperglycemia 
and hyperinsulinemia coexist, and which preceded the other. The other observation is that the 
younger patients who died of severe malaria (Table 3.2) had a relatively lower blood glucose 
level and insulin level, although the sample size is not large enough to make such a judgment. 
Hyperglycemia, was reported in Vietnamese patients with CM, in whom the blood glucose 
was found to be 100% derived from gluconeogenesis, as well as, it has been reported that 
there was a significantly higher blood cortisol in CM patients as compared with a control 
group300. 
In this setting, the CM had an average mortality rate of 39% (45% and 29%in the first and 
second season, respectively), while there was no mortality from other complications. We 
compared levels of hemoglobin and blood glucose between severe fatal and severe non-fatal 
malaria. Surprisingly, patients who died of severe malaria had higher hemoglobin and 
glucose levels when compared with patients who survived the severe attack of malaria. 
Interestingly, none of the CM patients who also had SMA died. 
4.1.1.2 Allelic polymorphism of MSP2 gene in severe P. falciparum malaria: 
The role of the malaria parasite in development of severe malaria is not a debatable issue, 
however, how the parasite contributes to development of SM, is not well understood. Certain 
molecular markers like certain var genes coding for PfEMP1, are known to be involved in 
parasite rosetting and cytoadherence302, and are believed to be an important pathogenic 
marker. Otherwise little is known about the markers of virulence or their linkage in the 
malaria parasite. Enthusiastically, the aim of this study was to identify number or quality 
(genotype) of clones, both or none are associated with development of SM. This study was 
conducted in an area of strictly seasonal and markedly unstable and low malaria transmission 
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in Sudan. Overlap or super-infections are less likely to be frequent, and the inhabitants are 
semi-immune to malaria. Thus, genotypes, multiplicity and dynamics of infecting parasites 
are less influenced by non-parasite confounding factors, such as age and immunity282.                                      
In this hospital based study, blood samples were obtained and genotyped from 231 
individual, of whom 103 had SM. Although, the individual infections were composed of low 
number of clones (mean clone number of 1.5), the generally circulating clones were 
numerous (more than 50 allele types of MSP2). In malaria endemic areas, most of the studies 
uncovered the huge genetic diversity of infectious parasites94, although only a limited number 
of molecular markers was usually used e.g. MSP1, MSP 2, GLURP and drug resistance 
associated genes. In fact there are large numbers of potential sources of parasite diversity, 
thus, it is possible that each parasite has its own unique genetic make up, although it was 
previously reported that a great homology between isolates obtained from a single 
household303. Whether all data was pooled and analyzed or each clinical group of patients 
was considered separately, no correlation between multiplicity of infection and age was 
found, in contradistinction to other studies in other sites of high transmission71,77. In this area 
people are semi-immune, and both UM and SM affects all age groups although clinical 
malaria infections are more common in young patients. Further more; there was no 
correlation between initial parasitemia and the clone number as reported from other sites304. 
However, the influence of both age and parasite densities on multiplicity of infection is likely 
to be immunity-dependent, so their effect is modest in areas of low transmission, such as in 
eastern Sudan. 
As previously mentioned, the overall mean clone number (MCN) was 1.5. By breakdown of 
data into groups of malaria infection, ASUM, UM and SM, and sub-groups of SM (CM, 
SMA, CAM and HTN), a differential pattern of clonality of infection was revealed. The 
frequency of single clone infections was ranging from 1.0 in individuals with ASUM, to 0.66 
in SM and 0.59 in UM. Interestingly, the low complexity of infection was recognized in the 
two clinical extremes of malaria infection, the asymptomatic infection and the fatal CM 
infection (1 and 1.1, respectively). So, the general analysis showed that, multiplicity of 
infection was associated with development of clinical malaria, but didn’t associate with the 
severity of malaria. This is some how in line with Roper et al.15 early findings in rural Eastern 
Sudan, where she reported that the risk of development of UM increases with the increased 
number of clones in a given infection. However, detailed analysis of this data indicated that 
fatal CM was not multi-clonal. The controversy of the clinical outcome in relation to the 
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complexity of infection in this study could be due to; the basically low complexity of 
infections in the area, or due to the difference in the types, but not the number, of alleles 
between fatal CM (IC1) and ASUM (FC27) infection. The clinical consequences of multi-
clone infections (MCIs) vary considerably between epidemiological settings115, and in 
different ages and immune status71,114. In Tanzania and Papua New Guinea the MCIs were 
found to be associated with reduced incidence of clinical malaria76,116,118. But, that protection 
was not evident in very young; immunologically relatively naïve hosts68. While in other 
studies conducted in; Tanzanian114,117, western Kenya120, Ghana121 and Mozambique122 the  
MCIs were found to be a risk factor for development of clinical malaria. However, most of 
these studies compared UM with asymptomatic infections, and a very limited number of 
studies were in fact made the comparison in a broad range of clinical malaria infection. 
The overall genotyping data, showed great similarity in the parasite populations that caused 
UM and SM infections. The prevalence of the 2 allele families of MSP2; the IC1 and FC27 
was not significantly different between UM and SM, although more FC27 parasites were 
recognized in UM. The size polymorphism, in both allele families; IC1 (30) and FC27 (23), 
was found to be comparable between UM and SM, not only in the total number of alleles, but 
also in the frequency of individual allele sizes, see Figure (3.5). However, more detailed 
analysis included clinical sub-groups of infections, revealed some significant variations in 
parasite genotypes. The frequency of single clone infection of FC27 genotype is relatively 
low in this setting (<25%) similar to other settings305, however, in other areas, the FC27 
genotypes predominates75,85. Interestingly, the frequency of FC27 infections was significantly 
high (68.2%) in the apparently healthy, malaria free, volunteers who were found to have 
ASUM infection. In heterogenic multi-clonal infections (mixed IC1/FC27), following 
treatment with quinine, the clearance of the IC1 genotype was significantly faster than that of 
FC27 genotype component of the mixed infection (figure 3.5). It was noted that the carriage 
of parasites during the follow up period was not associated with malaria symptoms 
(asymptomatic parasite carriage). Two explanations are possible for the later statement; a. 
infection with IC1 genotypes exceeded that of FC27 in multi-clone infections (super-
infection), b. the relative resistance of FC27 genotypes to treatment. In general, these 
observations indicate that the FC27 genotypes were generally associated with the mildest 
form of P. falciparum infection in this area, and that was consolidated by the reproduction of 
the results over the two seasons of the study. At least this data prove that the least virulent 
parasites belong to a subpopulation of derived from a common ancestor which carried the 
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FC27 alleles. On the contrary, fatal CM was strongly associated with IC1, all patients who 
died of CM (n=7) were infected with IC1 genotypes, only one of the patients had two clones 
one of them was FC27 allele type. In French Guiana, MSP-1 allele (B-KI), but not MSP-2 
allele (IC1) was associated with SM morbidity305. Thus, in the localities, where certain 
genotype family is associated with severe disease, it would be easier to zoom-in the search 
for virulence factors into a sub-group of parasites. Pre-selection of parasites, reduces the 
efforts and increases the number of candidate molecules to be investigated. Interestingly, it 
was observed in this study, that the parasites of FC27 genotype had significantly higher 
prevalence of pfcrt and pfmdr1 mutant alleles. Furthermore, it was found that mortality was 
associated with the wild types of pfcrt and pfmdr1 type162. All these findings were quite 
consistent and support the association between the FC27 genotypes and the clinical outcome 
of infection in the study area.                                                                                                                        
Twelve patients with SM had PCR detectable parasitemia throughout the follow up period 
(28 days). The D0 parasite genotypes of all 12 patients indicated the large degree of genetic 
diversity of quinine resistant parasites in this study (vertical heterogeneity) (see Figure 3.6). 
The genotypes of the parasites in D0, D3, D7 and D28 for each one of the 12 patients, 
showed very limited genetic diversity (horizontal homogeneity). The later was an indication 
for parasitological failure of treatment and thus, persistence of the same parasite genotype. 
This also reflects the importance of the use of size polymorphism, rather than the broad 
typing as IC1 and FC27 genotype, in the distinction between parasites.                        
The frequency of multi-clonal infection is comparable between SM and UM and accounts for 
(35% and 41%, respectively). However, the composition of the multiple infections was either 
homogeneic (consists of IC1 alone or FC27 alone) or heterogeneic (consists of both IC1 and 
FC27). Interestingly, most of the complex infections were heterogenic (75%), this and the 
significantly faster clearance of one genotype (in this study IC1) rather than the simultaneous 
clearance of all infecting clones, is supporting our previous assumption that multi-clone 
infections are predominantly due to super-infections. If the multi-clone infections were due to 
injection of multiple clones in one inoculum, the compositions of multi-clone infections will 
be random rather than being heterogenic and parasite clearance after treatment would be 
simultaneous. Also, the predominance of the heterogeneity of multi-clone infections was 
possibly indicating that infections with certain genotype provide a relatively stronger 
immunological protection from the same allele family than the other family. In other words 
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the above might be an indication of a stronger cross-immunity between alleles of the same 
MSP2 genotype family. 
4.1.1.3 Genetic fingerprints of parasites causing severe malaria in a setting 
of low transmission “one strain one patient”: 
The devastating effect of P. falciparum is attributed to severe malaria. In sub-Saharan Africa 
where the heaviest disease toll, cerebral malaria (CM) and severe malarial anemia (SMA), are 
the main fatal complications306. Usually, only a small fraction of the infections can progress 
into SM291 as recognized in this area also (1.2%). Thus, it is conceivable that a small 
relatively homogenous subpopulation of parasites, described as, “virulent strains” are 
associated with SM, more specifically CM261. But whether these virulent strains are 
genotypically identical or are not identical but share a common virulence marker/s, is not 
known. The present study was carried out to investigate the parasite population genetics in 
SM, using clinical and molecular data, and here we hypothesized that the parasite sub-
population that cause severe malaria are as diverse as the hosts who develop severe malaria. 
Since each individual have different genetic make up, each parasite described as virulent 
strain have a unique genetic fingerprint, and SM occurs by chance as a result of a highly 
specific host/ parasite interaction, in a key-and-lock manner.        
In this study it was found that, the parasites isolated from patients with SM, were extremely 
genetically diverse from each other, irrespective of the type of complication. It was almost, 
each single infection (in ~90% of the infections) was caused by genetically different strain, 
except for three pairs of infections. Given the limited number of markers used in the study, 
we speculated that, if more markers were included, there might be only two patients had been 
infected by identical parasites, as their history and clinical findings suggested. Those are 
brothers who lived in the same house (hut) and possibly got infected on the same night. 
However, such degree of diversity would have not been revealed unless multiple genetic loci 
were examined. Indeed, the more molecular markers used, the better the contrast can be 
generated, with a more clear distinction between isolates. It is worth noting that we used only 
4 markers out of a large number of potential sources of diversity94,307. Using one of the most 
polymorphic molecular marker for typing, the MSP266, in the present study it was reaveled 
that, only half of the expected polymorphism which was statistically significantly lower than 
the actual polymorphism when all the four markers were used together305, reported an 
association between specific msp-1 allele (B-K1) with a specific var gene (var-D), and their 
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over representation in SM, in French Guiana, a hypoendemic area. However, these findings 
are not mutual exclusive, as these parasites still could be of different genetic make up.       
 The diversity of infection (DOI), as explained before, was used to estimate the frequency of 
the genetically unique isolates in a population or a subpopulation of parasites. On the other 
hand, the multiplicity of infection (MOI) was generally used for estimation of the average 
number of clones per person17, however, both parameters depend on the type and number of 
the molecular markers used. Ideally, a number of markers should be analysed to generate 
multi-locus genetic profile for each individual parasite. The MOI and distribution of parasite 
genotypes in SM, was investigated before with a larger sample size (including the samples 
used in this study), but the MSP2 gene was the only molecular marker analyzed. In this study 
it was found that multiplicity of infection (MOI) was comparable between SM (1.45) and UM 
(1.53), and the detailed analysis showed that; the MOI in asymptomatic sub-microscopic 
malaria infection (ASUM) was 1.0, which was significantly lower than that of SMA, and 
non-fatal CM but not fatal-CM. Furthermore, found that the FC27 was over-represented in 
ASUM, and was not recognized in fatal CM. In addition, it was found that the ratio of IC1 
and FC27 allele families was comparable between SM and UM. 
Using the multi-locus genetic profile, the molecular data in this study clearly demonstrated a 
marked diversity between the parasites that caused SM (Figure 3.7). Although virulent strains 
can have different genetic fingerprints, but still, they could share a common or a limited 
number of virulence markers (which are not really identified). However, existence of virulent 
strains with a common or limited virulence markers was unlikely for many reasons; a. the 
extreme diversity of the clinical presentation and pathogenesis of SM e.g. CM and SMA261,306 
b. lack of SM clustering per household c. the relatively constant ratio of SM in relation to 
UM over long time291, compared to the fast expansion of drug resistant in relation to sensitive 
malaria parasites (the fast propagation in pfcrt, dhfr and dhps mutations) in different areas308. 
Thus, a virulent parasite for one individual might not be virulent for another comparable 
individual. However, the prevalence of SM in non-immnue adults is higher than what would 
be expected from the prevalence of virulent strains309, is indicating a considerable modulation 
of the host/parasite interaction by acquired immunity. 
Clustering of severe malaria is not recognized in this study, although this was a whole season 
data in an average size town, only 2 sibs were found to have SMA with similar parasite 
genotype profile. There was another 2 pair of patients infected with strains of similar genetic 
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profile, but from the history and clinical data, the isolates unlikely to be identical if more 
markers were used.  
Interestingly, the patients with uncomplicated malaria (representing almost 98.8% of malaria 
patients in this study), had the same DOI, moreover, MSP2 revealed more diversity than it did 
in SM. But analysis of MSP2 data collected over 2 malaria seasons included this season, 
showed no significant difference in the MOI between the two study groups. In all, this data 
indicates that the P. falciparum isolates from patients with SM are genetically diverse as the 
genetic diversity of the human host, suggesting a genetic fingerprint for individual parasites.  
Many hypotheses were proposed to explain the reasons or mechanisms of diversity in malaria 
infections in general, although, one view is that natural infections are derived from one or 
few genotypes, which undergo mating infrequency, implying mainly clonal reproduction259. 
However, recombinations do occur frequently in nature70,260 but with higher selfing rate in 
areas of low transmission105. In strain theory, it was suggested that malaria parasites only 
exist as a limited number of stable antigenic types, called strains261, and that cross-immunity 
between mild and virulent strains is slow51. However, many studies affirmed the genetic 
diversity of parasite populations in different endemic situations, although the magnitude of 
this diversity was never quantified, it was either described as limited, moderate or large 
diversity.  
4.1.2 In New Halfa area (November 2000- February 2001): 
4.1.2.1 Cerebral malaria is frequently associated with latent parasitemia among 
semi-immune population: 
Severe malaria, including cerebral malaria, has been an important cause of human death since 
time immemorial and still poses a great challenge. Both the delay or failure of treatment and 
the delay and failure of diagnosis of malaria are important factors in malaria mortality310. The 
proper diagnosis of malaria begins with clinical suspicion311, not only in non-immune 
travelers but also for the semi-immune inhabitants of malaria endemic regions. This study 
clearly suggests that a proportion of patients in this area, fairly described on the basis of 
serology as semi-immune, can develop acute fulminant and often fatal cerebral malaria 
symptoms with scanty, submicroscopic parasitemia. This phenomenon was predominantly 
recognized in adults, whose infections were revealed by PCR. Furthermore, the therapeutic 
response and fatality rates after quinine treatment were comparable with that of cerebral 
malaria with patent parasitemia in the same region as mentioned before in this study. 
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In febrile patients with microscopically unproved malaria, presentation with coma narrows 
the differential diagnosis by exclusion of febrile conditions like pneumonia, typhoid, and 
other infectious diseases that are not a common cause of coma. Still, other clinical conditions 
like meningitis, encephalitis and some viral infections could mimic cerebral malaria. 
Although meningitis can occur sporadically, it occurs in epidemics mainly before the rainy 
season, and it is mostly (but not absolutely) clinically distinct. However, the other infections 
occur sporadically but are not clustered during the short window of malaria transmission. 
Malaria and viral infections can co-exist in patients if either of them can be recognized 
independent of the other in the same community at the same time. That was not the case for 
conditions like meningitis, and viral encephalopathy, since no single case of either condition 
was recorded during the study period. Other non-febrile conditions presented with coma like 
cerebro-vascular accidents (CVA) can be ruled out since those patients do not present with 
fever. In this setting, clinicians are confronted in many occasions with such clinical cases 
making a dilemma in diagnosis and the decision to treat them as malaria or not, is critical and 
associated with survival or death of patients. 
P. falciparum infection was detected in a majority of the clinically suspected cases of 
cerebral malaria (CSCM), as well as in all patients with clinically suspected uncomplicated 
malaria (CSUM). Obviously, it was the peripheral parasitemia and not the absolute parasitic 
load, which was estimated by microscopy. In a recent post-mortem study carried out in 
Thailand and Vietnam, patients who died of cerebral malaria, showed a 26.6 times higher 
parasitemia in the post mortem brain vessels than in the pre-mortem peripheral blood312. In 
West Africa, Kurzhals et al.313 reported that between 20 to 25% of the patients with anemia 
did not have microscopically detected parasitemia. In some non-immune travelers, malaria 
parasites were detected only when patients were terminally ill or at postmortem310. However, 
in general, peripheral hyperparasitemia is associated with complications of severe malaria, 
and it is also considered as an independent risk factor in malaria infection306. 
The occurrence of asymptomatic parasitemia is rare in the study region16, as also reflected in 
this study, with low numbers of positive blood smears or PCR positives among the malaria 
symptom-free (MF) donors. Although the MF donors were not followed to know whether 
their asymptomatic infections became overt malaria or not, there was a significant difference 
in the prevalence of PCR-proved submicroscopic parasitemia between MF donors and 
patients suspected of having cerebral malaria. This appears different from the situation in 
Tanzania, where MF donors were shown to have the same prevalence of parasitemia as 
  107
patients suspected of having CM314. In the latter setting, other neurological diseases were 
diagnosed and cerebral malaria was excluded. 
There was a significant difference between CSCM and uncomplicated malaria (UM and 
CSUM) infections in the mean clone number, which tends to be smaller in the former group. 
This is in agreement with other studies, where less complex infections were found to be more 
associated with CM118. However, in this study the mean clone number in CM with latent 
parasitemia was found to be comparable with that of UM. 
Although prevalence and levels of Abs against MSP1 and MSP2, as serological markers for 
exposure is a rather crude approach at the individual level, it is still informative in 
epidemiological surveillances. Due to the seasonality of the modest malaria transmission in 
this study area, the prevalence of Abs against malaria Ags were previously found to be 
markers for recent exposure31,277. Clinical, molecular and serological data were in-favor of 
the diagnosis of malaria infection in most if not all of the comatose patients with 
microscopically undetectable parasitemia. Furthermore, this was supported by the occurrence 
of CSCM during the peak of the malaria transmission and the fair therapeutic response of the 
CSCM patients to anti-malarial treatment. In undiagnosed patients with prolonged fever in 
Pakistan, the thick smears of bone marrow revealed P. falciparum malaria parasite in high 
proportions of patients with sub-patent parasitemia315. 
A possible explanation for the sub-patent parasitemia in patients with cerebral malaria 
symptoms is sequestration of infected erythrocytes (IE) in the vascular bed of internal organs, 
with preference to the brain, which has been found to be associated with severe 
malaria316,317,318. Thus, the sub-patent parasitemia was only time-related and coinciding with 
the cytoadherence of the late stages in synchronized parasite growth. The single-clone 
infections (dominant in CSCM) logically should tend to synchronize easier than a multi-clonal 
infection. And by definition, parasites causing cerebral complications are more virulent and 
are characterized by the ability of cytoadhesion. However, the objective proof for 
sequestration would be the study of post-mortem brain specimens; the lack of such data is 
one of the limitations in this study. 
4.2 Estimation of antimalarial drug efficacy in Eastern Sudan: 
4.2.1 Gedarif area (October-December 2003): 
4.2.1.1 The efficacy of Sulfadoxine/pyrimethamine alone and in combination with 
chloroquine: 
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Although sporadic cases of resistance to SP was observed and reported more than 13 years 
back in the Sudan319, no compiled study was carried out to quantify the resistance to SP in the 
region before. In this study the prevalence of SP resistance was found to be 32.6% and the 
efficacy of SP alone and in combination with CQ was comparable. Addition of CQ to SP had 
no parasitological advantage over SP alone except on halting gametocytemia on D3 of follow 
up, which rebound later (after D7) to mimic the rate of gametocytemia in SP alone. But 
whether that difference was due to a short lived gametocidal effect of CQ or not, was not 
reported before. The findings in this study suggested that, parasites resistant to SP, is less 
likely to be sensitive to CQ. This statement is supported by the co-existence of SP and CQ 
resistance associate alleles; the (dhfr 108 & 50/51 and dhps 540 & 581) and the (pfcrt 76 and 
pfmdr1 86), mutations in parasite isolates obtained from the same study area. It is possibly 
that, during the parasite evolution the occurrence of mutations in the genes associated with 
CQ resistance precedes but enhances the mutations associated with SP resistance. However, 
these findings are in contradiction with a recently published work from West Africa, Nigeria, 
where the combination of CQ with SP, significantly improved the efficacy of the later in the 
treatment of UM320. While an earlier report from the Gambia showed no additional privilege 
from the use of CQ in combination with SP, except for symptomatic relief 321. 
The proportions of patients achieved adequate clinical and parasitological response (ACPR) 
in both arms of treatment were comparable although slightly higher in patients treated with 
SP alone, but that is more likely due to the smaller number of patients in the SP treatment 
group. Similarly, the proportion of patients with late treatment failure (LTF) was higher in the 
SP plus CQ treatment group, but the difference was not statistically significant. The 
frequency of early treatment failure (ETF) was also similar in the two treatment groups 
(11.3% and 15%). Patients with detectable parasitemia at D3 were not treated because their 
parasitemia were not flourishing and because they had only mild to moderate malaria 
symptoms. However, as the follow up days progressed, we observed that the patients in this 
group (ETF) were actually belonging to 2 different categories. Patients who achieved 
complete clinical recovery and cleared their parasitemia by D7, and others who continued to 
had malaria symptoms and detectable parasitemia, and for whom alternative treatment was 
given. Thus, the former group was defined as patients who had delayed parasitological 
response (DPR), and the later group as patients who had actual early treatment failure 
(AETF), see Fig. (3.9). However, that could be unique to this setting, as microscopically 
detectable parasitemia rarely dissociates from clinical symptoms and the individuals in this 
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area are semi-immune to malaria (sluggish parasite clearance). Less than 20% of the patients 
in the two treatment groups had detectable parasitemia at D3, but at D7, significantly more 
patients treated with SP alone compared to patients treated with SP plus CQ, were found 
carrying malaria parasites. This could be one of the few advantages of the added CQ, but that 
was for only short duration, as the 2 treatment groups were became comparable in the 
following days of the follow up. 
The role of the host immunity in clearance of the drug resistant parasites following treatment, 
was demonstrated in the field176, as well as in rodent malaria model, Plasmodium 
chabaudi322. The host age is an ideal surrogate marker for protective immunity in individual 
living in malaria endemic area, as there is no single measurable marker for evaluation of 
protective anti-malarial immunity. In the present study a statistically significant lower age of 
patients infected with parasites with any grade of resistance (ETF or LTF, over all the days of 
the follow up) to any of the two treatment arms, SP mono or combined therapy had been 
demonstrated. The better parasite clearance in older patients (age; mean ∼20, median ∼18 
years) was most likely attributed to some sort of anti-malarial immunity. Previously in this 
same study area, the risk of development of malaria episodes reduced to the half after the age 
of twenty, although all age groups are prone to develop malaria16. On the other hand the 
studies about malaria infection and immunity carried out in the same region, support the 
notion that inhabitant of this area are semi-immune to malaria31,277. All studies carried out in 
the recent years in region showed that the prevalence of SP resistance genes, dhfr and dhps 
were more than 70%323, while the prevalence of SP resistance as shown in this in-vivo study 
was only 32.6%. Taken together, the above findings strongly support the theory about role of 
immunity in clearance of drug resistant parasites. That means some parasites carried the SP 
mutant alleles were cleared, most likely through immunity. This study is the first 
demonstration for the role of partial immunity in clearance of drug resistant P. falciparum 
parasites in human, supporting the rodent malarial model322. 
Further more, in the longitudinal surveillance for gametocytes carriage (gametocytogenesis), 
in this study it was observed that patients carried gametocytes longitudinally were statistically 
significantly below the median age of the total malaria patients. This finding too, can best be 
explained by the role of the partially acquired immunity in clearance of the sexual stage of 
the parasite. The association between the longevity of gametocytemia and the clonal 
complexity of the infection was exploited before in the same setting, when a more sensitive 
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tool, the rt-PCR324, was used. It was found that, gametocytemia persist for longer periods in 
multi-colonal infection compared with monoclonal infections325. 
The bursting of gametocytemia following SP treatment compared with other antimalarial 
drugs like CQ326, quinine327, or artemisinin328 is a consistent finding, that worth meticulous 
exploitation, possibly at molecular level since the parasite genome was already known. It was 
assumed that the fast propagation in SP resistance, either due to intrinsic parasite/drug 
properties or cross resistance with drugs like septrin329. However, from this data it was 
hypothesized that, the fast propagation is due to a combination of two factors mutually 
related; the first is the strong selective effect of SP i.e. following malaria treatment with SP, 
only the resistant strains that can exist. Secondly, the robust gametocytogenic effect of SP, 
which leads to expansion of the selected resistant population at D14 and/or thereafter (Fig. 
3.13). 
4.2.1.2 Implication of the dhfr/dhps/pfcrt molecular markers in the 
evolution of Plasmodium falciparum malaria parasite beyond the 
Sulfadoxine/pyrimethamine resistance: more relevance and mutual 
association:  
The world is left with only limited feasible options for curative malaria treatment after the 
resurgence and fast propagation of the anti-malarial drug resistance, namely to CQ and SP as 
reviewing by White172. A number of studies have investigated the association between 
mutations (SNPs) of certain genes (dhfr and dhps) and the parasitologic and/or clinical 
response to SP treatment at an individual level182,234,330,331,332,333. The relatively recent 
emergence of mutations and their implication in drug resistance64,241, and the recovery of the 
wild alleles in the parasite population after the drug usage cease334, indicates an advanced 
parasite tactic. However, that is also inviting for drawing an evolutionary scenario for this 
organism, using the molecular markers as a tool. Although, the re-emergence of the wild 
alleles is explained by outgrowth of sensitive strains in absence of drug pressure166, the 
assumption of reverse mutation (mutant to wild) is an enticing hypothesis that needs to be 
disproved.       
The present study is the first large scale, comprehensive analysis for SPR molecular markers 
to be carried out in Sudan in addition to the CQ resistant mutation at pfcrt gene; it is coupled 
with a reliable clinical data and suffice treatment failure that permit the intended analysis. 
However, the main limitation was the exceedingly high dhfr/dhps mutation rate. 
Approximately, one third of the malaria infections were found to be resistant to SP treatment 
(in-vivo) as seen before in this study, while the frequency of the SP resistance associated 
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alleles of the dhfr/dhps genes were on average 3 times the actual TF. That means two thirds 
of the mutant infections were surmounted by the host immunity. From these results it had 
been suspected that in this study area, the mutations in dhps but not dhfr were associated with 
fansidar resistance. However Alifrangis335 in a study comparing different sites of endemicity 
in Sudan, Tanzania and Mozambique suggested that dhfr genotypes alone may be a suitable 
marker of the overall SP resistance level while others232,234,336 observed that, combination of 
dhfr and dhps mutations may still prove to be important mainly in areas of low endemicity 
such as Sudan. 
The role of immunity in clearance of resistant parasites was supported by the higher age of 
the successfully treated patients, as age stand-in for immunity in the same area337 and in other 
malaria endemic areas176. However, the magnitude of immunity varies considerably in 
different epidemiological settings; thus, the immunity factor is not fixed but varies with 
malaria transmission intensity, and possibly between individuals in the same area. However, 
it would be interesting to know if immunity can operate successfully in clearance of mutant 
parasites in the absence of treatment, although the later is not functioning? If the answer is 
yes, then probably two thirds of the malaria infections in this area were missed, which is very 
unlikely as asymptomatic parasitemia is rare. Otherwise, that means, the use of the useless 
drugs (to which the parasite is resistant) is still needed for the immune clearance of the 
mutant (resistant) parasites. In this study, the immune factor varied between 0.37 (for 
quintuple mutants) and 2.97 (for single mutant), and interpretation here is that the lower the 
immune factor the more efficient the immunity. 
The mutant-clearance immunity factor (MCIF) is comparable to genotype resistance index 
(GRI), the later was similarly calculated from different sites in Mali over 3 years, the drug 
was CQ and the GRI values varied between 1.6 and 2.8186,187. The term MCIF was introduced 
because the variables other than immunity e.g. micronutrients, host genetics and others, were 
considered to be of minor role, as all the patients were of similar socioeconomic and racial 
background. The MCIF values were coherent with previous findings that malaria incidence is 
reduced to the half after the age of twenty due to acquired immunity16, and comparable with 
GRI in Mali if we consider the differences in malaria intensity between the two areas.       
The mean age was not different between patients infected with parasites of different 
multiplicity of mutations (1 to 5), although, the age of patients who achieved ACR was 
significantly higher than the age of patients who presented with TF. Interestingly, patients 
attained ACR and others who had TF were similar in age when infected by wild parasites or 
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parasites had a single mutation However, when the infecting parasites had two mutations or 
more, significantly older patients who attained ACR compared to those who had TF. That 
indicated, the susceptibility to immune clearance required at least two mutations, then it 
reached a plateau as the parasites that had more mutations were not more susceptible to 
immune clearance. It is worth noting that, the inhabitants of the area were semi-immune 
rather than being fully immune to malaria, which reflect the immensity of the fitness cost of 
mutations and supporting our previous finding162. The association of older age with wild-type 
parasite infection169 cannot be worked out from this data, as half of the samples obtained 
from patients with ACR were not genotyped. However, a larger sample size or a higher 
prevalence of wild dhfr/dhps variants is needed to assess for any. 
It is apparent that there are at least three factors directly contributing to parasite clearance 
(ACPR), a. drug (SP), b. immunity (age), and c. parasite mutations (multiplicity of 
mutations). While the mutations provide the parasite the resistance to chemotherapy renders 
it more susceptible to host immunity as an incurred fitness cost. Interestingly, the resistance 
to SP increases with increasing number of dhfr/dhps mutations (which did not reach 
statistical significance in this study), while the susceptibility to the immune clearance needed 
only double mutation and did not increase with increasing number of mutations. Generally, 
from the above data, it is appealing to suggest that for plummeting parasite fitness only 2 
dhfr/dhps mutations were needed, while the parasite benefit from the mutations, acquisition 
of resistance to SP, needs and depends on higher MOM. To define the magnitude of the 
influence of the individual mutant alleles in the double mutants, a larger sample size is 
needed; however, it is apparent that dhfr51/108 and dhps 437/540 were the major players in 
this setting at this time. 
On the other hand, the in-vivo parasite growth which is reflected by parasite density, as 
sequestration is limited to severe malaria infections, is also affected by the dhfr/dhps 
mutations. The in-vivo growth rate of wild and single mutant parasites taken together was 
significantly higher than that of multi-mutant parasites. However, when wild isolates were 
taken separately, the growth rate was not different from multi-mutant parasites, but that was 
mainly due to the very low number of wild isolates. Interestingly, while at least two 
mutations were needed to retard the parasite growth dramatically, the multiplicity of 
mutations of more than two did not have further effect on parasite growth.  
It was reported before in this study, that the age (median, 22 years) of patients without 
gametocytemia during the follow up days, was significantly higher than the age of patients 
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who had different rates of gametocytemia (11 to 13 years). It was also shown that 
gametocytogenesis was significantly higher in parasites bearing the mutant rather than the 
wild alleles of dhfr/dhps genes, as recognized elsewhere171,338. However, the new finding is 
that; at least two (double) mutations were needed to trigger gametocytogenesis, and possibly 
that was all needed i.e. the further increase in mutations (up to quintuple mutants) did not 
influence the gametocytogenesis any more. In the in-vivo study, it was found that patient who 
achieved ACR had significantly lower frequency of gametocytemia and shorter gametocyte 
longevity compared to patients had TF. That is interesting because, there was no difference in 
the frequency of dhfr/dhps mutations between the two treatment-outcome-groups of patients, 
the ACR and TF group, see Table (3.10). The differences can’t be due to gametocytogenic 
effect of SP treatment, as both ACR and TF groups were treated with SP. Although, the 
gametocytogesis is the corner stone in the spread of the resistant strains, there are only few 
studies which had addressed the issue in molecular terms169,171. 
4.3 Submicroscopic P. falciparum infections during pregnancy: 
This appears to be the first research on submicroscopic P. falciparum infections during 
pregnancy in an area of unstable, low intensity malaria transmission (eastern Sudan). 
Approximately one in every three of the pregnant Sudanese women who had been found 
smear-negative for malaria had PCR-based evidence of submicroscopic P. falciparum 
infection. This prevalence is comparable with those, of 18%–46%, previously reported from 
areas of other African countries with high-intensity transmission339,340. 
Among both the pregnant (present study) and non-pregnant women of eastern Sudan280, the 
prevalences of submicroscopic P. falciparum infections in the wet season appear similar to 
those in the dry season. The reasons for this surprising lack of seasonality have yet to be 
elucidated. 
In the present study, the age, gravidity and gestational age of the pregnant women with 
submicroscopic P. falciparum infection were similar to those of the other smear negative 
pregnant women. Similar observations were recently made in an area of Gabon with intense 
malaria transmission339. In Ghana, however340 reported that the prevalence of submicroscopic 
P. falciparum parasitemia among pregnant women increased with increasing gravidity and 
gestational age — each pregnancy in a woman’s life enhancing her immune protection and 
reducing the likelihood that she would develop a parasitemia that was intense enough to be 
detected by routine microscopy. 
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The most prevalent MSP-2 allelic family in the parasite populations characterized in the 
present study was of the FC27 type, as also recently seen in Gabon339. The mean number of 
clones/submicroscopic infection seen in the pregnant women of New Halfa was only 1.016. 
In areas with intense transmission, the multiplicity of P. falciparum infections in pregnant 
women tends to be higher than this, with means of one to four clones/infection339,341,342. The 
extent of allelic diversity in the MSP-2 gene, as estimated by the total number of different 
alleles found in a given parasite population and the mean multiplicity of infections, appears to 
be positively correlated with the local level of endemicity343. 
In the present study, as in Mozambique342 and Gabon339, there was no evidence that 
submicroscopic P. falciparum infections led to increased risk of anemia in pregnant women. 
In endemic areas of Ghana, however, such infections may be associated with anemia among 
pregnant women340, and 20%–25% of children with anemia do not have parasitemia that are 
detectable by routine microscopy, although many such children have other evidence of 
malarial infection313. 
4.4 Conclusions: 
In Gedarif area, the pattern of severe malaria under the prevailing epidemiological situation 
in Eastern Sudan varies considerably from the classic sub-Saharan pattern of severe malaria. 
Only in such epidemiological setting a clear distinction between the individual complications 
of severe malaria can be made. This has broad implications, from the molecular 
understanding of pathogenesis, to case management and control programs at large. It is 
believed that, this is the first report about severe malaria in the Sudan and it is important for 
filling the paucity in the knowledge about the epidemiology of severe malaria. 
While complexity of infection was associated with clinical malaria compared to 
asymptomatic malaria infections in this study, the MCN was not significantly different 
between UM and SM. The low complexity of infection was associated with both 
asymptomatic malaria and fatal CM, but in the former the predominant single clone 
infections were FC27 genotype while in the later were only IC1 genotype infections. 
Otherwise, MSP2 genotype families, IC1 and FC27, and individual allele types (sizes) of 
both families were similarly distributed in SM and UM. Although the FC27 genotypes were 
associated with the milder forms of malaria infection, after quinine treatment of multi-clone 
infections, IC1 clones were cleared significantly earlier than FC27 clones. In general, in this 
setting the molecular characteristics of malaria infection including SM, varies from that in 
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areas of high malaria transmission and inclusion of detailed clinical data in analysis is critical 
for accuracy of conclusions                                                                   . 
Irrespective of the molecular marker that can be used, addition of any marker should be 
meaningful to disclose hidden diversity, would have not been revealed even with the most 
polymorphic markers when used alone. Furthermore, this data indicated an extreme diversity 
of parasites causing severe malaria including cerebral malaria, and possibly each individual 
infection was caused by a genetically unique parasite isolate. 
In New Halfa area, cerebral malaria may be associated with latent parasitemia in partially 
immune adults. One of the implications of this finding would be that the diagnosis of CM 
malaria should not be ruled out if the blood film result is proved to be negative, and there is 
strong clinical suspicion of CM. That urges development of a robust and friendly to use 
molecular tools for diagnosis of scanty peripheral parasitemia especially in naive and semi-
immune populations. Development of such tools might also result in reduction of malaria 
infection following use of microscopically screened blood for transfusions, in areas of low 
malaria endemicity. In conclusion, uniquely in this setting cerebral malaria can be associated 
with subpatent parasitemia, thus a more sensitive diagnostic tool than microscopy is needed. 
For the estimation of drug efficacy in Eastern Sudan, Gedarif area, this is the first and most 
comprehensive study for estimation of the magnitude of SP resistance in Eastern Sudan and 
the deployment of SP in combination with CQ for treatment of UM. While more than one 
third of the clinical malaria infections were resistant to SP, no advantage for the SP/CQ 
combination therapy over SP monotherapy. The finding about the role of the semi-immunity 
in clearance of residual parasitemia following therapeutic treatment of malaria is 
strengthened by the association of resistance with young age. Moreover, the 
disproportionately high prevalence of CQ and SP drug resistance associated alleles compared 
with the in-vivo drug resistance rate, is a further evidence for the role of semi-immunity in 
parasite clearance. We also showed that gametocytogenesis was provoked by SP treatment, 
and equally it was associated with young age and treatment failure. 
Although SP resistance is propagating fast in the area, semi-immunity to malaria contributes 
in clearance of SP resistant parasites was demonstrated. Furthermore, this data suggested that, 
the fast propagation in SP resistance is likely to be attributed to the selection of SP resistant 
parasites and the expansion of the resistant population through the gametocytogenic effect of 
SP. 
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The implication of dhfr/dhps mutations in parasite growth and gametocytogenesis was more 
prominent than the implication in resistance to SP. At least 2 mutations in the dhfr/dhps genes 
were needed to retard the parasite growth and to enhance gametocytogenesis considerably, 
while the drug response to SP treatment was reduced with increasing multiplicity of 
mutations but is not correlating with the in-vivo result. At least three factors were 
contributing in parasite clearance, the SP treatment, the parasite mutations and the host 
immunity. 
Fansidar and chloroquine resistance in Sudan was found to be very high; it seema that 
chloroquine is not working at all, since the percentage failure in the two groups was likely to 
be the same. Fansidar resistance is propagating rapidly in the area and it associated also with 
gametocyte carriage. Thus it is suggested that the policy of malaria treatment in the area 
should be changed by excluding fansidar from the first line of treatment. The fansidar and 
chloroquine can be reused again once resistance to them has decreased as they are both cheap 
and affordable drugs. 
The findings in the detection of submicroscopic parasitemia in pregnant women in New Halfa 
area in this study showed that, although the present study failed to demonstrate a significant 
difference in age, parity, gestational age or hemoglobin concentration between the pregnant 
women with and without submicroscopic P. falciparum infections, the prevalence of malarial 
infection during pregnancy in Sudan is clearly much higher than indicated by the results of 
routine microscopy. Many women found smear-negative at the delivery of their babies 
probably have the placental malarial infections that are associated with low birthweights and 
other adverse outcomes. Submicroscopic P. falciparum infections could represent a 
significant problem in terms of materno–foetal health. 
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Severe Malaria Protocol, Clinical questionnaire 
Gedarif Teaching Hospital & New Halfa Teaching Hospital 
 
Sample I D :………SC.           Dates: admission: …/…/2000;      discharge …/…../2000 
Name: ……………………………………………………….. …….Gender : M (  ), F (  ) 
Date of birth: ………………………… age : ……………………………………………..…… 
Residence (detailed) : ………………………………………………….…………….………… 
Contact address :…………………………………………………...………….……..………… 
Occupation:………………………………………..…………………………………………… 
Tribe : ………………………………………………………………………………………….. 
For females: pregnant (  ), lactating (  ).                     Last menstrual cycle ……..…………….. 
C/O: 
1. History obtained from: patient (  ), relative (  ) 
2. Fever : 
A/ Duration : …………….. days.         B/ Grade : mild (  ), moderate (  ), severe (  ) 
C/ continuous (  ), intermittent (  ).  D/ regular (  ) irregular (  ).     E/ rigors (Yes, No). 
F/ sweating (Yes, No). 
General ill health, headache (  ), joint pain (  ), back pain (  ), fatigue (  ), bitter taste (  ) 
Bleeding: no bleeding (  ),   epistaxis (  ), haematemsis (  ),   haemoptysis (  ), bleeding 
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from other site (……………………………….) 
CNS: confusion (  ), convulsions (  ), loss of consciousness (  ), Hallucination (  ), 
Coma (Y, N), duration ………   Seizures : (partial, general), (L side, R side), duration……… 
Abdominal symptoms: pain (  ), nausea (  ), anorexia (  ),  vomiting (  ), diarrhoea (  ). 
3. Respiratory symptoms: Cough (  ) , breathlessness (  ). 
4. Urinary system: anuria, polyurea, haematurea 
Medical History: 
1. Malaria history 
Number of attacks ≥ 1 a year (  ), 1 every two years (  ), 1 ≤ every three years (  ), not 
at all (  ). 
1. History of severe malaria (Yes, No), what type……………………………………... 
2. Last clinical attack :…………………… Method of diagnosis : laboratory (  ), clinical 
(  ) 
3. Treatment received: ……………………………………………………………………. 
3. History of: Diabetes mellitus (  ), hypertension (  ), renal diseases (  ), asthma (  ),  
 other diseases : …………………………………………………………………………….. 
4. History of prolonged drug use (more than 1 week): ………………………………………... 
Clinical examination: 
General condition:A/ ill (  ) well (  ); B/Normal (  ), pale (  ), Jaundiced (  ), cyanosed (  ) 
C/ drowsy (  ), confused (  ), comatose (  ), convulsions (  ), stiff neck (  ). 
Oral Temperature ……..°C           Weight :   …….kg,  Nails :    normal (  ) clubbing (  ),    
spooning (  ). Blood pressure: ……………, Pulse ……………….., RR ……………………... 
Speech: normal (  ), slurred speech (  ), dysphasia (  ). 
Tongue: normal (  ), dry (  ), coated (  ), angular stomatitis (  ). 
Skin: dry (  ), rash (  ). 
Systemic examination 
1. Central Nervous System : ……………………………………………………………… 
Position: normal (  ), decerebrate (  ), decorticate (  ), opisthotonus (  ). 
………………………………………………………………………………………….. 
2. Respiratory system: rhythm (regular, irregular), hyperventilation (  ), deep slow 
breathing (  ), shallow fast breathing (  ) intercostals recession (  ).          
auscultation……….. ………… 
3. Gastrointestinal system : Liver size, ……cm,     spleen,………cm 
others…………………………………………………………………………………… 
4. Genitourinary system: …………………………………………………………….…… 
………………………………………………………………………………….….…… 
5. Muscle-skeletal system: ……………………………………………..………………… 
……………………………………………………………………………………..……
………………………………………………………………………………………….. 
 
Investigations: 
Blood film for malaria: BF…………. 
Species:   falciparum (  ),   vivax (  ),    malariae (  ),     ovale (  ). 
Parasite count: ………/µl 
Complete haemogram: 
Hb ……% (……gm/dl), Haematocrit …… Reticulocytes………….TWBC: …………...……, 
lymphocytes …….%, Neutrohpils ……%, …….Basophils ……%, Esinophils ………….…% 
Thrombocyte count ………………………………ESR (1 hour) ……………………………... 
Biochemical analysis: 
Blood glucose: …………………………Urine general: ………………………………………. 
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…………………………………………………………………………………………..……… 
- Renal Function Test : 
Blood: pH ……..    Urea . …………., serum creatinine…………plasma bicarbonate. ………. 
Widal test for typhoid: ……………………Widal test for brucellosis: ………..……………… 
Chest X-ray (when needed): ………………………………………………..………………….. 
Current treatment 
1- anti-malarial……………………………………………2.Fluid:……………………………. 
3. Other drugs ……………………………………………4. Blood transfusion:……………… 
Annex (I) For Cerebral malaria (Adults) 
Eye: Ptosis (  ),    Nystagmus (  ),    squint (  ). Pupils: normal (  ), dilated (  ), constricted (  ),    
fixed (  ). 
Fundi exam: …………………………………………………………………...……………… 
Cranial nerves: ………………..……………………………………………………………… 
Upper limbs: ……………………………………………………………..…………………… 
Lower limbs: …………………………………………………………..……………………… 
Plantar reflex (down going, equivocal, up going) 
Modified Glasgow coma scale (    ) 
a. Best motor response                      b. Verbal response                    c. Eye movement 
5 - Obeys commands (  )                 - Oriented   (  )                           - ……………… 
4 - Localized pain      (  )                 - Confused  (  )                          - Spontaneously (   ) 
3 - Flexion to pain     (  )                 - Inappropriate words (  )           - To speech        (   ) 
2 - Extension to pain (  )                  - Incomprehensible sounds (  )  - To pain            (   ) 
1 - None (  )                                     - None (  )                                   - Never              (   ) 
 
Annex (II) For Children 
Fontanelle; normal (  ), sunken (  ), bulging (  ), absent (  ). 
Can the child sit without support (Y,N), drink/breastfeed (Y,N). 
Nasal flaring (Y,N) 
Blantyre coma scale 
a. Motor response                               b. Verbal response            c. Eye movement 
2.  - Localized painful stimulus             - Appropriate cry                  - 
1.  - Withdraw limb from pain               - moan / inappropriate cry    - Directed 
0. - Non-specific or absent response      - None                                   - Not directed 
Annex (III) For pregnant ladies 
Gravidity: ……………………………………………………………………………………… 
Abortions: No…………… causes: fever (  ) others (  ). 
Current pregnancy : …….weeks. 
1st trimester (  ), 2nd trimester (  ), 3rd trimester (  ). 
Follow up 
Day 3 …………………………………………………………………………………...……… 
………………………………………………………………………………………….…….…
………………………………………………………………………………………………..… 
Day 7 ……………………………………………………………………………………........... 
………………………………………………………………………………………………….. 
Day 14…………………………………………………………………………………............. 
…………………………………………………………………………………………………..
………………………………………………………………………………………………….. 
Day 28…………………………………………………………………………………............. 
………………………………………………………………………………………………….
….……………………………………………………………………………………………… 
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Appendix 3: Schematic representation of MSP-1 of P. falciparum and of recombinant 
Merozoite surface protein-1 (MSP-1). The division into 17 blocks is as outlined by Tanabe et 
al., (1987); blocks of conserved sequences are denoted by open boxes 
 
 
S2 
MSP-2
FC27 
S3 S1 
IC1
S4 
Conserved 
Dimorphic block 
Repetitive (block)
Dimorphic (block)
Dimorphic (block)  
  
 
Appendix 4:  Schematic representation of Merozoite surface protein-2 
(MSP-2) of P. falciparum 
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  Appendix 5:  Schematic representation of Glutamate rich protein (GLURP) of P.falciparum 
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 اﻟﻤﻮاﻓﻘﺔ ﻋﻦ ﻋﻠﻢ
  
ﺔ ﺃﳕـﺎﻁ  ﺟﺎﻣﻌﺔ ﺍﳋﺮﻃﻮﻡ ﺑﺎﻟﺘﻌﺎﻭﻥ ﻣﻊ ﺑﻌﺾ ﺍﳌﺆﺳﺴﺎﺕ ﺍﻟﺴﻮﺩﺍﻧﻴﺔ ﻭﺍﻷﻭﺭﺑﻴـﺔ ﻣﻬﺘﻤـﺔ ﺑﺪﺭﺍﺳ  ـ– ﻛﻠﻴﺔ ﺍﻟﻄﺐ – ﳎﻤﻮﻋﺔ ﺃﲝﺎﺙ ﺍﳌﻼﺭﻳﺎ ﺍﻟﺘﺎﺑﻌﺔ ﺇﱄ ﻣﺮﻛﺰ ﺃﲝﺎﺙ ﺍﳌﻼﺭﻳﺎ -
  .ﰲ ﺍﻟﺴﻮﺩﺍﻥ(  ﺍﱁ ... ، ﺍﻷﻧﻴﻤﻴﺎ، ﺍﳌﻼﺭﻳﺎ ﺍﻟﺪﻣﺎﻏﻴﺔ) ﻭﺧﺼﺎﺋﺺ ﺍﳌﻼﺭﻳﺎ ﺍﳌﺰﻣﻨﺔ ﻭﺍﳌﻌﻘﺪﺓ ﻭﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﱵ ﺗﺴﺎﻫﻢ ﰲ ﺗﻌﻘﻴﺪﻫﺎ ﻭﻇﻬﻮﺭ ﺍﳊﺎﻻﺕ ﺍﳌﺴﺘﻌﺼﻴﺔ 
ﻟﺴﺎﺑﻘﺔ ﰲ ﺍﳌﻨﻄﻘﺔ، ﻭﺳﻴﻜﻮﻥ ﻣﻮﺿﻮﻉ ﺍﻟﺒﺤﺚ ﻫﻮ ﺩﺭﺍﺳﺔ  ﻟﻘﺪ ﰎ ﺇﺧﺘﻴﺎﺭ ﻣﺴﺘﺸﻔﻲ ﺍﻟﻘﻀﺎﺭﻑ ﺍﻟﺘﻌﻠﻴﻤﻲ ﳍﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻧﺴﺒﺔﹰ ﻟﺘﻔﺸﻲ ﻫﺬﺍ ﺍﻟﻨﻮﻉ ﻣﻦ ﺍﳌﻼﺭﻳﺎ ﰲ ﺍﻟﺴﻨﲔ ﺍﻟﻘﻠﻴﻠﺔ ﺍ -
  .ﻭﻓﻬﻢ ﻃﺒﻴﻌﺔ ﺍﳌﺮﺽ ﻭﻫﺬﺍ ﺍﻟﻔﻬﻢ ﳋﺼﺎﺋﺺ ﺍﳌﻼﺭﻳﺎ ﺍﳌﺰﻣﻨﺔ ﺳﻮﻑ ﻳﺴﺎﻋﺪ ﰲ ﺗﻘﻠﻴﻞ ﺣﺎﻻﺕ ﺍﻹﺻﺎﺑﺔ ﻭﲣﻔﻴﻒ ﺣﺪﺎ ﺃﻭ ﻋﻠﻲ ﺃﻗﻞ ﺗﻘﺪﻳﺮ ﰲ ﺳﺮﻋﺔ ﻣﻌﺎﳉﺘﻬﺎ
 ﺇﱄ ﻛﺸﻒ ﻃﱯ ﻣﺘﻜﺎﻣﻞ ﻭﺗﺘﻢ ﻣﺘﺎﺑﻌﺘﻬﻢ ﻃﺒﻴﺎﹰ ﻟﻔﺘﺮﺓ ﺃﻗﻠﻬﺎ ﺃﺳﺒﻮﻋﲔ ﻟﻠﺘﺄﻛﺪ ﻣﻦ ﺷـﻔﺎﺋﻬﻢ  ﻛﻞ ﺍﳌﺮﺿﻲ ﺍﻟﺬﻳﻦ ﻳﺘﻢ ﺇﺩﺧﺎﳍﻢ ﺇﱄ ﺍﳌﺴﺘﺸﻔﻲ ﺬﺍ ﺍﻟﻨﻮﻉ ﻣﻦ ﺍﳌﻼﺭﻳﺎ ﺳﻮﻑ ﳜﻀﻌﻮﺍ -
  .ﺍﻟﺘﺎﻡ
 ﺃﻳﺎﻡ ﻭﺑﻌﺪ ﺷﻬﺮ، ﻫﺬﻩ ﺍﻟﻌﻴﻨﺎﺕ ﺳﻮﻑ ﻳـﺘﻢ ﺃﺳـﺘﺨﺪﺍﻣﻬﺎ 7 ﺃﻳﺎﻡ، 3ﻣﻦ ﺍﳌﺮﻳﺾ ﻓﻮﺭ ﺩﺧﻮﻟﻪ ﺍﳌﺴﺘﺸﻔﻲ، ﰒ ﺑﻌﺪ (  ﺳﻲ ﺳﻲ 5) ﺑﻌﺪ ﺍﻟﻔﺤﺺ ﺍﻟﻄﱯ ﺍﻟﺸﺎﻣﻞ ﻳﺘﻢ ﺃﺧﺪ ﻋﻴﻨﺔ ﺩﻡ -
ﻓﺤﺺ ﻋﻤﻮﻣﻲ )ﻟﻠﺘﺄﻛﺪ ﻣﻦ ﺧﻠﻮ ﺍﻟﺪﻡ ﻣﻦ ﻃﻔﻴﻞ ﺍﳌﻼﺭﻳﺎ ﻭ( ﺍﳌﻼﺭﻳﺎ)، (ﻧﺴﺒﺔ ﺍﻟﺴﻜﺮ ﰲ ﺍﻟﺪﻡ)،(margomeaH etelpmoC)ﺎﻣﻞ ﻟﻠﺪﻡ ﻹﺟﺮﺍﺀ ﺑﻌﺾ ﺍﻟﻔﺤﻮﺻﺎﺕ ﻣﺜﻞ ﻓﺤﺺ ﻛ
  .ﻭﻟﻦ ﻳﺘﺤﻤﻞ ﺍﳌﺮﻳﺾ ﺃﻭ ﺫﻭﻭﻩ ﺃﻱ ﺃﻋﺒﺎﺀ ﻣﺎﺩﻳﺔ ﻧﺘﻴﺠﺔ ﻹﺷﺘﺮﺍﻛﻪ ﰲ ﻫﺬﺍ ﺍﻟﺒﺤﺚ(. ﻟﻠﺒﻮﻝ
  .ﻓﺾ ﰲ ﺍﻟﺪﺧﻮﻝ ﰲ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔﺍﳊﻖ ﰲ ﺍﳌﻮﺍﻓﻘﺔ ﺃﻭ ﺍﻟﺮ( ﺣﺎﻻﺕ ﺍﻹﻏﻤﺎﺀ ﻭﺍﻷﻃﻔﺎﻝ)  ﻟﻠﻤﺮﻳﺾ ﺃﻭ ﻣﺮﺍﻓﻘﻪ -
  . ﺍﳌﺮﺿﻲ ﺍﻟﺬﻳﻦ ﻻ ﻳﺮﻏﺒﻮﻥ ﰲ ﺍﻟﺪﺧﻮﻝ ﰲ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺳﻮﻑ ﺗﺘﻢ ﻣﺘﺎﺑﻌﺘﻬﻢ ﺑﺎﻟﻄﺮﻳﻘﺔ ﺍﳌﻌﺘﺎﺩﺓ ﰲ ﺍﳌﺴﺘﺸﻔﻲ-
  . ﺗﺴﺘﻔﻴﺪ ﻣﻦ ﺇﺷﺘﺮﺍﻛﻚ ﰲ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻷﻧﻚ ﺃﻭ ﻗﺮﻳﺒﻚ ﺍﳌﺮﻳﺾ ﺳﻮﻑ ﺗﺘﻢ ﻣﺘﺎﺑﻌﺘﻜﻢ ﻣﺘﺎﺑﻌﺔ ﻟﺼﻴﻘﺔ ﻭﺑﻜﺜٍﲑ ﻣﻦ ﺍﻟﻌﻨﺎﻳﺔ ﻃﻮﺍﻝ ﻓﺘﺮﺓ ﺍﻟﺪﺭﺍﺳﺔ-
  . * ﻋﻠﻲ ﺃﰎ ﺇﺳﺘﻌﺪﺍﺩ ﻟﻺﺟﺎﺑﺔ ﻋﻠﻲ ﺃﻱ ﺳﺆﺍﻝ ﺃﻭ ﺇﺳﺘﻔﺴﺎﺭﳓﻦ* 
  
  
 
 
  
 
  …………………………: ﺍﻟﻌﻤﺮ........................... .…………………:..............ﺍﻹﺳﻢ    
  ……………………………: ﺍﻟﻨﻮﻉ............................. ..…………………:.........ﺍﻟﺴﻜﻦ    
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